



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmjjournals.org>).

If you have any questions on BMJ Open's open peer review process please email
info.bmjopen@bmj.com

BMJ Open

Trends and Predictors of Biomedical Research Quality: A Meta-Research Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030342
Article Type:	Research
Date Submitted by the Author:	09-Mar-2019
Complete List of Authors:	Catillon, Maryaline; Harvard University, Ph.D. Program in Health Policy
Keywords:	STATISTICS & RESEARCH METHODS, Health informatics < BIOTECHNOLOGY & BIOINFORMATICS, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts

1
2
3 **Trends and Predictors of Biomedical Research Quality:**
4
5 **A Meta-Research Study**
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Word count: 2,125 (main text)

Maryaline Catillon (0000-0002-1360-8133)

Ph.D. Program in Health Policy, Harvard University, 14 Story Street, 4th Floor, Cambridge, MA 02138

mcatillon@g.harvard.edu

[\(+1\) 857 222 6863](tel:+18572226863)

ABSTRACT

Objective: To measure the frequency of adequate methods, inadequate methods and poor reporting in published clinical trials and test potential factors associated with adequacy of methods and reporting.

Design: Retrospective analysis of studies included in Cochrane reviews. Time series describe the proportion of studies using adequate methods, inadequate methods and poor reporting. A multinomial logit model tests potential factors associated with methods and reporting, including funding source, first author affiliation, clinical trial registration status, study novelty, team characteristics, technology and geography.

Data: Risk of bias assessment for random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data and selective reporting, for each study, mapped to bibliometric and funding data.

Outcomes: Risk of bias on six methodological dimensions, and study-level assessment of adequate methods, inadequate methods or poor reporting.

Results: This study analyzed 20,571 biomedical research articles. 5.7% of studies used adequate methods ($N=1,173$), 59.3% used inadequate methods ($N=12,190$) and 35.0% were poorly reported ($N=7,208$). The proportion of poorly reported studies decreased from 42.5% in 1990 to 30.2% in 2015. The proportion of studies using adequate methods increased from 2.6% in 1990 to 10.3% in 2015. The proportion of studies using inadequate methods increased from 54.9% in 1990 to 59.5% in 2015. Industry funding, top pharmaceutical company affiliation, trial registration, larger authorship teams, international teams, and drug trials were associated with a greater likelihood of using adequate methods. NIH funding and university prestige were not.

1
2
3 **Conclusion:** Even though reporting has improved since 1990, the proportion of studies using
4 inadequate methods is high (59.3%) and increasing, potentially contributing to the
5
6 reproducibility crisis. Stronger incentives for the use of adequate methods are needed.
7
8
9
10
11
12
13

14 STRENGTHS AND LIMITATIONS OF THIS STUDY

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- This study combines the full-text and systematic assessment of study methods with bibliometric and funding information in a sample of 20,571 biomedical research articles.
- This study analyzes trends in methods and reporting over the past 25 years and identifies factors associated with biomedical research quality including funding source, first author affiliation, clinical trial registration status, study novelty, team characteristics, technology and geography.
- This study does not identify causal mechanisms explaining biomedical research quality.
- PubMed identifier, full-text and/or funding information were not available for all studies.
- Classification of sectors relies on reported affiliation.

INTRODUCTION

The quality and reliability of biomedical research are of paramount importance to treatment decisions and patient outcomes. Flawed research conclusions can lead to poor treatment and harm patients. As much as 85% of the annual \$265 billion spent on biomedical research may be wasted due to inadequate methods.[1-8]

Previous scientific work aiming to evaluate the reliability of biomedical research has been limited by data and methodological issues. Data challenges include the time and resources necessary to assess methods and reporting, resulting in the use of small selected samples and/or limited information available for each scientific article evaluated in larger samples.[9-27] As a result, it remains unknown what the overall magnitude of waste due to inadequate methods and reporting in biomedical research is and what factors are associated with the use of adequate versus inadequate research methods.

To address these questions, this study combines the full text of studies and systematic assessment of study methods with bibliometric and funding information in a large sample of biomedical research articles included in “gold standard” systematic reviews. The study describes the evolution of adequate research methods and reporting over time. A multinomial logit model tests potential factors associated with methods and reporting, including funding source, first author affiliation, clinical trial registration status, study novelty, team characteristics, technology and geography.

METHODS

Data

Cochrane reviews constitute a valuable data source to assess biomedical research quality as they follow strict methods and precise reporting guidelines as defined in the Cochrane Handbook.[28-

31] The research method dimensions evaluated in Cochrane reviews include random sequence
generation, allocation concealment, blinding of participants and personnel, blinding of outcome
assessment, incomplete outcome data, and selective reporting (detailed in Supplementary Table
A1).

13 Sample

16 Supplementary Figure A1 summarizes the data flow. All studies assessed for risk of bias after the
17 2011 update of the Risk of Bias Assessment Tool and through October 2017 were considered for
18 inclusion (N=63,748 studies included in 4,195 reviews).

23 Criteria for study inclusion were: (1) the review included all six assessments (to allow
24 comparison of the overall use of adequate methods, inadequate methods and poor reporting
25 across reviews) (1,988 reviews dropped), (2) the article reporting the study was referenced in
26 PubMed (to allow bibliometric data to enter the analysis)(N=9,201 studies dropped) and (3) the
27 study quality was assessed consistently when assessed multiple times (N=404 studies dropped).
28

36 Applying these criteria, the analysis sample for the descriptive statistics and the time-series of
37 methods included 20,571 study publications referenced in PubMed, and consistently assessed for
38 risk of bias on all six dimensions of the Cochrane Risk of Bias Assessment Tool. A full-text PDF
39 was available from the Harvard Library for 11,686 study publications. This subsample was
40 needed to retrieve private funding information from the full-text of the paper and constitutes the
41 analysis sample for regressions including funding information.
42

49 Analysis

53 The outcomes were risk of bias on the six assessed methodological dimensions and study-level
54 assessment of adequate methods, inadequate methods or poor reporting. The six methodological
55

dimensions assessed included (1) random sequence generation, (2) allocation concealment, (3) blinding of participants and personnel, (4) blinding of outcome assessment, (5) incomplete outcome data and (6) selective reporting. The category “Other bias” was not used in this study, as it includes concerns not necessarily about methods or reporting, such as conflicts of interest.

Following guidelines for assessing the quality of evidence,[28] the study-level assessment was “adequate methods” if the study was at low risk of bias on all dimensions assessed. It was “inadequate methods” if the study was at high risk of bias for one or more reasons. It was “poorly reported” if the reviewers did not have enough information to assess whether the methods used were adequate or inadequate (if the study was at “unclear” risk of bias for at least one reason).

Of the studies assessed on all six dimensions, 69.5% matched with a PubMed identifier, which was used to retrieve bibliometric and public funding information.

Sector affiliation with university, government, hospital, non-profit, top pharmaceutical company or other firm, as well as geographic variables were derived from the first author affiliation address. Top 25 Universities were identified using the 2007 Academic Ranking of World Universities in Clinical Medicine and Pharmacy (see supplementary material, Appendix A).

Firms were classified as top pharmaceutical companies or other firms using the listing of pharmaceutical companies with a revenue greater than \$10 billion in any year since 2011 (see supplementary material, Appendix B). Technologies were retrieved from the keywords and abstracts of the Cochrane Reviews. Private funding information was retrieved from the full-text PDF of the main reference when available.

Two analyses were performed. The first reports the time series of the proportion of studies using adequate methods, inadequate methods and poor reporting, for each dimension and in aggregate. The second tests whether adequate methods, inadequate methods and poor reporting are associated with funding source (NIH grant or industry funding), sector affiliation of first author (Top University, Other University, Government, Hospital, Non-Profit, Top Pharmaceutical Company, Other Firm), clinical trial registration status, study novelty (first or subsequent study on a particular research question), team characteristics (number of authors and international collaboration), technology (drug, device, procedure, behavioral intervention or other intervention), and geography of first author (Canada, Europe, UK, USA, or other country). A multinomial logit model using these variables predicted overall adequate methods, inadequate methods and poor reporting, as well as risk of bias along each dimension assessed.

Patient involvement

Patients were not involved in any aspect of the study design, conduct, or in the development of the research question or outcome measures. This study is a meta-research study, based on existing published research. There was no patient recruitment for data collection.

RESULTS

Prevalence of Adequate Methods, Inadequate Methods, and Poor Reporting

Table 1 presents descriptive statistics. Only 5.7% of studies used adequate methods (N=1,173). 59.3% used inadequate methods (N=12,190) and 35.0% were poorly reported (N=7,208).

Figure 1 shows the proportion of studies at low, high or unclear risk of bias for random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data and selective reporting, for all studies assessed on all six

dimensions (N=20,571). 38% of trials used inadequate methods for blinding of participants and personnel. 15 to 20% of trials used inadequate methods for blinding of outcome assessment (20%), incomplete outcome data (19%) and selective reporting (15%). The proportion of trials using inadequate methods for random sequence generation and allocation concealment was lowest (respectively 5% and 7%), but these two dimensions were frequently poorly reported (respectively 47% and 58% of trials).

Methods and reporting over time

Figure 2 shows the overall proportion of studies using adequate methods, inadequate methods and poorly reported methods by year of publication. The proportion of poorly reported studies decreased from 42.5% in 1990 to 30.2% in 2015. The proportion of studies using adequate methods increased from 2.6% in 1990 to 10.3% in 2015. The proportion of studies using inadequate methods increased from 54.9% in 1990 to 59.5% in 2015.

Reporting improved on all dimensions. The proportion of studies using adequate methods for random sequence generation, allocation concealment, blinding of outcome assessment, incomplete outcome data and selective reporting increased. In contrast, the proportion of trials using inadequate methods for blinding of participants and personnel increased.

Figure A2 (supplementary material) provides graphs similar to figure 2 for all studies assessed on at least one dimension (N=63,748). Similar patterns suggest that the evolutions observed for the studies assessed on all dimensions (N=20,571) reflect the evolutions in all studies assessed on at least one dimension.

Factors associated with methods and reporting

Figure 3 reports regression results from a multinomial logit model predicting overall quality.

Tables A2 and A3 (Supplementary material) report all regression results.

Public funding was not associated with the overall use of adequate methods. However, NIH funded studies were less likely to use inadequate methods for random sequence generation ($RR=0.29$, $p<0.001$) and allocation concealment ($RR=0.51$, $p<0.001$). Industry funded studies were slightly more likely to use adequate methods ($RR=0.84$, $p<0.05$), because of better blinding of participants and personnel ($RR=0.87$, $p<0.05$).

First author affiliation with a top pharmaceutical company was associated with increased use of adequate methods ($RR=0.43$, $p<0.01$). First author affiliation with top universities was not.

Registered trials ($RR=0.42$, $p<0.001$), larger authorship teams ($RR=0.95$, $p<0.001$), international teams ($RR=0.51$, $p<0.01$) and studies on drugs ($RR=0.50$, $p<0.001$) were less likely to use inadequate methods.

DISCUSSION

In the context of the “reproducibility crisis”, there are concerns about the quality of biomedical research. This study assessed whether or not methods and reporting improved over time and identified the characteristics of better and worse studies.

This study has five main results. First, in a large sample of studies assessed in systematic reviews, only 5.7% used adequate methods, 59.3% used inadequate methods, and 35.0% were poorly reported. Since the 1990s, the proportion of poorly reported studies has decreased. In contrast, the proportion of trials using both adequate and inadequate methods has increased. This finding is consistent with previous empirical results in small samples,[22] but contrasts with

1
2
3 research in larger samples analyzing each methodological dimension separately to conclude that
4 methods improved over time.[24]
5
6

7
8 Second, NIH funded studies were not more likely to use adequate methods. This is surprising
9 given the rigorous grant application process, shown to select better scientific proposals,[33] and
10 the public stakes in the reliability of publicly funded research.[34] Notably, the efforts of the
11 NIH to address the reproducibility crisis began just at the end of the study period.[35]
12
13

14 Third, top pharmaceutical company affiliation was significantly associated with better methods.
15 Affiliation with other companies was not. Heterogeneity across firms may explain inconsistency
16 of previous research on the effect of industry funding or affiliation on research methods and
17 outcomes.[27,36]
18
19

20 Fourth, University prestige was not associated with greater use of adequate methods. The current
21 scientific reward system focuses on numbers of publications and citations rather than the
22 assessment of research methods.[37] The resulting incentives affect both scientists and
23 institutions, as through the allocation of grant funding.[38,39] Thus, in a climate of
24 hypercompetition,[40] the careful sharing of materials and methods yields little reward while
25 exposing scientists to better informed scrutiny.
26
27

28 Finally, team size and international collaboration are associated with greater use of adequate
29 methods. Larger teams and international teams produce more frequently cited research, [41,42]
30 and other team characteristics were associated with performance in other settings, opening
31 avenues for future research.[43,44]
32
33

34 Limitations

35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

This paper does not identify causal mechanisms explaining biomedical research quality. PubMed identifier, full-text and/or funding information were not available for all studies. Classification of sectors relies on reported affiliation.

CONCLUSION

Even though reporting has improved since 1990, the proportion of studies using inadequate methods is high (59.3%) and increasing, potentially contributing to the reproducibility crisis. Stronger incentives for the use of adequate methods are needed.

Contributorship statement

Maryaline Catillon designed the study, performed the analysis, interpreted the results, wrote the manuscript and approved the final version to be published. Maryaline Catillon accepts full responsibility for the work and the conduct of the study, had access to the data, and controlled the decision to publish.

Acknowledgments

The author thanks David Cutler, Richard Freeman, Mack Lipkin, Ariel Stern, Richard Zeckhauser and the participants at the NBER-IFS International Network on the Value of Medical Research meetings for helpful conversations and feedback, and Harvard Business School Research Computing Services for technical advice and support.

Funding

The author gratefully acknowledges support by the National Institute on Aging of the National Institutes of Health under Award Number R24AG048059 to the National Bureau of Economic Research (NBER). The content of this article is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health or the NBER.

Ethical approval

Not applicable. This is a meta-research study.

Data sharing

All data sources necessary to reproduce the analysis are described in the main text or the supplementary material. No additional data available.

What is already known on this subject

Poor reporting and inadequate methods are common in randomized controlled trials.

Reporting has improved since the 1990s.

Previous research has been limited by the use of small selected samples and/or limited information available for each scientific article evaluated in larger samples

What this study adds

This study combines the full-text and systematic assessment of study methods with bibliometric and funding information to analyze trends and predictors of methods and reporting in a sample of 20,571 biomedical research studies.

Only 5.7% of studies used adequate methods, 59.3% used inadequate methods and 35.0% were poorly reported.

Since the 1990s, while the proportion of poorly reported studies decreased, both the proportion of studies using adequate methods and inadequate methods increased.

Industry funding, top pharmaceutical company affiliation, trial registration, larger authorship teams, international teams, and drug trials were associated with a greater likelihood of using adequate methods, but NIH funding and university prestige were not.

Bibliography

- 1
- 2
- 3
- 4
- 5
- 6 1. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research
7 evidence. *The Lancet*. 2009 Jul 4;374(9683):86-9.
- 8
- 9
- 10 2. Macleod MR, Michie S, Roberts I, Dirmagl U, Chalmers I, Ioannidis JP, Salman RA, Chan
11 AW, Glasziou P. Biomedical research: increasing value, reducing waste. *The Lancet*. 2014
12 Jan 11;383(9912):101-4.
- 13
- 14 3. Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Gülmezoglu AM, Howells
15 DW, Ioannidis JP, Oliver S. How to increase value and reduce waste when research
16 priorities are set. *The Lancet*. 2014 Jan 11;383(9912):156-65.
- 17
- 18 4. Glasziou P, Altman DG, Bossuyt P, Boutron I, Clarke M, Julious S, Michie S, Moher D,
19 Wager E. Reducing waste from incomplete or unusable reports of biomedical research. *The
20 Lancet*. 2014 Jan 18;383(9913):267-76.
- 21
- 22 5. Ioannidis JP, Greenland S, Hlatky MA, Khoury MJ, Macleod MR, Moher D, Schulz KF,
23 Tibshirani R. Increasing value and reducing waste in research design, conduct, and
24 analysis. *The Lancet*. 2014 Jan 11;383(9912):166-75.
- 25
- 26 6. Moses H, Matheson DH, Cairns-Smith S, George BP, Palisch C, Dorsey ER. The anatomy
27 of medical research: US and international comparisons. *Jama*. 2015 Jan 13;313(2):174-89.
- 28
- 29 7. Yordanov Y, Dechartres A, Porcher R, Boutron I, Altman DG, Ravaud P. Avoidable waste
30 of research related to inadequate methods in clinical trials. *bmj*. 2015 Mar 24;350:h809.
- 31
- 32 8. Moher D, Glasziou P, Chalmers I, Nasser M, Bossuyt PM, Korevaar DA, Graham ID,
33 Ravaud P, Boutron I. Increasing value and reducing waste in biomedical research: who's
34 listening?. *The Lancet*. 2016 Apr 9;387(10027):1573-86.
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 9. Lee KP, Schotland M, Bacchetti P, Bero LA. Association of journal quality indicators with
4 methodological quality of clinical research articles. *Jama*. 2002 Jun 5;287(21):2805-8.
5
6 10. Bala MM, Akl EA, Sun X, Bassler D, Mertz D, Mejza F, Vandvik PO, Malaga G, Johnston
7 BC, Dahm P, Alonso-Coello P. Randomized trials published in higher vs. lower impact
8 journals differ in design, conduct, and analysis. *Journal of clinical epidemiology*. 2013 Mar
9 1;66(3):286-95.
10
11 17. Lee SY, Teoh PJ, Camm CF, Agha RA. Compliance of randomized controlled trials in
12 trauma surgery with the CONSORT statement. *Journal of Trauma and Acute Care Surgery*.
13 2013 Oct 1;75(4):562-72.
14
15 24. Agha RA, Camm CF, Doganay E, Edison E, Siddiqui MR, Orgill DP. Randomised
16 controlled trials in plastic surgery: a systematic review of reporting quality. *European*
17 *journal of plastic surgery*. 2014 Feb 1;37(2):55-62.
18
19 31. Chen B, Liu J, Zhang C, Li M. A retrospective survey of quality of reporting on randomized
20 controlled trials of metformin for polycystic ovary syndrome. *Trials*. 2014 Dec;15(1):128.
21
22 35. Chen X, Zhai X, Wang X, Su J, Li M. Methodological reporting quality of randomized
36 controlled trials in three spine journals from 2010 to 2012. *European Spine Journal*. 2014
37 Aug 1;23(8):1606-11.
38
39 42. Kim KH, Kang JW, Lee MS, Lee JD. Assessment of the quality of reporting for treatment
43 components in Cochrane reviews of acupuncture. *BMJ open*. 2014 Jan 1;4(1):e004136.
44
45 47. Lempesi E, Koletsi D, Fleming PS, Pandis N. The reporting quality of randomized
46 controlled trials in orthodontics. *Journal of Evidence Based Dental Practice*. 2014 Jun
47 1;14(2):46-52.
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 17. Yao AC, Khajuria A, Camm CF, Edison E, Agha R. The reporting quality of parallel
4 randomised controlled trials in ophthalmic surgery in 2011: a systematic review. *Eye*. 2014
5 Nov;28(11):1341.
6
7 18. Zhuang L, He J, Zhuang X, Lu L. Quality of reporting on randomized controlled trials of
8 acupuncture for stroke rehabilitation. *BMC complementary and alternative medicine*. 2014
9 Dec;14(1):151.
10
11 19. Chen Z, Chen Y, Zeng J, Wang Y, Ye T, Zhou Q, Du X, Su W, Ding Z. Quality of
12 randomized controlled trials reporting in the treatment of melasma conducted in China.
13
14 Trials. 2015 Dec;16(1):156.
15
16 20. Glujsovsky D, Boggino C, Riestra B, Coscia A, Sueldo CE, Ciapponi A. Quality of
17 reporting in infertility journals. *Fertility and sterility*. 2015 Jan 1;103(1):236-41.
18
19 21. Kloukos D, Papageorgiou SN, Doulis I, Petridis H, Pandis N. Reporting quality of
20 randomised controlled trials published in prosthodontic and implantology journals. *Journal*
21 of oral rehabilitation. 2015 Dec;42(12):914-25.
22
23 22. Reveiz L, Chapman E, Asial S, Munoz S, Bonfill X, Alonso-Coello P. Risk of bias of
24 randomized trials over time. *Journal of clinical epidemiology*. 2015 Sep 1;68(9):1036-45.
25
26 23. Zhai X, Wang Y, Mu Q, Chen X, Huang Q, Wang Q, Li M. Methodological reporting
27 quality of randomized controlled trials in 3 leading diabetes journals from 2011 to 2013
28 following CONSORT statement: a system review. *Medicine*. 2015 Jul;94(27).
29
30 24. Dechartres A, Trinquart L, Atal I, Moher D, Dickersin K, Boutron I, Perrodeau E, Altman
31 DG, Ravaud P. Evolution of poor reporting and inadequate methods over time in 20 920
32 randomised controlled trials included in Cochrane reviews: research on research study.
33
34 BMJ. 2017 Jun 8;357:j2490.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 25. Saltaji H, Armijo-Olivo S, Cummings GG, Amin M, Flores-Mir C. Randomized clinical
4 trials in dentistry: Risks of bias, risks of random errors, reporting quality, and methodologic
5 quality over the years 1955–2013. *PLoS one.* 2017 Dec 22;12(12):e0190089.
6
7
8
9
10 26. Karlsen AP, Dahl JB, Mathiesen O. Evolution of bias and sample size in postoperative pain
11 management trials after hip and knee arthroplasty. *Acta Anaesthesiologica Scandinavica.*
12 2018 May;62(5):666-76.
13
14
15
16 27. Salandra R. Knowledge dissemination in clinical trials: exploring influences of
17 institutional support and type of innovation on selective reporting. *Research Policy.* 2018
18 Sep 1;47(7):1215-28.
19
20
21
22
23
24 28. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz
25 KF, Weeks L, Sterne JA. The Cochrane Collaboration's tool for assessing risk of bias in
26 randomised trials. *Bmj.* 2011 Oct 18;343:d5928.
27
28
29
30
31 29. Bunn F, Trivedi D, Alderson P, Hamilton L, Martin A, Iliffe S. The impact of Cochrane
32 systematic reviews: a mixed method evaluation of outputs from Cochrane review groups
33 supported by the UK National Institute for Health Research. *Systematic reviews.* 2014
34 Dec;3(1):125.
35
36
37
38
39
40 30. Davoli M, Amato L, Clark N, Farrell M, Hickman M, Hill S, Magrini N, Poznyak V,
41 Schünemann HJ. The role of Cochrane reviews in informing international guidelines: a
42 case study of using the Grading of Recommendations, Assessment, Development and
43 Evaluation system to develop World Health Organization guidelines for the psychosocially
44 assisted pharmacological treatment of opioid dependence. *Addiction.* 2015
45 Jun;110(6):891-8.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 31. Page MJ, Shamseer L, Altman DG, Tetzlaff J, Sampson M, Tricco AC, Catalá-López F, Li
4 L, Reid EK, Sarkis-Onofre R, Moher D. Epidemiology and reporting characteristics of
5 systematic reviews of biomedical research: a cross-sectional study. PLoS medicine. 2016
6 May 24;13(5):e1002028.
7
8 32. Liu NC. The story of academic ranking of world universities. International Higher
9 Education. 2015 Mar 25(54).
10
11 33. Li D, Agha L. Big names or big ideas: do peer-review panels select the best science
12 proposals?. Science. 2015 Apr 24;348(6233):434-8.
13
14 34. Sampat BN. Mission-oriented biomedical research at the NIH. Research Policy. 2012 Dec
15 1;41(10):1729-41.
16
17 35. Collins FS, Tabak LA. NIH plans to enhance reproducibility. Nature. 2014 Jan
18 30;505(7485):612-3.
19
20 36. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research
21 outcome. Cochrane Database Syst Rev. 2012 Dec 12;12(12).
22
23 37. Stephan, P. How Economics Shapes Science, 2012
24
25 38. Ali MM, Bhattacharyya P, Olejniczak AJ. The effects of scholarly productivity and
26 institutional characteristics on the distribution of federal research grants. The Journal of
27 Higher Education. 2010 Mar 1;81(2):164-78.
28
29 39. Alberts B, Kirschner MW, Tilghman S, Varmus H. Rescuing US biomedical research from
30 its systemic flaws. Proceedings of the National Academy of Sciences. 2014 Apr
31 22;111(16):5773-7.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 40. Edwards MA, Roy S. Academic research in the 21st century: Maintaining scientific
4 integrity in a climate of perverse incentives and hypercompetition. *Environmental
5 Engineering Science*. 2017 Jan 1;34(1):51-61.
6
7
8
9
10 41. Wuchty S, Jones BF, Uzzi B. The increasing dominance of teams in production of
11 knowledge. *Science*. 2007 May 18;316(5827):1036-9.
12
13
14 42. National Research Council. Enhancing the effectiveness of team science. National
15 Academies Press; 2015 Jul 15.
16
17
18 43. Huckman RS, Staats BR, Upton DM. Team familiarity, role experience, and performance:
19 Evidence from Indian software services. *Management Science*. 2009 Jan;55(1):85-100.
20
21
22 44. Huckman RS, Staats BR. Fluid tasks and fluid teams: The impact of diversity in experience
23 and team familiarity on team performance. *Manufacturing & Service Operations
24 Management*. 2011 Jul;13(3):310-28.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **List of Figures and Tables**
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Descriptive statistics

Figure 1: Proportion of studies at low risk, high risk and unclear risk, for each dimension assessed

Figure 2: Evolution of methods and reporting over time

Figure 3: Main regression results predicting relative risk ratios for overall quality

	All	Adequate	Inadequate Methods	Poor Reporting
Sample 1	20,571 (100%)	1,173 (5.7%)	12,190 (59.3%)	7,208 (35.0%)
Sample 2 (with full text)	11,686 (56.8%)	833 (7.1%)	6,783 (58.0%)	4,070 (34.8%)
Funder type				
NIH Grant	2,147 (10.4%)	146 (6.8%)	1,282 (59.7%)	719 (33.5%)
Industry funding	2,783 (13.5%)	283 (10.2%)	1,464 (52.6%)	978 (35.1%)
First Author Affiliation				
Top University	1,063 (5.2%)	51 (4.8%)	601 (56.5%)	411 (38.7%)
Other University	11,120 (54.1%)	677 (6.1%)	6,589 (59.3%)	3,854 (34.7%)
Hospital	4,450 (21.6%)	185 (4.2%)	2,608 (58.6%)	1,657 (37.2%)
Government	1,744 (8.5%)	108 (6.2%)	1,071 (61.4%)	565 (32.4%)
Non-Profit	751 (3.7%)	48 (6.4%)	454 (60.5%)	249 (33.2%)
Top Pharma	239 (1.2%)	26 (10.9%)	115 (48.1%)	98 (41.0%)
Other Firm	195 (1.0%)	13 (6.7%)	115 (59.0%)	67 (34.3%)
Other research institution	200 (1.0%)	18 (9.0%)	120 (60.0%)	62 (31.0%)
Other industry affiliation	570 (2.8%)	44 (7.7%)	287 (50.4%)	239 (41.9%)
Registered studies (NCT)	1,888 (9.2%)	298 (15.8%)	1,011 (53.6%)	579 (30.7%)
Novelty				
First study	2,284 (11.1%)	126 (5.5%)	1,390 (60.9%)	768 (33.6%)
Second study	2,124 (10.3%)	127 (6.0%)	1,262 (59.4%)	735 (34.6%)
Team characteristics				
Number of Authors - Avg (Std)	6.15 (3.9)	8.04 (5.5)	5.99 (3.8)	6.13 (6.8)
International	748 (3.64%)	60 (8.02%)	379 (50.67%)	309 (41.31%)
Technology*				
Drug	13,485 (65.6%)	914 (6.8%)	7,306 (54.2%)	5,265 (39.0%)
Device	5,347 (26.0%)	235 (4.4%)	3,366 (63.0%)	1,746 (32.7%)
Procedure	8,710 (42.3%)	460 (5.3%)	4,925 (56.5%)	3,325 (38.2%)
Behavioral	4,543 (22.1%)	122 (2.7%)	3,239 (71.3%)	1,182 (26.0%)
Other	1,199 (5.8%)	78 (6.5%)	819 (68.3%)	302 (25.2%)
Geography**				
Canada	680 (3.3%)	61 (9.0%)	362 (53.2%)	257 (37.8%)
Europe	4,467 (21.7%)	254 (5.7%)	2,693 (60.3%)	1,520 (34.0%)
UK	2,306 (11.2%)	154 (6.7%)	1,399 (60.7%)	753 (32.7%)
USA	4,465 (21.7%)	284 (6.4%)	2,592 (58.1%)	1,589 (35.6%)
Other	4,165 (20.3%)	253 (6.1%)	2,444 (58.7%)	1,468 (35.3%)
Publication Year - Avg (Std)	2001 (10.2)	2005 (8.1)	2001 (10.4)	2001 (9.9)
Study Age at Review - Avg (Std)	13.44 (10.1)	9.81 (8.0)	13.39 (10.3)	14.14 (9.9)

Table 1. Descriptive statistics. Unless otherwise specified, column 1 reports the number of studies and their proportion as of the total number of studies (N=20,571). Columns 2-4 report the number of studies in each category and their proportion as of the number of studies in column 1. For number of authors, publication year and study age at time of review, Table 1 reports the average and standard deviation. *One study can belong to several technology categories. ** For some studies, affiliation address is not provided.




Fig. 1. Proportion of trials at low risk, high risk and unclear risk, for each dimension assessed. An observation is a study assessed on all six dimensions (N=20,571).




Fig. 2. Evolution of methods and reporting over time.




Fig. 3. Main regression results predicting relative risk ratios (RRR) for overall quality. RRR and 95% confidence intervals from estimating the multinomial logit model. An observation is a study ($N=11,686$). The dependent variable can take three values: adequate methods, inadequate methods and poor reporting. The reference category is adequate methods. Omitted sector category is other university, omitted technology category includes all other interventions, and omitted countries include all other countries. The regression includes topic and year fixed effects.




Fig. A1: Data flow and analysis sample




Fig. A2: This figure represents the proportion of studies at "low risk of bias", "high risk of bias", or "unclear risk of bias" for each dimension assessed, by publication year. An observation is a study. On each dimension, all studies assessed are included.

Supplementary Materials, Tables and Figures

Appendix A: List of top 25 universities in clinical medicine and pharmacy

Appendix B: List of top pharmaceutical companies

Table A1: Cochrane Risk of Bias Assessment Tool

Table A2: Main regression results predicting adequate methods, inadequate methods and poor reporting

Table A3: Regression results predicting relative risk ratios for each dimension

Figure A1: Flow diagram

Figure A2: Proportion of studies assessed at low risk of bias, high risk of bias and unclear risk of bias on each criterion, by publication year (including all studies assessed on at least one dimension)

1
2
3 **Appendix A: List of top 25 universities in clinical medicine and pharmacy (AWRU, 2007)**
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- Harvard University
- University of California, San Francisco
- University of Washington
- The Johns Hopkins University
- Columbia University
- University of California, Los Angeles
- The University of Texas Southwestern Medical Center at Dallas
- University of Michigan - Ann Arbor
- Karolinska Institute
- University of Pittsburgh
- Stanford University
- Mayo Medical School
- University of Oxford
- University of Minnesota, Twin Cities
- University of Cambridge
- Yale University
- University College London
- The University of Texas M. D. Anderson Cancer Center
- University of Wisconsin - Madison
- Vanderbilt University
- University of Pennsylvania
- Duke University
- University of California, San Diego
- Tufts University
- The Imperial College of Science, Technology and Medicine

1
2
3 **Appendix B: List of top pharmaceutical companies used in this study (by revenue)**
4
5

- 6
- 7 • Johnson & Johnson
 - 8 • Roche
 - 9 • Pfizer
 - 10 • Novartis
 - 11 • Bayer
 - 12 • Merck & Co
 - 13 • GlaxoSmithKline
 - 14 • Sanofi
 - 15 • Abbvie
 - 16 • Abbott Laboratories
 - 17 • Eli Lilly & Co
 - 18 • Amgen
 - 19 • Bristol-Myers Squibb
 - 20 • Gilead Sciences
 - 21 • AstraZeneca
 - 22 • Teva Pharmaceutical Industries
 - 23 • Boehringer Ingelheim
 - 24 • Merck Group
 - 25 • Novo Nordisk
 - 26 • Takeda Pharmaceutical
 - 27 • Allergan plc
 - 28 • Shire
 - 29 • Celgene
 - 30 • Biogen
- 31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59

Table A1: Cochrane Risk of Bias Assessment Tool

Bias domain	Source of bias	Support for judgement	Review Authors judgement
Selection bias	Random sequence generation	Describe the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.	Selection bias (biased allocation to intervention) due to inadequate generation of a randomized sequence.
Selection bias	Allocation concealment	Describe the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been foreseen before or during enrollment.	Selection bias (biased allocation to interventions) due to inadequate concealment of allocations before assignment.
Performance bias	Blinding of participants and personnel	Describe all measures used, if any, to blind participants and researchers from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective.	Performance bias due to knowledge of the allocated intervention by participants and personnel during the study.
Detection bias	Blinding of outcome assessment	Describe all measures used, if any, to blind outcome assessment from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective.	Performance bias due to knowledge of the allocated intervention by outcome assessment.
Attrition bias	Incomplete outcome data	Describe the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. State whether attritions and exclusions were reported, the numbers in each intervention group (compared with total randomized participants), reasons for attrition or exclusion where reported, and any re-inclusion in the analysis for the review.	Attrition bias due to amount, nature or handling of incomplete outcome data
Reporting bias	Selective reporting	State how selective outcome reporting was examined and what was found.	Reporting bias due to selective outcome reporting.
Other bias	Anything else, pre-specified	State any important concerns about bias not covered in other domains in the tool.	Bias due to problems not covered elsewhere.

Source: Adapted from Higgins et al, 2011

1
2
3 **Table A2: Main regression results predicting adequate methods, inadequate methods and**
4 **poor reporting (Relative Risk Ratios)**

	Inadequate Methods	Poor Reporting
Funding		
NIH Grant	0.83	0.76
Industry	0.84*	0.85
Sector (First Author)		
Top University	0.76	0.76
Government	1.21	1.05
Hospital	1.19	1.16
Non-Profit	1.40	1.27
Top Pharma	0.43**	0.74
Other Firms	1.38	1.06
Sector (Other Author)		
Any Firm	0.66	0.79
Study/Team		
Registered trial	0.42***	0.45***
First Study	0.90	0.80
Second Study	0.85	0.81
Number of Authors	0.95***	0.97***
International	0.51**	0.64*
Technology		
Drug	0.50***	0.73*
Device	1.71**	1.23
Procedure	1.01	1.28
Behavioral	2.63***	1.44
Geography		
USA	1.11	1.39*
Canada	0.71	0.81
Europe	1.29*	1.22
UK	1.06	0.91

43 * p<0.05, ** p<0.01, *** p<0.001

44
45 This table presents relative risk ratios and p-values from estimating the multinomial logit model. An observation in
46 this regression is a study (N=11,686). The dependent variable can take three values: adequate methods, inadequate
47 methods and poor reporting. The reference category is adequate methods. Omitted sector category is other
48 university, omitted technology category includes all other interventions, and omitted countries include all other
49 countries. The regression includes topic and year fixed effects.

Table A3: Regression results predicting relative risk ratios for each dimension

	Random Sequence		Allocation Conceal.		Blinding PP		Blinding OA		Incomplete Data		Selective Reporting	
	High	Unclear	High	Unclear	High	Unclear	High	Unclear	High	Unclear	High	Unclear
Funding												
NIH Grant	0.29***	0.90	0.51***	0.93	1.12	1.06	1.01	0.93	1.03	1.04	1.33	0.99
Industry	1.03	1.07	1.18	1.06	0.87*	0.92	0.98	0.98	0.97	0.99	1.36	1.04
Sector (First Author)												
Top University	0.99	0.96	0.91	0.88	0.85	0.83	0.84	0.85	0.90	1.05	1.29	1.08
Government	0.91	1.01	0.85	0.98	1.00	0.96	1.00	0.92	1.29**	1.14	1.24	1.12
Hospital	1.07	1.06	1.05	1.00	1.08	0.96	1.12	1.04	1.05	0.95	0.99	1.03
Non-Profit	1.40	1.05	1.34	0.91	1.08	1.02	1.13	0.99	1.01	1.03	1.33	1.07
Top Pharma	0.49	0.96	0.60	0.83	0.34***	0.73	0.56*	0.74	0.86	0.61	0.90	0.59*
Other Firms	2.19	1.64*	2.01	1.60*	0.64	0.94	0.56	1.41	1.30	1.12	2.16*	1.05
Sector (Other Author)												
Any Firm	0.18**	0.92	0.53	1.04	0.65**	0.94	0.86	1.21	1.39*	1.06	0.94	1.02
Study/Team												
Registered trial	0.31***	0.42***	0.39***	0.41***	0.72***	0.60***	0.58***	0.63***	0.67***	0.71***	0.66**	0.52***
First Study	0.95	0.81**	1.09	0.84*	1.15	1.07	1.02	0.85	0.97	0.90	1.24	1.03
Second Study	1.00	0.83*	1.01	0.80**	1.02	1.03	1.04	1.01	0.87	0.88	1.26	1.01
Number of Authors	0.92***	0.97***	0.93***	0.95***	0.98**	0.96***	0.95***	0.97***	0.98*	0.99	0.99	0.96***
International	0.88	0.79*	0.53*	0.74**	0.79	0.94	0.73*	0.75*	0.91	0.86	0.66*	0.82
Technology												
Drug	0.66*	1.14	0.76	1.11	0.41***	0.48***	0.82	0.87	0.92	0.94	1.00	1.05
Device	1.31	1.02	1.34	1.10	1.52**	0.93	1.27	0.93	0.91	1.02	1.22	0.83
Procedure	0.90	1.21**	0.93	1.22*	0.91	1.24	1.18	1.22	0.85	1.06	1.24	1.13
Behavioral	0.88	1.03	1.21	1.16	2.83***	1.53**	2.09***	1.27	1.34**	1.18	0.99	1.41*
Geography												
USA	1.04	1.15	0.93	1.12	0.73***	0.95	0.81	1.02	1.23*	1.22*	0.96	0.93
Canada	0.55	0.69**	0.69	0.61***	0.75	0.75	0.85	0.66**	0.94	1.09	0.96	0.88
Europe	0.80	1.05	0.79	0.96	1.13	1.05	1.29**	1.09	1.13	0.97	1.21	0.92
UK	0.89	0.89	0.65**	0.67***	1.03	0.87	1.11	0.96	1.04	1.01	1.07	0.86

Regression results predicting relative risk ratio for risk of bias for each dimension (reference category: low risk). *p<0.05, **p<0.01, ***p<0.001

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 STROBE Statement—checklist of items that should be included in reports of observational studies
3
4

5 6 Item No	7 8 Recommendation	9 10 Page 11 No
12 Title and abstract	13 14 (a) Indicate the study's design with a commonly used term in the title or 15 the abstract 16 (b) Provide in the abstract an informative and balanced summary of what 17 was done and what was found	18 19 1,2 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Introduction
Background/rationale	2 Explain the scientific background and rationale for the investigation being reported	4
Objectives	3 State specific objectives, including any prespecified hypotheses	4
Methods		
Study design	4 Present key elements of study design early in the paper	4
Setting	5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4,5
Participants	6 (a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	5 N/A
Variables	7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5,6
Data sources/ measurement	8* For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6
Bias	9 Describe any efforts to address potential sources of bias	7,8
Study size	10 Explain how the study size was arrived at	5
Quantitative variables	11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	N/A
Statistical methods	12 (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses	7 N/A 8 N/A N/A

Continued on next page

1
2 **Results**
3

4	Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially 5 eligible, examined for eligibility, confirmed eligible, included in the study, 6 completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	5 5 32
10	Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	21 21 N/A
15	Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	23 N/A N/A
20	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	7,8,9 N/A N/A
25	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A

30 **Discussion**
31

32	Key results	18	Summarise key results with reference to study objectives	9,10
33	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10
34	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	9,10
35	Generalisability	21	Discuss the generalisability (external validity) of the study results	8

39 **Other information**
40

41	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	11
----	---------	----	---	----

44 *Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.
45
46

48 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.
55
56
57
58
59
60

BMJ Open

Trends and Predictors of Biomedical Research Quality, 1990-2015: A Meta-Research Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030342.R1
Article Type:	Research
Date Submitted by the Author:	13-May-2019
Complete List of Authors:	Catillon, Maryaline; Harvard University, Ph.D. Program in Health Policy
Primary Subject Heading:	Research methods
Secondary Subject Heading:	Health policy, Health informatics, Health economics
Keywords:	STATISTICS & RESEARCH METHODS, Health informatics < BIOTECHNOLOGY & BIOINFORMATICS, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts

1
2
3 **Trends and Predictors of Biomedical Research Quality, 1990-2015:**
4
5

6 **A Meta-Research Study**
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Word count: 2855 (main text)

Maryaline Catillon (0000-0002-1360-8133)

Ph.D. Program in Health Policy, Harvard University, 14 Story Street, 4th Floor, Cambridge, MA 02138

mcatillon@g.harvard.edu

[\(+1\) 857 222 6863](tel:+18572226863)

ABSTRACT

Objective: To measure the frequency of adequate methods, inadequate methods and poor reporting in published randomized controlled trials and test potential factors associated with adequacy of methods and reporting.

Design: Retrospective analysis of randomized controlled trials (RCTs) included in Cochrane reviews. Time series describe the proportion of RCTs using adequate methods, inadequate methods and poor reporting. A multinomial logit model tests potential factors associated with methods and reporting, including funding source, first author affiliation, clinical trial registration status, study novelty, team characteristics, technology and geography.

Data: Risk of bias assessments for random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data and selective reporting, for each RCT, were mapped to bibliometric and funding data.

Outcomes: Risk of bias on six methodological dimensions, and RCT-level overall assessment of adequate methods, inadequate methods or poor reporting.

Results: This study analyzed 20,571 RCTs. 5.7% of RCTs used adequate methods (N=1,173). 59.3% used inadequate methods (N=12,190) and 35.0% were poorly reported (N=7,208). The proportion of poorly reported RCTs decreased from 42.5% in 1990 to 30.2% in 2015. The proportion of RCTs using adequate methods increased from 2.6% in 1990 to 10.3% in 2015. The proportion of RCTs using inadequate methods increased from 54.9% in 1990 to 59.5% in 2015. Industry funding, top pharmaceutical company affiliation, trial registration, larger authorship teams, international teams, and drug trials were associated with a greater likelihood of using adequate methods. NIH funding and university prestige were not.

1
2
3 **Conclusion:** Even though reporting has improved since 1990, the proportion of RCTs using
4 inadequate methods is high (59.3%) and increasing, potentially slowing progress in medical
5 knowledge and contributing to the reproducibility crisis. Stronger incentives for the use of
6 adequate methods are needed.
7
8
9
10
11
12

13 STRENGTHS AND LIMITATIONS OF THIS STUDY 14

- 15
- 16 • This work combines the strengths of expert human assessments with data science
17 techniques to build a comprehensive database on biomedical research quality, including
18 the full-text and systematic assessment of RCT methods with bibliometric and funding
19 information in a sample of 20,571 RCTs.
20
21
 - 22 • The study analyzes trends in methods and reporting over 25 years and identifies factors
23 associated with biomedical research quality including funding source, first author
24 affiliation, clinical trial registration status, study novelty, team characteristics, technology
25 and geography.
26
27
 - 28 • PubMed identifier, full-text and/or funding information were not available for all RCTs.
29 30.5% of RCTs (unpublished or published in journals not indexed in PubMed) did not
30 have a PubMed identifier. 43.2% of RCTs with PubMed identifier did not have a full-text
31 available from the Harvard Library. 23.6% of included RCTs were reported in articles
32 disclosing NIH or industry funding. Classification of sectors relies on primary reported
33 affiliation.
34
35
 - 36 • Cochrane reviewers may have been able to obtain more information on more recent
37 RCTs (from authors, registries, or protocols rather than the primary report), suggesting
38 some of the apparent improvement in reporting may reflect an improvement in access to
39 study details.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- This study does not identify causal mechanisms explaining biomedical research quality.

INTRODUCTION

The quality and reliability of biomedical research are of paramount importance to treatment decisions and patient outcomes. Flawed research conclusions can lead to poor treatment and harm patients. As much as 85% of the annual \$265 billion spent on biomedical research may be wasted due to inadequate methods.[1-8]

Previous scientific work aiming to evaluate the reliability of biomedical research has been limited by data and methodological issues. Data challenges included the time and resources necessary to assess methods and reporting, resulting in the use of small selected samples and/or limited information available for each scientific article evaluated in larger samples.[9-28] As a result, it remains unknown what is the overall magnitude of waste due to inadequate methods and reporting in biomedical research and what factors are associated with the use of adequate versus inadequate research methods.

To address these questions, this study combines the full text of RCTs and full systematic assessment of study methods with bibliometric and funding information in a large sample of RCTs included in “gold standard” systematic reviews. The study describes the evolution of adequate research methods and reporting over time. A multinomial logit model tests potential factors associated with methods and reporting, including funding source, first author affiliation, clinical trial registration status, study novelty, team characteristics, technology and geography.

METHODS

This work combines the strengths of human expert assessments with data science techniques to build a comprehensive database on biomedical research quality, including full-text, systematic

1
2
3 assessment of study methods, bibliometric and funding information in a sample of 20,571 RCTs.
4
5 Python 3.6 and Stata 15 were used to assemble the database and conduct the analysis.
6
7
8

Data

9
10 Cochrane reviews constitute a valuable data source to assess biomedical research quality as they
11 follow strict methods and precise reporting guidelines defined in the Cochrane Handbook.[29-
12 30] This study does not involve new assessment of the methods and reporting of included RCTs,
13 but relies entirely on the assessments available in the Cochrane reviews, which are systematically
14 performed by two expert reviewers who compare their assessments and reach consensus on the
15 final assessment.[29] The research method dimensions evaluated in Cochrane reviews include
16 random sequence generation, allocation concealment, blinding of participants and personnel,
17 blinding of outcome assessment, incomplete outcome data, and selective reporting (detailed in
18 Supplementary Table A1).[31]

19
20 The database assembly had seven steps: (1) All included references were extracted from each
21 review, including PubMed identifiers. (2) All risk of bias assessments on the six dimensions of
22 the 2011 update of the Cochrane Risk of Bias Assessment Tool (see Table A1) were extracted
23 from each review. Each assessment included three variables: bias type (e.g., random sequence
24 generation), judgement (e.g., low risk) and support for judgement (e.g., computer random
25 number generator). (3) Each RCT was matched with its main published reference as identified by
26 Cochrane reviewers. (4) PubMed records corresponding to these publications, including
27 bibliometric information and first author affiliation, were retrieved using the E-utilities public
28 API. (5) Affiliation information for other authors (not available from PubMed over the study
29 period) was retrieved from SCOPUS. (6) Full-text for references with PubMed identifier were
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 retrieved from the Harvard Library. (7) Industry funding information was extracted from the full-
4 text PDFs.
5
6

7
8 Sector affiliation with university, government, hospital, non-profit, top pharmaceutical company
9 or other firm, as well as geographic variables were derived from the first author affiliation
10 address. Top 25 Universities were identified using the 2007 Academic Ranking of World
11 Universities in Clinical Medicine and Pharmacy (see supplementary material, Appendix A).
12
13 Firms were classified as top pharmaceutical companies or other firms using the listing of
14 pharmaceutical companies with a revenue greater than \$10 billion in any year since 2011 (see
15 supplementary material, Appendix B). Technologies were retrieved from the keywords and
16 abstracts of the Cochrane Reviews. Private funding information was retrieved from the full-text
17 PDF of the main reference.
18
19

20 Sample

21
22
23
24
25
26
27
28
29

30 Figure 1 summarizes the data flow. All RCTs assessed for risk of bias after 2011 (update of the
31 Risk of Bias Assessment Tool) and through October 2017 were considered for inclusion
32 (N=63,748 RCTs included in 4,195 reviews). This list of Cochrane reviews is reported in
33 Appendix C.

34
35 Criteria for study inclusion were: (1) the review included all six assessments (to allow
36 comparison of the overall use of adequate methods, inadequate methods and poor reporting
37 across reviews) (1,988 reviews dropped), (2) the article reporting the study was referenced in
38 PubMed (to allow bibliometric data to enter the analysis)(N=9,201 RCTs dropped) and (3)
39 Duplicates were removed. (4) RCTs assessed multiple times with different outcomes (e.g., high
40 risk in one review, unclear risk in another) were dropped. (N=404 RCTs dropped).
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Applying these criteria, the analysis sample for the descriptive statistics and the time-series of
4 methods included 20,571 RCTs. A full-text PDF was available from the Harvard Library for
5 11,686 RCTs. This subsample was needed to retrieve private funding information from the full-
6 text of the paper and constitutes the analysis sample for those regressions including funding
7 information.
8
9

10
11 **Analysis**
12
13

14
15 The outcomes were risk of bias on the six assessed methodological dimensions and RCT-level
16 assessment of adequate methods, inadequate methods or poor reporting. The six methodological
17 dimensions assessed included (1) random sequence generation, (2) allocation concealment, (3)
18 blinding of participants and personnel, (4) blinding of outcome assessment, (5) incomplete
19 outcome data and (6) selective reporting (detailed in Supplementary Table A1). The category
20 “Other bias” was not used in this study, as it includes concerns not necessarily about methods or
21 reporting, such as conflicts of interest.
22
23

24
25 Following guidelines for assessing the quality of evidence[31] and previous empirical work [7],
26 the RCT-level assessment was “adequate methods” if the study was at low risk of bias on all
27 dimensions assessed. It was “inadequate methods” if the study was at high risk of bias for one or
28 more reasons. It was “poorly reported” if the reviewers did not have enough information to
29 assess whether the methods used were adequate or inadequate (if the study was at “unclear” risk
30 of bias for at least one reason).
31
32

33 Several reasons support the use of at least one high risk of bias assessment as the definition for
34 inadequate methods. Some risk of bias domains might translate into more statistical bias than
35 others, but empirical evidence on the relative importance of the risk of bias domains is limited,
36
37

and the effect of several versus one high risk assessment on research outcomes is unknown[32,33] The empirical relationship between risk of bias assessments and research outcomes (including actual statistical bias) requires further research.

There is also a theoretical reason to use at least one high risk of bias assessment as the definition of method inadequacy. Cochrane risk of bias domains can be mapped to important conditions to make RCTs valuable. If not truly randomized or if differences between the treatment and control group are introduced post-randomization, a RCT may not produce an unbiased estimate of the treatment effect.[34] These two conditions imply that one inadequacy in the randomization process (non-random sequence generation or inadequate allocation concealment), or one difference introduced post randomization between the treatment and control groups (through inadequate blinding of participants, personnel, or outcome assessors) or after the trial (due to incomplete outcome data or selective reporting) should be the default threshold for assessing methods adequacy.

Two analyses were performed. The first reports the time series of the proportion of RCTs using adequate methods, inadequate methods and poor reporting, for each dimension and in aggregate. The second tests whether adequate methods, inadequate methods and poor reporting are associated with funding source (NIH grant or industry funding), sector affiliation of first author (Top University, Other University, Government, Hospital, Non-Profit, Top Pharmaceutical Company, Other Firm), other industry affiliation, clinical trial registration status, study novelty (first or subsequent study on a particular research question), team characteristics (number of authors and international collaboration), technology (drug, device, surgery, behavioral intervention or other intervention), and geography of first author (Canada, Europe, UK, USA, or other country). A multinomial logit model using these variables predicts overall adequate

1
2
3 methods, inadequate methods and poor reporting, as well as risk of bias along each dimension
4 assessed.
5
6
7
8

Patient involvement

9
10 Patients were not involved in any aspect of the study design, conduct, or in the development of
11 the research question or outcome measures. As a meta-research study, based on existing
12 published research, there was no patient recruitment for data collection.
13
14
15

RESULTS

Prevalence of Adequate Methods, Inadequate Methods, and Poor Reporting

22 Table 1 presents descriptive statistics. Only 5.7% of RCTs used adequate methods on all six
23 dimensions (N=1,173). 59.3% used inadequate methods on at least one dimension (N=12,190)
24 and 35.0% were poorly reported (N=7,208).
25
26
27
28
29
30
31

32 Figure 2 shows the proportion of RCTs at low, high or unclear risk of bias for random sequence
33 generation, allocation concealment, blinding of participants and personnel, blinding of outcome
34 assessment, incomplete outcome data and selective reporting, for all RCTs assessed on all six
35 dimensions (N=20,571). 38% of trials used inadequate methods for blinding of participants and
36 personnel. 15 to 20% of trials used inadequate methods for blinding of outcome assessment
37 (20%), incomplete outcome data (19%) and selective reporting (15%). The proportion of trials
38 using inadequate methods for random sequence generation and allocation concealment was
39 lowest (respectively 5% and 7%), but these two dimensions were frequently poorly reported
40 (respectively 47% and 58% of trials).
41
42
43
44
45
46
47
48
49
50
51
52
53

Methods and reporting over time

Figure 3 shows the overall proportion of RCTs using adequate methods, inadequate methods and poorly reported methods by year of publication. The proportion of poorly reported RCTs decreased, 5 percentage points per decade, from 42.5% in 1990 to 30.2% in 2015. The proportion of RCTs using adequate methods increased linearly, 3 percentage points per decade, from 2.6% in 1990 to 10.3% in 2015. The proportion of RCTs using inadequate methods increased from 54.9% in 1990 to 59.5% in 2015.

Reporting improved on all dimensions. The proportion of RCTs using adequate methods for random sequence generation, allocation concealment, blinding of outcome assessment, incomplete outcome data and selective reporting increased. In contrast, the proportion of trials using inadequate methods for blinding of participants and personnel increased.

Figure 4 provides graphs similar to figure 3 for all RCTs assessed on at least one dimension ($N=63,748$). Similar patterns suggest that the evolution over time observed for the RCTs assessed on all dimensions ($N=20,571$) reflects the evolution over time in all RCTs assessed on at least one dimension.

Factors associated with methods and reporting

Figure 5 reports regression results from a multinomial logit model predicting overall quality. Tables A2 and A3 (Supplementary material) report all regression results.

Public funding was not associated with the overall use of adequate methods. However, NIH funded RCTs were less likely to use inadequate methods for random sequence generation ($RR=0.29, p<0.001$) and allocation concealment ($RR=0.51, p<0.001$). Industry funded RCTs were slightly more likely to use adequate methods ($RR=0.84, p<0.05$), because of better blinding of participants and personnel ($RR=0.87, p<0.05$).

1
2
3 First author affiliation with a top pharmaceutical company was associated with increased use of
4 adequate methods ($RR=0.43$, $p<0.01$). First author affiliation with top universities was not.
5
6

7
8 Registered trials ($RR=0.42$, $p<0.001$), larger authorship teams ($RR=0.95$, $p<0.001$), international
9 teams ($RR=0.51$, $p<0.01$) and RCTs on drugs ($RR=0.50$, $p<0.001$) were less likely to use
10 inadequate methods. RCTs on medical devices were more likely to use inadequate methods
11 ($RR=1.71$, $p<0.01$).
12
13

14 DISCUSSION 15 16

17 In 1951, the first review assessing the quality of clinical trials found that only 27 of 100 were
18 well controlled[35,36]. Since, a steady stream of scholarly work periodically voiced concerns
19 about the quality of medical research[37,38,1-8]. Recent medical reversals[39], and the
20 reproducibility crisis[40], have sharpened focus on medical research quality. Newly available
21 large scale data, and data science techniques provide powerful tools to measure the overall
22 magnitude of the problem, investigate its determinants, and provide an evidence base to inform
23 the design and evaluation of future interventions. This study assessed whether methods and
24 reporting improved over time and identified the characteristics of better and worse RCTs.
25
26

27 This study has six main results. First, in a large sample of RCTs assessed in systematic reviews,
28 only 5.7% used adequate methods, 59.3% used inadequate methods, and 35.0% were poorly
29 reported. Since the 1990s, reporting has improved. But in parallel with this improvement in
30 reporting, the proportion of trials using both adequate and inadequate methods has increased.
31
32

33 The overall proportion of poorly reported trials decreased by about 5 percentage points per
34 decade. This is good news but much remains to be done. At the current rate of improvement, it
35 would take 50 years for 95% of RCTs to be adequately reported. These results are consistent
36
37

1
2
3 with previous research finding improvements in reporting in several clinical areas such as
4 physiotherapy[10], and dentistry[26]. The trends for each dimension assessed separately are also
5 very similar to those found in another large sample of RCTs.[25]
6
7

8 These improvement in reporting happened over a period of time when the Consolidated
9 Standards of Reporting Trials (CONSORT) statement, a minimum set of evidence-based
10 reporting recommendations, and other initiatives, such as the EQUATOR Network, developed to
11 improve reporting practices.[41-45]. Since the 1990s, the CONSORT statement has been
12 endorsed by over 50% of the core clinical journals indexed in PubMed and may improve
13 reporting of RCTs they publish.[46] Spurred by the CONSORT statement, the EQUATOR
14 (Enhancing the QUAlity and Transparency Of health Research) Network, was launched in 2008
15 in the UK to improve the reliability of medical publications by promoting transparent and
16 accurate reporting of health research.[47] Since, it has developed into a global initiative aiming
17 to improve research reporting worldwide.[36]

18 In parallel with this improvement in reporting, the proportion of trials using both adequate and
19 inadequate methods has increased. The linear increase in the proportion of RCTs using adequate
20 methods is heartening. However, improvement in the use of adequate methods is even slower
21 than improvement in reporting. At the current rate of improvement (3 percentage points per
22 decade), it would take more than a century for half the RCTs to use adequate methods. This
23 finding is consistent with previous empirical results in small samples,[23] but contrasts with
24 research in larger samples analyzing each methodological dimension separately to conclude that
25 methods improved over time.[25]

26 Second, NIH funded RCTs were not more likely to use adequate methods. This is surprising
27 given the rigorous grant application process, shown to select better scientific proposals,[48] and
28

1
2
3 the public stakes in the reliability of publicly funded research.[49] Notably, the efforts of the
4 NIH to address the reproducibility crisis began just at the end of the study period.[50]
5
6

7 Third, top pharmaceutical company affiliation was significantly associated with better methods.
8 Affiliation with other companies was not. Heterogeneity across firms may explain inconsistency
9 of previous research on the effect of industry funding or affiliation on research methods and
10 outcomes. [28,51]

11
12
13 Fourth, University prestige was not associated with greater use of adequate methods. The current
14 scientific reward system focuses on numbers of publications and citations rather than the
15 assessment of research methods.[52] The resulting incentives affect both scientists and
16 institutions, as through the allocation of grant funding.[53,54] Thus, in a climate of
17 hypercompetition,[55] the use of adequate methods and reporting might yield little reward while
18 exposing scientists to better informed scrutiny.

19
20 Fifth, team size and international collaboration were associated with greater use of adequate
21 methods. Increasing the number of authors by one was associated with a small, but highly
22 significant improvement in methods and reporting. Many RCTs are published by large teams so
23 it is not surprising that the effect of one additional author was small. But this effect was also
24 highly significant, consistent with previous research finding that larger teams and international
25 teams produce more frequently cited research.[56,57] Other team characteristics were associated
26 with performance in other settings, opening avenues for future research.[58,59]

27
28 Finally, RCTs on drugs were more likely to use adequate methods than RCTs on other
29 interventions, while RCTs on devices were more likely to use inadequate methods. In many
30 countries, trials on drugs are more tightly regulated than trials on devices. In the US, under the
31 Federal Food, Drug, and Cosmetic Act (FDCA, 1938), drugs and devices face different
32

1
2 premarket review and post-market compliance requirements. The finding is also consistent with
3 specific barriers to the conduct of RCTs on medical devices, in particular for randomization and
4 blinding, and with the lack of scientific advice and regulations for medical device trials [60].
5
6

7 RCTs on drugs were using better methods and reporting than RCTs on other interventions, but
8 much remains to be done. This finding is consistent with previous work showing that even RCTs
9 used in the drug approval process frequently use inadequate methods and reporting.[61]
10
11

12 Future research should carefully evaluate the effect of method adequacy on research outcomes,
13 and identify successful strategies and incentives to accelerate the diffusion of good reporting
14 practices and the adoption of adequate methods. Given the size of the medical research industry
15 and its effect on human lives, successful evidence based policies could have tremendous impact.
16
17

27 Limitations

28
29

30 PubMed identifier, full-text and/or funding information were not available for all RCTs. 30.5%
31 of RCTs (unpublished or published in journals not indexed in PubMed) did not have a PubMed
32 identifier. 43.2% of RCTs with PubMed identifier did not have a full-text available from the
33 Harvard Library. 23.6% of included RCTs were reported in articles disclosing NIH or industry
34 funding. Classification of sectors relies on primary reported affiliation. This paper does not
35 identify causal mechanisms explaining biomedical research quality.
36
37

38 Cochrane reviewers may have been able to obtain more information on more recent RCTs (from
39 authors, registries, or protocols rather than the primary report), suggesting that some of the
40 apparent improvement in reporting may in fact be an improvement in access to study details.
41
42

52 CONCLUSION

53
54
55
56
57
58
59

Even though reporting has improved since 1990, the proportion of RCTs using inadequate methods is high (59.3%) and increasing, potentially slowing progress in medical knowledge and contributing to the reproducibility crisis. Stronger incentives for the use of adequate methods are needed.

Contributorship statement

Maryaline Catillon designed the study, performed the analysis, interpreted the results, wrote the manuscript and approved the final version to be published. Maryaline Catillon accepts full responsibility for the work and the conduct of the study, had access to the data, and controlled the decision to publish.

Acknowledgments

The author thanks David Cutler, Richard Freeman, Mack Lipkin, Ariel Stern, Richard Zeckhauser and the participants at the NBER-IFS International Network on the Value of Medical Research meetings for helpful conversations and feedback, and Harvard Business School Research Computing Services for technical advice and support. The author also thanks the editors and the two referees, Paul Glasziou and Simon Gandevia, for their most helpful and generous feedback and clear guidance.

Funding Statement

Maryaline Catillon gratefully acknowledges support by the National Institute on Aging of the National Institutes of Health under Award Number R24AG048059 to the National Bureau of Economic Research (NBER). The content of this article is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health or the NBER.

Competing Interests Statement

Maryaline Catillon has completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declares: the author reports grants from the National Institute on Aging of the National Institutes of Health during the conduct of the study.

Ethical approval

Not applicable. This is a meta-research study.

Data sharing

All data sources necessary to reproduce the analysis are described in the main text or the supplementary material. No additional data available.

Licence statement

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (“BMJ”) its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in our licence.

Bibliography

- 1
- 2
- 3
- 4
- 5
- 6 1. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research
7 evidence. *The Lancet*. 2009 Jul 4;374(9683):86-9.
- 8
- 9
- 10 2. Macleod MR, Michie S, Roberts I, Dirmagl U, Chalmers I, Ioannidis JP, Salman RA, Chan
11 AW, Glasziou P. Biomedical research: increasing value, reducing waste. *The Lancet*. 2014
12 Jan 11;383(9912):101-4.
- 13
- 14 3. Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Gürmezoglu AM, Howells
15 DW, Ioannidis JP, Oliver S. How to increase value and reduce waste when research
16 priorities are set. *The Lancet*. 2014 Jan 11;383(9912):156-65.
- 17
- 18 4. Glasziou P, Altman DG, Bossuyt P, Boutron I, Clarke M, Julious S, Michie S, Moher D,
19 Wager E. Reducing waste from incomplete or unusable reports of biomedical research. *The
20 Lancet*. 2014 Jan 18;383(9913):267-76.
- 21
- 22 5. Ioannidis JP, Greenland S, Hlatky MA, Khoury MJ, Macleod MR, Moher D, Schulz KF,
23 Tibshirani R. Increasing value and reducing waste in research design, conduct, and
24 analysis. *The Lancet*. 2014 Jan 11;383(9912):166-75.
- 25
- 26 6. Moses H, Matheson DH, Cairns-Smith S, George BP, Palisch C, Dorsey ER. The anatomy
27 of medical research: US and international comparisons. *Jama*. 2015 Jan 13;313(2):174-89.
- 28
- 29 7. Yordanov Y, Dechartres A, Porcher R, Boutron I, Altman DG, Ravaud P. Avoidable waste
30 of research related to inadequate methods in clinical trials. *bmj*. 2015 Mar 24;350:h809.
- 31
- 32 8. Moher D, Glasziou P, Chalmers I, Nasser M, Bossuyt PM, Korevaar DA, Graham ID,
33 Ravaud P, Boutron I. Increasing value and reducing waste in biomedical research: who's
34 listening?. *The Lancet*. 2016 Apr 9;387(10027):1573-86.
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 9. Lee KP, Schotland M, Bacchetti P, Bero LA. Association of journal quality indicators with
4 methodological quality of clinical research articles. *Jama*. 2002 Jun 5;287(21):2805-8.
5
6 10. Moseley AM, Herbert RD, Maher CG, Sherrington C, Elkins MR. Reported quality of
7 randomized controlled trials of physiotherapy interventions has improved over time.
8 *Journal of clinical epidemiology*. 2011 Jun 1;64(6):594-601.
9
10 11. Bala MM, Akl EA, Sun X, Bassler D, Mertz D, Mejza F, Vandvik PO, Malaga G, Johnston
11 BC, Dahm P, Alonso-Coello P. Randomized trials published in higher vs. lower impact
12 journals differ in design, conduct, and analysis. *Journal of clinical epidemiology*. 2013 Mar
13 1;66(3):286-95.
14
15 12. Lee SY, Teoh PJ, Camm CF, Agha RA. Compliance of randomized controlled trials in
16 trauma surgery with the CONSORT statement. *Journal of Trauma and Acute Care Surgery*.
17 2013 Oct 1;75(4):562-72.
18
19 13. Agha RA, Camm CF, Doganay E, Edison E, Siddiqui MR, Orgill DP. Randomised
20 controlled trials in plastic surgery: a systematic review of reporting quality. *European*
21 *journal of plastic surgery*. 2014 Feb 1;37(2):55-62.
22
23 14. Chen B, Liu J, Zhang C, Li M. A retrospective survey of quality of reporting on randomized
24 controlled trials of metformin for polycystic ovary syndrome. *Trials*. 2014 Dec;15(1):128.
25
26 15. Chen X, Zhai X, Wang X, Su J, Li M. Methodological reporting quality of randomized
27 controlled trials in three spine journals from 2010 to 2012. *European Spine Journal*. 2014
28 Aug 1;23(8):1606-11.
29
30 16. Kim KH, Kang JW, Lee MS, Lee JD. Assessment of the quality of reporting for treatment
31 components in Cochrane reviews of acupuncture. *BMJ open*. 2014 Jan 1;4(1):e004136.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 17. Lempesi E, Koletsi D, Fleming PS, Pandis N. The reporting quality of randomized
4 controlled trials in orthodontics. *Journal of Evidence Based Dental Practice*. 2014 Jun
5 1;14(2):46-52.
6
7 18. Yao AC, Khajuria A, Camm CF, Edison E, Agha R. The reporting quality of parallel
8 randomised controlled trials in ophthalmic surgery in 2011: a systematic review. *Eye*. 2014
9 Nov;28(11):1341.
10
11 19. Zhuang L, He J, Zhuang X, Lu L. Quality of reporting on randomized controlled trials of
12 acupuncture for stroke rehabilitation. *BMC complementary and alternative medicine*. 2014
13 Dec;14(1):151.
14
15 20. Chen Z, Chen Y, Zeng J, Wang Y, Ye T, Zhou Q, Du X, Su W, Ding Z. Quality of
16 randomized controlled trials reporting in the treatment of melasma conducted in China.
17 *Trials*. 2015 Dec;16(1):156.
18
19 21. Glujovsky D, Boggino C, Riestra B, Coscia A, Sueldo CE, Ciapponi A. Quality of
20 reporting in infertility journals. *Fertility and sterility*. 2015 Jan 1;103(1):236-41.
21
22 22. Kloukos D, Papageorgiou SN, Doulis I, Petridis H, Pandis N. Reporting quality of
23 randomised controlled trials published in prosthodontic and implantology journals. *Journal*
24 of oral rehabilitation. 2015 Dec;42(12):914-25.
25
26 23. Reveiz L, Chapman E, Asial S, Munoz S, Bonfill X, Alonso-Coello P. Risk of bias of
27 randomized trials over time. *Journal of clinical epidemiology*. 2015 Sep 1;68(9):1036-45.
28
29 24. Zhai X, Wang Y, Mu Q, Chen X, Huang Q, Wang Q, Li M. Methodological reporting
30 quality of randomized controlled trials in 3 leading diabetes journals from 2011 to 2013
31 following CONSORT statement: a system review. *Medicine*. 2015 Jul;94(27).
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 25. Dechartres A, Trinquart L, Atal I, Moher D, Dickersin K, Boutron I, Perrodeau E, Altman
4 DG, Ravaud P. Evolution of poor reporting and inadequate methods over time in 20 920
5 randomised controlled trials included in Cochrane reviews: research on research study.
6
7 BMJ. 2017 Jun 8;357:j2490.
- 8
9 26. Saltaji H, Armijo-Olivo S, Cummings GG, Amin M, Flores-Mir C. Randomized clinical
10 trials in dentistry: Risks of bias, risks of random errors, reporting quality, and methodologic
11 quality over the years 1955–2013. PloS one. 2017 Dec 22;12(12):e0190089.
- 12
13 27. Karlsen AP, Dahl JB, Mathiesen O. Evolution of bias and sample size in postoperative pain
14 management trials after hip and knee arthroplasty. Acta Anaesthesiologica Scandinavica.
15 2018 May;62(5):666-76.
- 16
17 28. Salandra R. Knowledge dissemination in clinical trials: exploring influences of
18 institutional support and type of innovation on selective reporting. Research Policy. 2018
19 Sep 1;47(7):1215-28.
- 20
21 29. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of
22 Interventions [updated March 2011]. The Cochrane Collaboration 2011; Available from
23 http://handbook.cochrane.org/.
- 24
25 30. Page MJ, Shamseer L, Altman DG, Tetzlaff J, Sampson M, Tricco AC, Catalá-López F, Li
26 L, Reid EK, Sarkis-Onofre R, Moher D. Epidemiology and reporting characteristics of
27 systematic reviews of biomedical research: a cross-sectional study. PLoS medicine. 2016
28 May 24;13(5):e1002028.
- 29
30 31. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz
31 KF, Weeks L, Sterne JA. The Cochrane Collaboration's tool for assessing risk of bias in
32 randomised trials. Bmj. 2011 Oct 18;343:d5928.

- 1
2
3 32. Savović J, Turner RM, Mawdsley D, Jones HE, Beynon R, Higgins JP, Sterne JA.
4 Association between risk-of-bias assessments and results of randomized trials in cochrane
5 reviews: the ROBES meta-epidemiologic study. *American Journal of Epidemiology*. 2017
6 Oct 19;187(5):1113-22.
7
8 33. Rhodes KM, Turner RM, Savović J, Jones HE, Mawdsley D, Higgins JP. Between-trial
9 heterogeneity in meta-analyses may be partially explained by reported design
10 characteristics. *Journal of clinical epidemiology*. 2018 Mar 1;95:45-54.
11
12 34. Deaton A, Cartwright N. Understanding and misunderstanding randomized controlled
13 trials. *Social Science & Medicine*. 2018 Aug 1;210:2-1.
14
15 35. Ross OB. Use of controls in medical research. *Journal of the American Medical
16 Association*. 1951 Jan 13;145(2):72-5.
17
18 36. Altman, D.G. and Simera, I., 2016. A history of the evolution of guidelines for reporting
19 medical research: the long road to the EQUATOR Network. *Journal of the Royal Society
20 of Medicine*, 109(2), pp.67-77.
21
22
23 37. DerSimonian R, Charette LJ, McPeek B, Mosteller F. Reporting on methods in clinical
24 trials. *New England Journal of Medicine*. 1982 Jun 3;306(22):1332-7.
25
26
27 38. Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical trials. *New
28 England journal of medicine*. 1987 Aug 13;317(7):426-32.
29
30
31 39. Prasad V, Vandross A, Toomey C, Cheung M, Rho J, Quinn S, Chacko SJ, Borkar D, Gall
32 V, Selvaraj S, Ho N. A decade of reversal: an analysis of 146 contradicted medical
33 practices. In *Mayo Clinic Proceedings* 2013 Aug 1 (Vol. 88, No. 8, pp. 790-798). Elsevier.
34
35 40. Baker M. 1,500 scientists lift the lid on reproducibility. *Nature News*. 2016 May
36 26;533(7604):452.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 41. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF,
4 Simel D, Stroup DF. Improving the quality of reporting of randomized controlled trials:
5 the CONSORT statement. *Jama*. 1996 Aug 28;276(8):637-9.
6
7 42. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations
8 for improving the quality of reports of parallel group randomized trials. *BMC medical*
9 research methodology. 2001 Dec;1(1):2.
10
11 43. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for
12 reporting parallel group randomised trials. *BMC medicine*. 2010 Dec;8(1):18.
13
14 44. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang
15 T. The revised CONSORT statement for reporting randomized trials: explanation and
16 elaboration. *Annals of internal medicine*. 2001 Apr 17;134(8):663-94.
17
18 45. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D,
19 Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines
20 for reporting parallel group randomised trials. *Journal of clinical epidemiology*. 2010 Aug
21 1;63(8):e1-37.
22
23 46. Turner L, Shamseer L, Altman DG, Schulz KF, Moher D. Does use of the CONSORT
24 Statement impact the completeness of reporting of randomised controlled trials published
25 in medical journals? A Cochrane review a. Systematic reviews. 2012 Dec;1(1):60.
26
27 47. Altman DG, Simera I, Hoey J, Moher D, Schulz K. EQUATOR: reporting guidelines for
28 health research. *The Lancet*. 2008 Apr 5;371(9619):1149-50.
29
30 48. Li D, Agha L. Big names or big ideas: do peer-review panels select the best science
31 proposals?. *Science*. 2015 Apr 24;348(6233):434-8.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 49. Sampat BN. Mission-oriented biomedical research at the NIH. *Research Policy*. 2012 Dec
4 1;41(10):1729-41.
5
6
7 50. Collins FS, Tabak LA. NIH plans to enhance reproducibility. *Nature*. 2014 Jan
8 30;505(7485):612-3.
9
10
11 51. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research
12 outcome. *Cochrane Database Syst Rev*. 2012 Dec 12;12(12).
13
14
15 52. Stephan PE. How economics shapes science. Cambridge, MA: Harvard University Press;
16 2012 Sep.(p.228-241)
17
18
19 53. Ali MM, Bhattacharyya P, Olejniczak AJ. The effects of scholarly productivity and
20 institutional characteristics on the distribution of federal research grants. *The Journal of
21 Higher Education*. 2010 Mar 1;81(2):164-78.
22
23
24
25
26
27 54. Alberts B, Kirschner MW, Tilghman S, Varmus H. Rescuing US biomedical research from
28 its systemic flaws. *Proceedings of the National Academy of Sciences*. 2014 Apr
29 22;111(16):5773-7.
30
31
32
33
34 55. Edwards MA, Roy S. Academic research in the 21st century: Maintaining scientific
35 integrity in a climate of perverse incentives and hypercompetition. *Environmental
36 Engineering Science*. 2017 Jan 1;34(1):51-61.
37
38
39
40
41 56. Wuchty S, Jones BF, Uzzi B. The increasing dominance of teams in production of
42 knowledge. *Science*. 2007 May 18;316(5827):1036-9.
43
44
45
46 57. National Research Council. Enhancing the effectiveness of team science. National
47 Academies Press; 2015 Jul 15.
48
49
50
51 58. Huckman RS, Staats BR, Upton DM. Team familiarity, role experience, and performance:
52 Evidence from Indian software services. *Management Science*. 2009 Jan;55(1):85-100.
53
54
55
56
57
58
59
60

- 1
2
3 59. Huckman RS, Staats BR. Fluid tasks and fluid teams: The impact of diversity in experience
4 and team familiarity on team performance. *Manufacturing & Service Operations*
5
6 Management. 2011 Jul;13(3):310-28.
7
8
9
10 60. Neugebauer EA, Rath A, Antoine SL, Eikermann M, Seidel D, Koenen C, Jacobs E, Pieper
11 D, Laville M, Pitel S, Martinho C. Specific barriers to the conduct of randomised clinical
12 trials on medical devices. *Trials*. 2017 Dec;18(1):427.
13
14 61. Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS. Clinical trial evidence
15 supporting FDA approval of novel therapeutic agents, 2005-2012. *Jama*. 2014 Jan
16 22;311(4):368-77.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

List of Figures and Tables

Table 1: Descriptive statistics

Figure 1: Data flow

Figure 2: Proportion of RCTs at low risk, high risk and unclear risk, for each dimension assessed for all RCTs assessed on all six dimensions

Figure 3: Evolution of methods and reporting over time. Proportion of RCTs at low risk, high risk and unclear risk, for each dimension assessed for all RCTs assessed on at least one dimension

Figure 4: Evolution of methods and reporting over time. Proportion of RCTs at low risk, high risk and unclear risk, for each dimension assessed for all RCTs assessed on at least one dimension

Figure 5: Main regression results predicting relative risk ratios for overall quality

	All	Adequate	Inadequate Methods	Poor Reporting
Sample 1	20,571 (100%)	1,173 (5.7%)	12,190 (59.3%)	7,208 (35.0%)
Sample 2 (with full text)	11,686 (56.8%)	833 (7.1%)	6,783 (58.0%)	4,070 (34.8%)
Funder type				
NIH Grant	2,147 (10.4%)	146 (6.8%)	1,282 (59.7%)	719 (33.5%)
Industry funding	2,725 (13.2%)	283 (10.2%)	1,464 (52.6%)	978 (35.1%)
First Author Affiliation				
Top University	1,063 (5.2%)	51 (4.8%)	601 (56.5%)	411 (38.7%)
Other University	11,120 (54.1%)	677 (6.1%)	6,589 (59.3%)	3,854 (34.7%)
Hospital	4,450 (21.6%)	185 (4.2%)	2,608 (58.6%)	1,657 (37.2%)
Government	1,744 (8.5%)	108 (6.2%)	1,071 (61.4%)	565 (32.4%)
Non-Profit	751 (3.7%)	48 (6.4%)	454 (60.5%)	249 (33.2%)
Top Pharma	239 (1.2%)	26 (10.9%)	115 (48.1%)	98 (41.0%)
Other Firm	195 (1.0%)	13 (6.7%)	115 (59.0%)	67 (34.3%)
Other research institution	200 (1.0%)	18 (9.0%)	120 (60.0%)	62 (31.0%)
Other industry affiliation	570 (2.8%)	44 (7.7%)	287 (50.4%)	239 (41.9%)
Registered RCTs (NCT)	1,888 (9.2%)	298 (15.8%)	1,011 (53.6%)	579 (30.7%)
Novelty				
First study	2,284 (11.1%)	126 (5.5%)	1,390 (60.9%)	768 (33.6%)
Second study	2,124 (10.3%)	127 (6.0%)	1,262 (59.4%)	735 (34.6%)
Team characteristics				
Number of Authors - Avg (Std)	6.15 (3.9)	8.04 (5.5)	5.99 (3.8)	6.13 (6.8)
International	748 (3.64%)	60 (8.02%)	379 (50.67%)	309 (41.31%)
Technology*				
Drug	13,485 (65.6%)	914 (6.8%)	7,306 (54.2%)	5,265 (39.0%)
Device	5,347 (26.0%)	235 (4.4%)	3,366 (63.0%)	1,746 (32.7%)
Procedure	8,710 (42.3%)	460 (5.3%)	4,925 (56.5%)	3,325 (38.2%)
Behavioral	4,543 (22.1%)	122 (2.7%)	3,239 (71.3%)	1,182 (26.0%)
Other	1,199 (5.8%)	78 (6.5%)	819 (68.3%)	302 (25.2%)
Geography**				
Canada	680 (3.3%)	61 (9.0%)	362 (53.2%)	257 (37.8%)
Europe	4,467 (21.7%)	254 (5.7%)	2,693 (60.3%)	1,520 (34.0%)
UK	2,306 (11.2%)	154 (6.7%)	1,399 (60.7%)	753 (32.7%)
USA	4,465 (21.7%)	284 (6.4%)	2,592 (58.1%)	1,589 (35.6%)
Other	4,165 (20.3%)	253 (6.1%)	2,444 (58.7%)	1,468 (35.3%)
Publication Year - Avg (Std)	2001 (10.2)	2005 (8.1)	2001 (10.4)	2001 (9.9)
Study Age at Review - Avg (Std)	13.44 (10.1)	9.81 (8.0)	13.39 (10.3)	14.14 (9.9)

Table 1. Descriptive statistics. Unless otherwise specified, column 1 reports the number of RCTs and their proportion as of the total number of RCTs (N=20,571). A RCT uses adequate methods if it is at “low risk of bias” on all six dimensions assessed (see Table A1). Methods are inadequate if a RCT is at “high risk of bias” for at least one reason. Methods are poorly reported there is no evidence of methods inadequacy, but at least one assessment is “unclear risk of bias”. Columns 2-4 report the number of RCTs in each category and their proportion as of the number of RCTs in column 1. For number of authors, publication year and study age at time of review, Table 1 reports the average and standard deviation. *One RCT can belong to several technology categories. ** For some RCTs, affiliation address is not provided.




Fig.1. Data Flow




Fig.2. Number and proportion of RCTs at low risk of bias, high risk of bias and unclear risk of bias (N=20,571)




Fig.3. Evolution of methods and reporting over time. A.: Proportion of RCTs using adequate methods, inadequate methods and poorly reported. B. to G.: Proportion of RCTs at low risk of bias, high risk of bias and unclear risk of bias for each dimension assessed. See Table A1 for the definition of each dimension. N=20,571 RCTs. An observation is a RCT assessed on all six dimensions. See Figure 1 for more detailed information about the sample.




Fig.4. Same figure as Figure 3, but including all RCTs assessed on at least one dimension (as opposed to RCTs assessed on all six dimensions). Evolution of methods and reporting over time. A.: Proportion of RCTs using adequate methods, inadequate methods and poorly reported. B. to G.: Proportion of RCTs at low risk of bias, high risk of bias and unclear risk of bias for each dimension assessed. See Table A1 for the definition of each dimension.




Fig.5. Main regression results (relative risk ratios and 95% confidence intervals) from the multinomial logit model predicting overall RCT quality. The arrow heads on the confidence intervals indicate that the upper bound of the 95% confidence interval is greater than 2. The dependent variable is a categorical variable and can take three values: adequate methods, inadequate methods and poor reporting. Adequate methods is the reference outcome category. The regression sample includes 11,686 RCTs with accessible full-text. See Figure 1 for more detailed information about the sample. The relative risk ratios represent the likelihood of a RCT with specific funding, sector, study/team, technology and country characteristics using inadequate methods (or being poorly reported), as compared to the likelihood of a RCT in a reference group without these characteristics using inadequate methods (or being poorly reported). In the regression, sector, technology and country are categorical variables. The omitted category for sector is other university. The omitted category for technology is other interventions. The omitted category for country is other countries. The regression includes topic and year fixed effects. The regression coefficients are reported in Table A2. Regression results predicting relative risk ratios for high or unclear risk of bias on each dimension assessed (as opposed to overall quality) are reported in Table A3.

289x216mm (72 x 72 DPI)

Supplementary Materials, Tables and Figures

Table A1: Cochrane Risk of Bias Assessment Tool

Table A2: Main regression results predicting adequate methods, inadequate methods and poor reporting

Table A3: Regression results predicting relative risk ratios for each dimension

Appendix A: List of top 25 universities in clinical medicine and pharmacy

Appendix B: List of top pharmaceutical companies

Appendix C: List of included Cochrane reviews

Table A1: Cochrane Risk of Bias Assessment Tool

Bias domain	Source of bias	Support for judgement	Review Authors judgement
Selection bias	Random sequence generation	Describe the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.	Selection bias (biased allocation to intervention) due to inadequate generation of a randomized sequence.
Selection bias	Allocation concealment	Describe the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been foreseen before or during enrollment.	Selection bias (biased allocation to interventions) due to inadequate concealment of allocations before assignment.
Performance bias	Blinding of participants and personnel	Describe all measures used, if any, to blind participants and researchers from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective.	Performance bias due to knowledge of the allocated intervention by participants and personnel during the study.
Detection bias	Blinding of outcome assessment	Describe all measures used, if any, to blind outcome assessment from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective.	Performance bias due to knowledge of the allocated intervention by outcome assessment.
Attrition bias	Incomplete outcome data	Describe the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. State whether attritions and exclusions were reported, the numbers in each intervention group (compared with total randomized participants), reasons for attrition or exclusion where reported, and any re-inclusion in the analysis for the review.	Attrition bias due to amount, nature or handling of incomplete outcome data
Reporting bias	Selective reporting	State how selective outcome reporting was examined and what was found.	Reporting bias due to selective outcome reporting.
Other bias	Anything else, pre-specified	State any important concerns about bias not covered in other domains in the tool.	Bias due to problems not covered elsewhere.

Source: Adapted from Higgins et al, 2011

1
2
3 **Table A2: Main regression results predicting adequate methods, inadequate methods and**
4 **poor reporting (Relative Risk Ratios)**

	Inadequate Methods	Poor Reporting
Funding		
NIH Grant	0.83	0.76
Industry	0.84*	0.85
Sector (First Author)		
Top University	0.76	0.76
Government	1.21	1.05
Hospital	1.19	1.16
Non-Profit	1.40	1.27
Top Pharma	0.43**	0.74
Other Firms	1.38	1.06
Sector (Other Author)		
Any Firm	0.66	0.79
Study/Team		
Registered trial	0.42***	0.45***
First Study	0.90	0.80
Second Study	0.85	0.81
Number of Authors	0.95***	0.97***
International	0.51**	0.64*
Technology		
Drug	0.50***	0.73*
Device	1.71**	1.23
Procedure	1.01	1.28
Behavioral	2.63***	1.44
Geography		
USA	1.11	1.39*
Canada	0.71	0.81
Europe	1.29*	1.22
UK	1.06	0.91

43 * p<0.05, ** p<0.01, *** p<0.001

44 This table presents main regression results (relative risk ratios and p-values) from estimating the multinomial logit
45 model predicting overall RCT quality. The dependent variable is a categorical variable and can take three values:
46 adequate methods, inadequate methods and poor reporting. Adequate methods is the reference outcome category.
47 The regression sample includes 11,686 RCTs with accessible full-text. See Figure A1 for more detailed information
48 about the sample. The relative risk ratios represent the likelihood of a RCT with specific funding, sector, study/team,
49 technology and country characteristics using inadequate methods (or being poorly reported), as compared to the
50 likelihood of a RCT in a reference group without these characteristics using inadequate methods (or being poorly
51 reported). In the regression, sector, technology and country are categorical variables. The omitted category for
52 sector is other university. The omitted category for technology is other interventions. The omitted category for
53 country is other countries. The regression includes topic and year fixed effects. These results are plotted in Figure 3.
54 Other regression results predicting relative risk ratios for high or unclear risk of bias on each dimension assessed (as
55 opposed to overall quality) are reported in Table A3.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
Table A3: Regression results predicting relative risk ratios for each dimension

	Random Sequence		Allocation Conceal.		Blinding PP		Blinding OA		Incomplete Data		Selective Reporting	
	High	Unclear	High	Unclear	High	Unclear	High	Unclear	High	Unclear	High	Unclear
Funding												
NIH Grant	0.29***	0.90	0.51***	0.93	1.12	1.06	1.01	0.93	1.03	1.04	1.03	0.99
Industry	1.03	1.07	1.18	1.06	0.87*	0.92	0.98	0.98	0.97	0.99	1.06	1.04
Sector (First Author)												
Top University	0.99	0.96	0.91	0.88	0.85	0.83	0.84	0.85	0.90	1.05	1.19	1.08
Government	0.91	1.01	0.85	0.98	1.00	0.96	1.00	0.92	1.29**	1.14	1.15	1.12
Hospital	1.07	1.06	1.05	1.00	1.08	0.96	1.12	1.04	1.05	0.95	0.89	1.03
Non-Profit	1.40	1.05	1.34	0.91	1.08	1.02	1.13	0.99	1.01	1.03	1.03	1.07
Top Pharma	0.49	0.96	0.60	0.83	0.34***	0.73	0.56*	0.74	0.86	0.61	0.70	0.59*
Other Firms	2.19	1.64*	2.01	1.60*	0.64	0.94	0.56	1.41	1.30	1.12	2.16*	1.05
Sector (Other Author)												
Any Firm	0.18**	0.92	0.53	1.04	0.65**	0.94	0.86	1.21	1.39*	1.06	0.94	1.02
Study/Team												
Registered trial	0.31***	0.42***	0.39***	0.41***	0.72***	0.60***	0.58***	0.63***	0.67***	0.71***	0.66***	0.52***
First Study	0.95	0.81**	1.09	0.84*	1.15	1.07	1.02	0.85	0.97	0.90	1.14	1.03
Second Study	1.00	0.83*	1.01	0.80**	1.02	1.03	1.04	1.01	0.87	0.88	1.06	1.01
Number of Authors	0.92***	0.97***	0.93***	0.95***	0.98**	0.96***	0.95***	0.97***	0.98*	0.99	0.99	0.96***
International	0.88	0.79*	0.53*	0.74**	0.79	0.94	0.73*	0.75*	0.91	0.86	0.66*	0.82
Technology												
Drug	0.66*	1.14	0.76	1.11	0.41***	0.48***	0.82	0.87	0.92	0.94	1.00	1.05
Device	1.31	1.02	1.34	1.10	1.52**	0.93	1.27	0.93	0.91	1.02	1.02	0.83
Procedure	0.90	1.21**	0.93	1.22*	0.91	1.24	1.18	1.22	0.85	1.06	1.06	1.13
Behavioral	0.88	1.03	1.21	1.16	2.83***	1.53**	2.09***	1.27	1.34**	1.18	0.89	1.41*
Geography												
USA	1.04	1.15	0.93	1.12	0.73***	0.95	0.81	1.02	1.23*	1.22*	0.96	0.93
Canada	0.55	0.69**	0.69	0.61***	0.75	0.75	0.85	0.66**	0.94	1.09	0.76	0.88
Europe	0.80	1.05	0.79	0.96	1.13	1.05	1.29**	1.09	1.13	0.97	1.01	0.92
UK	0.89	0.89	0.65**	0.67***	1.03	0.87	1.11	0.96	1.04	1.01	1.07	0.86

*p<0.05, **p<0.01, ***p<0.001

This table presents main regression results (relative risk ratios and p-values) from estimating the multinomial logit model predicting risk of bias for each dimension assessed. The dependent variable is a categorical variable and can take three values: low risk, high risk or unclear risk. Low risk is the reference outcome category. The regression sample includes 11,686 RCTs with accessible full-text. See Figure A1 for more detailed information about the sample. The relative risk ratios represent the likelihood of a RCT with specific funding, sector, study/team, technology and country characteristics being assessed at high risk (or unclear risk) as compared to the likelihood of a RCT in a reference group without these characteristics being assessed at high risk (or unclear risk). In the regression, sector, technology and country are categorical variables. The omitted category for sector is other university. The omitted category for technology is other interventions. The omitted category for country is other countries. The regression includes topic and year fixed effects. Other regression results predicting relative risk ratios for overall quality (as opposed to relative risk ratios for high or unclear risk of bias on each dimension assessed) are reported in Table A2.

1
2
3 **Appendix A: List of top 25 universities in clinical medicine and pharmacy (AWRU, 2007)**
4

- 5 • Harvard University
6 • University of California, San Francisco
7 • University of Washington
8 • The Johns Hopkins University
9 • Columbia University
10 • University of California, Los Angeles
11 • The University of Texas Southwestern Medical Center at Dallas
12 • University of Michigan - Ann Arbor
13 • Karolinska Institute
14 • University of Pittsburgh
15 • Stanford University
16 • Mayo Medical School
17 • University of Oxford
18 • University of Minnesota, Twin Cities
19 • University of Cambridge
20 • Yale University
21 • University College London
22 • The University of Texas M. D. Anderson Cancer Center
23 • University of Wisconsin - Madison
24 • Vanderbilt University
25 • University of Pennsylvania
26 • Duke University
27 • University of California, San Diego
28 • Tufts University
29 • The Imperial College of Science, Technology and Medicine
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Appendix B: List of top pharmaceutical companies used in this study (by revenue)

- Johnson & Johnson
- Roche
- Pfizer
- Novartis
- Bayer
- Merck & Co
- GlaxoSmithKline
- Sanofi
- Abbvie
- Abbott Laboratories
- Eli Lilly & Co
- Amgen
- Bristol-Myers Squibb
- Gilead Sciences
- AstraZeneca
- Teva Pharmaceutical Industries
- Boehringer Ingelheim
- Merck Group
- Novo Nordisk
- Takeda Pharmaceutical
- Allergan plc
- Shire
- Celgene
- Biogen

Appendix C: List of included Cochrane reviews (DOIs)

10.1002/14651858.CD007585.pub4
10.1002/14651858.CD009667.pub2
10.1002/14651858.CD003626.pub2
10.1002/14651858.CD006882.pub2
10.1002/14651858.CD008258.pub2
10.1002/14651858.CD007712.pub2
10.1002/14651858.CD003623.pub3
10.1002/14651858.CD007749.pub2
10.1002/14651858.CD008960.pub2
10.1002/14651858.CD004787.pub2
10.1002/14651858.CD002800.pub3
10.1002/14651858.CD006933.pub2
10.1002/14651858.CD006006.pub2
10.1002/14651858.CD003619.pub3
10.1002/14651858.CD009052.pub2
10.1002/14651858.CD006002.pub2
10.1002/14651858.CD009144.pub2
10.1002/14651858.CD007864.pub2
10.1002/14651858.CD006224.pub3
10.1002/14651858.CD007506.pub3
10.1002/14651858.CD007677.pub3
10.1002/14651858.CD008565.pub2
10.1002/14651858.CD005354.pub2
10.1002/14651858.CD006586.pub4
10.1002/14651858.CD008995.pub2
10.1002/14651858.CD003415.pub4
10.1002/14651858.CD002122.pub2
10.1002/14651858.CD004993.pub3
10.1002/14651858.CD008585.pub2
10.1002/14651858.CD006568.pub3
10.1002/14651858.CD003053.pub5
10.1002/14651858.CD006768.pub2
10.1002/14651858.CD002221.pub2
10.1002/14651858.CD008228.pub2
10.1002/14651858.CD001860.pub3
10.1002/14651858.CD007842.pub2
10.1002/14651858.CD007685.pub2
10.1002/14651858.CD007630.pub2
10.1002/14651858.CD004003.pub4
10.1002/14651858.CD006746.pub3

1
2
3 10.1002/14651858.CD004239.pub3
4 10.1002/14651858.CD007293.pub3
5 10.1002/14651858.CD005137.pub3
6 10.1002/14651858.CD004916.pub3
7 10.1002/14651858.CD004567.pub2
8 10.1002/14651858.CD005996.pub3
9 10.1002/14651858.CD001122.pub4
10 10.1002/14651858.CD008950.pub2
11 10.1002/14651858.CD007687.pub2
12 10.1002/14651858.CD005556.pub2
13 10.1002/14651858.CD005287.pub4
14 10.1002/14651858.CD007244.pub2
15 10.1002/14651858.CD000479.pub5
16 10.1002/14651858.CD003857.pub3
17 10.1002/14651858.CD000402.pub4
18 10.1002/14651858.CD001894.pub5
19 10.1002/14651858.CD002808.pub3
20 10.1002/14651858.CD008528.pub2
21 10.1002/14651858.CD004829.pub3
22 10.1002/14651858.CD005072.pub3
23 10.1002/14651858.CD008994.pub2
24 10.1002/14651858.CD000400.pub3
25 10.1002/14651858.CD008088.pub3
26 10.1002/14651858.CD010042.pub2
27 10.1002/14651858.CD008575.pub2
28 10.1002/14651858.CD009391.pub2
29 10.1002/14651858.CD005292.pub3
30 10.1002/14651858.CD009672.pub2
31 10.1002/14651858.CD010167.pub2
32 10.1002/14651858.CD001396.pub3
33 10.1002/14651858.CD009452.pub2
34 10.1002/14651858.CD005071.pub4
35 10.1002/14651858.CD003416.pub4
36 10.1002/14651858.CD006920.pub3
37 10.1002/14651858.CD007410.pub2
38 10.1002/14651858.CD010550.pub2
39 10.1002/14651858.CD009505.pub2
40 10.1002/14651858.CD001502.pub4
41 10.1002/14651858.CD001501.pub4
42 10.1002/14651858.CD000329.pub2
43 10.1002/14651858.CD010241.pub2
44 10.1002/14651858.CD006900.pub3
45 10.1002/14651858.CD003433.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD007114.pub2
4 10.1002/14651858.CD003658.pub3
5 10.1002/14651858.CD002219.pub2
6 10.1002/14651858.CD010287.pub2
7 10.1002/14651858.CD007421.pub3
8 10.1002/14651858.CD001395.pub4
9 10.1002/14651858.CD001861.pub3
10 10.1002/14651858.CD004399.pub3
11 10.1002/14651858.CD006769.pub2
12 10.1002/14651858.CD001775.pub2
13 10.1002/14651858.CD009379.pub2
14 10.1002/14651858.CD001211.pub3
15 10.1002/14651858.CD005022.pub3
16 10.1002/14651858.CD009078.pub2
17 10.1002/14651858.CD009510.pub2
18 10.1002/14651858.CD006421.pub3
19 10.1002/14651858.CD005135.pub3
20 10.1002/14651858.CD006030.pub3
21 10.1002/14651858.CD003737.pub3
22 10.1002/14651858.CD009306.pub2
23 10.1002/14651858.CD006032.pub4
24 10.1002/14651858.CD006132.pub3
25 10.1002/14651858.CD008813.pub2
26 10.1002/14651858.CD008428.pub2
27 10.1002/14651858.CD003303.pub3
28 10.1002/14651858.CD008797.pub2
29 10.1002/14651858.CD005431.pub3
30 10.1002/14651858.CD008812.pub2
31 10.1002/14651858.CD008420.pub3
32 10.1002/14651858.CD006126.pub3
33 10.1002/14651858.CD007059.pub2
34 10.1002/14651858.CD007284.pub2
35 10.1002/14651858.CD001132.pub2
36 10.1002/14651858.CD006122.pub3
37 10.1002/14651858.CD004122.pub4
38 10.1002/14651858.CD009490
39 10.1002/14651858.CD008762.pub2
40 10.1002/14651858.CD003861.pub3
41 10.1002/14651858.CD001733.pub3
42 10.1002/14651858.CD001737.pub4
43 10.1002/14651858.CD008058.pub2
44 10.1002/14651858.CD001177.pub3
45 10.1002/14651858.CD004983.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD002302.pub2
4 10.1002/14651858.CD000265.pub3
5 10.1002/14651858.CD002106.pub4
6 10.1002/14651858.CD006477.pub2
7 10.1002/14651858.CD009907.pub2
8 10.1002/14651858.CD010424.pub2
9 10.1002/14651858.CD009111.pub3
10 10.1002/14651858.CD009101.pub3
11 10.1002/14651858.CD009110.pub3
12 10.1002/14651858.CD009099.pub3
13 10.1002/14651858.CD006810.pub3
14 10.1002/14651858.CD009362.pub2
15 10.1002/14651858.CD008738.pub2
16 10.1002/14651858.CD009726.pub2
17 10.1002/14651858.CD006214.pub4
18 10.1002/14651858.CD010268.pub2
19 10.1002/14651858.CD003826.pub3
20 10.1002/14651858.CD003588.pub3
21 10.1002/14651858.CD006823.pub2
22 10.1002/14651858.CD006665.pub3
23 10.1002/14651858.CD010318.pub2
24 10.1002/14651858.CD006354.pub4
25 10.1002/14651858.CD005571.pub3
26 10.1002/14651858.CD010427.pub2
27 10.1002/14651858.CD004551.pub3
28 10.1002/14651858.CD005570.pub4
29 10.1002/14651858.CD004549.pub3
30 10.1002/14651858.CD008059.pub3
31 10.1002/14651858.CD010425.pub2
32 10.1002/14651858.CD006471.pub3
33 10.1002/14651858.CD005485.pub3
34 10.1002/14651858.CD010365.pub2
35 10.1002/14651858.CD009958.pub2
36 10.1002/14651858.CD005360.pub4
37 10.1002/14651858.CD003557.pub5
38 10.1002/14651858.CD001899.pub4
39 10.1002/14651858.CD003948.pub3
40 10.1002/14651858.CD008805.pub3
41 10.1002/14651858.CD009697.pub2
42 10.1002/14651858.CD003325.pub3
43 10.1002/14651858.CD003216.pub2
44 10.1002/14651858.CD009224.pub2
45 10.1002/14651858.CD001273.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
50

1
2
3 10.1002/14651858.CD002303.pub3
4 10.1002/14651858.CD008990.pub3
5 10.1002/14651858.CD009261.pub3
6 10.1002/14651858.CD006215.pub4
7 10.1002/14651858.CD008394.pub3
8 10.1002/14651858.CD001488.pub5
9 10.1002/14651858.CD010266.pub2
10 10.1002/14651858.CD004287.pub4
11 10.1002/14651858.CD007174.pub2
12 10.1002/14651858.CD011226.pub2
13 10.1002/14651858.CD004985.pub5
14 10.1002/14651858.CD006353.pub4
15 10.1002/14651858.CD003949.pub4
16 10.1002/14651858.CD011334.pub2
17 10.1002/14651858.CD011278.pub2
18 10.1002/14651858.CD011277.pub2
19 10.1002/14651858.CD005083.pub4
20 10.1002/14651858.CD011070.pub2
21 10.1002/14651858.CD001836.pub3
22 10.1002/14651858.CD002933.pub6
23 10.1002/14651858.CD004123.pub4
24 10.1002/14651858.CD011354.pub2
25 10.1002/14651858.CD010075.pub3
26 10.1002/14651858.CD010182.pub3
27 10.1002/14651858.CD002930.pub6
28 10.1002/14651858.CD007610.pub3
29 10.1002/14651858.CD010259.pub3
30 10.1002/14651858.CD001735.pub5
31 10.1002/14651858.CD010367.pub2
32 10.1002/14651858.CD007258.pub3
33 10.1002/14651858.CD008474.pub2
34 10.1002/14651858.CD008599.pub2
35 10.1002/14651858.CD009061.pub2
36 10.1002/14651858.CD010577.pub2
37 10.1002/14651858.CD008548.pub2
38 10.1002/14651858.CD008056.pub3
39 10.1002/14651858.CD010764.pub2
40 10.1002/14651858.CD009213.pub2
41 10.1002/14651858.CD009432.pub2
42 10.1002/14651858.CD004288.pub3
43 10.1002/14651858.CD011712.pub2
44 10.1002/14651858.CD002929.pub3
45 10.1002/14651858.CD008062.pub4
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD011586.pub2
4 10.1002/14651858.CD008378.pub3
5 10.1002/14651858.CD010694.pub2
6 10.1002/14651858.CD006899.pub3
7 10.1002/14651858.CD010140.pub2
8 10.1002/14651858.CD011193.pub2
9 10.1002/14651858.CD011111.pub2
10 10.1002/14651858.CD011426.pub2
11 10.1002/14651858.CD011923.pub2
12 10.1002/14651858.CD008251.pub2
13 10.1002/14651858.CD003091.pub4
14 10.1002/14651858.CD011375.pub2
15 10.1002/14651858.CD001180.pub4
16 10.1002/14651858.CD005987.pub3
17 10.1002/14651858.CD011038.pub2
18 10.1002/14651858.CD011979.pub2
19 10.1002/14651858.CD011609.pub2
20 10.1002/14651858.CD011947.pub2
21 10.1002/14651858.CD001333.pub4
22 10.1002/14651858.CD005191.pub3
23 10.1002/14651858.CD009308
24 10.1002/14651858.CD008063.pub2
25 10.1002/14651858.CD005031.pub4
26 10.1002/14651858.CD009307
27 10.1002/14651858.CD009113
28 10.1002/14651858.CD004147.pub4
29 10.1002/14651858.CD003410.pub4
30 10.1002/14651858.CD004145.pub4
31 10.1002/14651858.CD007381.pub2
32 10.1002/14651858.CD009879.pub2
33 10.1002/14651858.CD007775.pub2
34 10.1002/14651858.CD003409.pub4
35 10.1002/14651858.CD008358.pub2
36 10.1002/14651858.CD009287.pub2
37 10.1002/14651858.CD002950.pub3
38 10.1002/14651858.CD006318.pub3
39 10.1002/14651858.CD009695.pub2
40 10.1002/14651858.CD006749.pub3
41 10.1002/14651858.CD002207.pub4
42 10.1002/14651858.CD007210.pub3
43 10.1002/14651858.CD010704.pub2
44 10.1002/14651858.CD008544.pub2
45 10.1002/14651858.CD009269.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
50

1
2
3 10.1002/14651858.CD003020.pub3
4 10.1002/14651858.CD008940.pub2
5 10.1002/14651858.CD006037.pub3
6 10.1002/14651858.CD006754.pub4
7 10.1002/14651858.CD009652.pub2
8 10.1002/14651858.CD003352.pub4
9 10.1002/14651858.CD010910.pub2
10 10.1002/14651858.CD010862.pub2
11 10.1002/14651858.CD008969.pub3
12 10.1002/14651858.CD006306.pub3
13 10.1002/14651858.CD010901.pub2
14 10.1002/14651858.CD006748.pub4
15 10.1002/14651858.CD002024.pub5
16 10.1002/14651858.CD011117.pub2
17 10.1002/14651858.CD011983.pub2
18 10.1002/14651858.CD005336.pub4
19 10.1002/14651858.CD007380.pub4
20 10.1002/14651858.CD007025.pub4
21 10.1002/14651858.CD008502.pub5
22 10.1002/14651858.CD002021.pub4
23 10.1002/14651858.CD002025.pub5
24 10.1002/14651858.CD011866.pub2
25 10.1002/14651858.CD011479.pub2
26 10.1002/14651858.CD009146.pub2
27 10.1002/14651858.CD004887.pub3
28 10.1002/14651858.CD008264.pub2
29 10.1002/14651858.CD009145.pub2
30 10.1002/14651858.CD007338.pub3
31 10.1002/14651858.CD007512.pub2
32 10.1002/14651858.CD004544.pub2
33 10.1002/14651858.CD008714.pub2
34 10.1002/14651858.CD009051.pub2
35 10.1002/14651858.CD002799.pub2
36 10.1002/14651858.CD007605.pub2
37 10.1002/14651858.CD005444.pub3
38 10.1002/14651858.CD006578.pub3
39 10.1002/14651858.CD008516.pub2
40 10.1002/14651858.CD008344.pub2
41 10.1002/14651858.CD009498.pub3
42 10.1002/14651858.CD000551.pub3
43 10.1002/14651858.CD009004.pub2
44 10.1002/14651858.CD008717.pub2
45 10.1002/14651858.CD009497.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD009058.pub2
4 10.1002/14651858.CD003617.pub2
5 10.1002/14651858.CD005640.pub3
6 10.1002/14651858.CD005641.pub3
7 10.1002/14651858.CD007176.pub2
8 10.1002/14651858.CD007196.pub3
9 10.1002/14651858.CD005440.pub3
10 10.1002/14651858.CD004547.pub2
11 10.1002/14651858.CD006798.pub4
12 10.1002/14651858.CD007088.pub2
13 10.1002/14651858.CD006575.pub3
14 10.1002/14651858.CD010163.pub2
15 10.1002/14651858.CD006004.pub4
16 10.1002/14651858.CD006574.pub4
17 10.1002/14651858.CD006573.pub3
18 10.1002/14651858.CD006804.pub3
19 10.1002/14651858.CD009059.pub2
20 10.1002/14651858.CD006803.pub4
21 10.1002/14651858.CD008623.pub2
22 10.1002/14651858.CD003327.pub4
23 10.1002/14651858.CD010479.pub2
24 10.1002/14651858.CD003046.pub3
25 10.1002/14651858.CD003047.pub3
26 10.1002/14651858.CD007109.pub2
27 10.1002/14651858.CD005642.pub3
28 10.1002/14651858.CD009933.pub2
29 10.1002/14651858.CD005441.pub3
30 10.1002/14651858.CD010478.pub2
31 10.1002/14651858.CD006660.pub3
32 10.1002/14651858.CD007049.pub2
33 10.1002/14651858.CD006930.pub3
34 10.1002/14651858.CD009060.pub2
35 10.1002/14651858.CD007337.pub3
36 10.1002/14651858.CD008261.pub2
37 10.1002/14651858.CD009182.pub2
38 10.1002/14651858.CD011132.pub2
39 10.1002/14651858.CD010252.pub2
40 10.1002/14651858.CD010125.pub2
41 10.1002/14651858.CD006745.pub3
42 10.1002/14651858.CD010253.pub2
43 10.1002/14651858.CD010164.pub2
44 10.1002/14651858.CD011313.pub2
45 10.1002/14651858.CD010180.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD007606.pub3
4 10.1002/14651858.CD006390.pub2
5 10.1002/14651858.CD003044.pub4
6 10.1002/14651858.CD008545.pub2
7 10.1002/14651858.CD011314.pub2
8 10.1002/14651858.CD011647.pub2
9 10.1002/14651858.CD011649.pub2
10 10.1002/14651858.CD011644.pub2
11 10.1002/14651858.CD008716.pub3
12 10.1002/14651858.CD011650.pub2
13 10.1002/14651858.CD010683.pub3
14 10.1002/14651858.CD011645.pub2
15 10.1002/14651858.CD011343.pub2
16 10.1002/14651858.CD001939.pub4
17 10.1002/14651858.CD011640.pub2
18 10.1002/14651858.CD011648.pub2
19 10.1002/14651858.CD011646.pub2
20 10.1002/14651858.CD011639.pub2
21 10.1002/14651858.CD002798.pub4
22 10.1002/14651858.CD005162.pub4
23 10.1002/14651858.CD011598.pub2
24 10.1002/14651858.CD008586.pub2
25 10.1002/14651858.CD007302.pub2
26 10.1002/14651858.CD002217.pub2
27 10.1002/14651858.CD009429.pub2
28 10.1002/14651858.CD003277.pub3
29 10.1002/14651858.CD002750.pub2
30 10.1002/14651858.CD003615.pub3
31 10.1002/14651858.CD001901.pub2
32 10.1002/14651858.CD009945.pub2
33 10.1002/14651858.CD005398.pub3
34 10.1002/14651858.CD001415.pub2
35 10.1002/14651858.CD001416.pub3
36 10.1002/14651858.CD001908.pub3
37 10.1002/14651858.CD001417.pub3
38 10.1002/14651858.CD001770.pub3
39 10.1002/14651858.CD006370.pub2
40 10.1002/14651858.CD009270.pub3
41 10.1002/14651858.CD005612.pub3
42 10.1002/14651858.CD009258.pub2
43 10.1002/14651858.CD006779.pub2
44 10.1002/14651858.CD010062.pub2
45 10.1002/14651858.CD003723.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD005062.pub4
4 10.1002/14651858.CD010682.pub2
5 10.1002/14651858.CD010236.pub2
6 10.1002/14651858.CD001902.pub2
7 10.1002/14651858.CD007286.pub3
8 10.1002/14651858.CD008841.pub2
9 10.1002/14651858.CD005222.pub3
10 10.1002/14651858.CD002896.pub2
11 10.1002/14651858.CD011311.pub2
12 10.1002/14651858.CD009472.pub3
13 10.1002/14651858.CD009887.pub3
14 10.1002/14651858.CD009027.pub2
15 10.1002/14651858.CD005502.pub3
16 10.1002/14651858.CD005399.pub3
17 10.1002/14651858.CD009900.pub2
18 10.1002/14651858.CD006118.pub3
19 10.1002/14651858.CD009324.pub3
20 10.1002/14651858.CD006245.pub3
21 10.1002/14651858.CD001903.pub3
22 10.1002/14651858.CD006244.pub3
23 10.1002/14651858.CD008781.pub3
24 10.1002/14651858.CD007144.pub2
25 10.1002/14651858.CD001769.pub3
26 10.1002/14651858.CD001909.pub2
27 10.1002/14651858.CD011792.pub2
28 10.1002/14651858.CD006967.pub4
29 10.1002/14651858.CD011014.pub2
30 10.1002/14651858.CD011025.pub2
31 10.1002/14651858.CD011922.pub2
32 10.1002/14651858.CD001031.pub3
33 10.1002/14651858.CD007124.pub5
34 10.1002/14651858.CD012065.pub2
35 10.1002/14651858.CD009202.pub4
36 10.1002/14651858.CD003032.pub3
37 10.1002/14651858.CD001904.pub3
38 10.1002/14651858.CD008312.pub3
39 10.1002/14651858.CD010224.pub2
40 10.1002/14651858.CD010008.pub3
41 10.1002/14651858.CD010483.pub4
42 10.1002/14651858.CD003031.pub3
43 10.1002/14651858.CD001911.pub3
44 10.1002/14651858.CD008557.pub3
45 10.1002/14651858.CD008295.pub4
46
47
48
49
50
51
52
53
54
55
56
57
58
59
50

1
2
3 10.1002/14651858.CD001524.pub3
4 10.1002/14651858.CD008497.pub3
5 10.1002/14651858.CD011412.pub2
6 10.1002/14651858.CD007679.pub4
7 10.1002/14651858.CD006461.pub4
8 10.1002/14651858.CD007738.pub2
9 10.1002/14651858.CD009700.pub2
10 10.1002/14651858.CD007325.pub3
11 10.1002/14651858.CD005139.pub3
12 10.1002/14651858.CD011230.pub2
13 10.1002/14651858.CD008811.pub3
14 10.1002/14651858.CD005430.pub3
15 10.1002/14651858.CD008721.pub2
16 10.1002/14651858.CD011234.pub2
17 10.1002/14651858.CD008213.pub2
18 10.1002/14651858.CD003659.pub4
19 10.1002/14651858.CD010792.pub2
20 10.1002/14651858.CD001538.pub4
21 10.1002/14651858.CD010621.pub2
22 10.1002/14651858.CD006127.pub2
23 10.1002/14651858.CD010015.pub3
24 10.1002/14651858.CD008350.pub2
25 10.1002/14651858.CD004241.pub4
26 10.1002/14651858.CD009080.pub2
27 10.1002/14651858.CD008732.pub2
28 10.1002/14651858.CD002898.pub5
29 10.1002/14651858.CD009566.pub2
30 10.1002/14651858.CD003434.pub3
31 10.1002/14651858.CD008671.pub3
32 10.1002/14651858.CD001430.pub4
33 10.1002/14651858.CD007603.pub2
34 10.1002/14651858.CD008214.pub3
35 10.1002/14651858.CD007324.pub3
36 10.1002/14651858.CD004242.pub5
37 10.1002/14651858.CD006537.pub3
38 10.1002/14651858.CD010868.pub2
39 10.1002/14651858.CD006259.pub2
40 10.1002/14651858.CD009380.pub2
41 10.1002/14651858.CD004008.pub3
42 10.1002/14651858.CD010472.pub2
43 10.1002/14651858.CD011346.pub2
44 10.1002/14651858.CD011146.pub2
45 10.1002/14651858.CD009782.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD010469.pub2
4 10.1002/14651858.CD005655.pub2
5 10.1002/14651858.CD011349.pub2
6 10.1002/14651858.CD009799.pub2
7 10.1002/14651858.CD002218.pub2
8 10.1002/14651858.CD011841.pub2
9 10.1002/14651858.CD010735.pub2
10 10.1002/14651858.CD004764.pub3
11 10.1002/14651858.CD006927.pub5
12 10.1002/14651858.CD009729.pub2
13 10.1002/14651858.CD011503.pub2
14 10.1002/14651858.CD010293.pub2
15 10.1002/14651858.CD007824.pub2
16 10.1002/14651858.CD011308.pub2
17 10.1002/14651858.CD006683.pub3
18 10.1002/14651858.CD011160.pub2
19 10.1002/14651858.CD003169.pub4
20 10.1002/14651858.CD006539.pub4
21 10.1002/14651858.CD011965.pub2
22 10.1002/14651858.CD011080.pub2
23 10.1002/14651858.CD006364.pub3
24 10.1002/14651858.CD006757.pub4
25 10.1002/14651858.CD011075.pub2
26 10.1002/14651858.CD010520.pub2
27 10.1002/14651858.CD012131.pub2
28 10.1002/14651858.CD007097.pub3
29 10.1002/14651858.CD010746.pub2
30 10.1002/14651858.CD009327.pub3
31 10.1002/14651858.CD009781.pub2
32 10.1002/14651858.CD006499.pub4
33 10.1002/14651858.CD011109.pub2
34 10.1002/14651858.CD006775.pub3
35 10.1002/14651858.CD007419.pub5
36 10.1002/14651858.CD000253.pub4
37 10.1002/14651858.CD010516.pub2
38 10.1002/14651858.CD004918.pub3
39 10.1002/14651858.CD000254.pub4
40 10.1002/14651858.CD010510.pub2
41 10.1002/14651858.CD006210.pub3
42 10.1002/14651858.CD009094
43 10.1002/14651858.CD006563.pub2
44 10.1002/14651858.CD005528.pub2
45 10.1002/14651858.CD003318.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD008451.pub2
4 10.1002/14651858.CD007673.pub2
5 10.1002/14651858.CD007019.pub2
6 10.1002/14651858.CD000125.pub4
7 10.1002/14651858.CD001270.pub2
8 10.1002/14651858.CD006413.pub2
9 10.1002/14651858.CD004538.pub2
10 10.1002/14651858.CD002212.pub2
11 10.1002/14651858.CD005609.pub2
12 10.1002/14651858.CD007899.pub2
13 10.1002/14651858.CD009401.pub2
14 10.1002/14651858.CD007672.pub2
15 10.1002/14651858.CD000259.pub3
16 10.1002/14651858.CD005315.pub2
17 10.1002/14651858.CD002964.pub2
18 10.1002/14651858.CD007990.pub2
19 10.1002/14651858.CD008476.pub2
20 10.1002/14651858.CD007813.pub2
21 10.1002/14651858.CD008959.pub2
22 10.1002/14651858.CD007849.pub2
23 10.1002/14651858.CD008223.pub2
24 10.1002/14651858.CD007992.pub2
25 10.1002/14651858.CD009009.pub2
26 10.1002/14651858.CD004398.pub3
27 10.1002/14651858.CD006411.pub4
28 10.1002/14651858.CD010398
29 10.1002/14651858.CD002213.pub3
30 10.1002/14651858.CD009035.pub2
31 10.1002/14651858.CD002097.pub3
32 10.1002/14651858.CD006559.pub2
33 10.1002/14651858.CD009853.pub2
34 10.1002/14651858.CD002894.pub3
35 10.1002/14651858.CD010076.pub2
36 10.1002/14651858.CD008194.pub3
37 10.1002/14651858.CD006208.pub3
38 10.1002/14651858.CD005979.pub2
39 10.1002/14651858.CD004749.pub3
40 10.1002/14651858.CD005610.pub2
41 10.1002/14651858.CD006732.pub3
42 10.1002/14651858.CD009186.pub2
43 10.1002/14651858.CD008165.pub3
44 10.1002/14651858.CD009404.pub3
45 10.1002/14651858.CD007071.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD009149.pub2
4 10.1002/14651858.CD001730.pub3
5 10.1002/14651858.CD005470.pub3
6 10.1002/14651858.CD007193.pub2
7 10.1002/14651858.CD005314.pub3
8 10.1002/14651858.CD007017.pub2
9 10.1002/14651858.CD006731.pub2
10 10.1002/14651858.CD007988.pub2
11 10.1002/14651858.CD000313.pub5
12 10.1002/14651858.CD009095.pub3
13 10.1002/14651858.CD009231.pub2
14 10.1002/14651858.CD009926.pub2
15 10.1002/14651858.CD007492.pub2
16 10.1002/14651858.CD008986.pub3
17 10.1002/14651858.CD006560.pub3
18 10.1002/14651858.CD009794.pub2
19 10.1002/14651858.CD010123.pub2
20 10.1002/14651858.CD009855.pub2
21 10.1002/14651858.CD007495.pub2
22 10.1002/14651858.CD008145.pub3
23 10.1002/14651858.CD009677.pub2
24 10.1002/14651858.CD008856.pub2
25 10.1002/14651858.CD010669.pub2
26 10.1002/14651858.CD003540.pub3
27 10.1002/14651858.CD002098.pub2
28 10.1002/14651858.CD007491.pub2
29 10.1002/14651858.CD010034.pub2
30 10.1002/14651858.CD008992.pub3
31 10.1002/14651858.CD011227.pub2
32 10.1002/14651858.CD009844.pub2
33 10.1002/14651858.CD011153.pub2
34 10.1002/14651858.CD004910.pub3
35 10.1002/14651858.CD000072.pub3
36 10.1002/14651858.CD000356.pub4
37 10.1002/14651858.CD001175.pub4
38 10.1002/14651858.CD003543.pub4
39 10.1002/14651858.CD008131.pub2
40 10.1002/14651858.CD003681.pub3
41 10.1002/14651858.CD009218.pub2
42 10.1002/14651858.CD008372.pub2
43 10.1002/14651858.CD009085.pub2
44 10.1002/14651858.CD003018.pub3
45 10.1002/14651858.CD003495.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD001930.pub3
4 10.1002/14651858.CD005039.pub3
5 10.1002/14651858.CD008511.pub2
6 10.1002/14651858.CD007986.pub2
7 10.1002/14651858.CD009260.pub2
8 10.1002/14651858.CD009456.pub2
9 10.1002/14651858.CD007991.pub2
10 10.1002/14651858.CD008225.pub2
11 10.1002/14651858.CD004796.pub2
12 10.1002/14651858.CD005652.pub2
13 10.1002/14651858.CD007507.pub2
14 10.1002/14651858.CD002796.pub2
15 10.1002/14651858.CD009115.pub2
16 10.1002/14651858.CD009084.pub2
17 10.1002/14651858.CD008898.pub2
18 10.1002/14651858.CD009774.pub2
19 10.1002/14651858.CD009000.pub2
20 10.1002/14651858.CD001444.pub2
21 10.1002/14651858.CD005038.pub3
22 10.1002/14651858.CD004383.pub3
23 10.1002/14651858.CD004534.pub3
24 10.1002/14651858.CD004677.pub3
25 10.1002/14651858.CD009584.pub2
26 10.1002/14651858.CD009728.pub2
27 10.1002/14651858.CD008785.pub2
28 10.1002/14651858.CD006546.pub3
29 10.1002/14651858.CD004381.pub3
30 10.1002/14651858.CD006997.pub2
31 10.1002/14651858.CD010544.pub2
32 10.1002/14651858.CD002020.pub4
33 10.1002/14651858.CD010543.pub2
34 10.1002/14651858.CD003942.pub3
35 10.1002/14651858.CD010534.pub2
36 10.1002/14651858.CD007989.pub2
37 10.1002/14651858.CD009383.pub2
38 10.1002/14651858.CD009384.pub2
39 10.1002/14651858.CD009924.pub2
40 10.1002/14651858.CD010766.pub2
41 10.1002/14651858.CD003406.pub4
42 10.1002/14651858.CD010012.pub2
43 10.1002/14651858.CD008958.pub2
44 10.1002/14651858.CD004380.pub3
45 10.1002/14651858.CD010459.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD009257.pub2
4 10.1002/14651858.CD011546.pub2
5 10.1002/14651858.CD007007.pub3
6 10.1002/14651858.CD009996.pub2
7 10.1002/14651858.CD009043.pub3
8 10.1002/14651858.CD009398.pub3
9 10.1002/14651858.CD005043.pub3
10 10.1002/14651858.CD009999.pub2
11 10.1002/14651858.CD003680.pub3
12 10.1002/14651858.CD009747.pub2
13 10.1002/14651858.CD010922.pub2
14 10.1002/14651858.CD006047.pub5
15 10.1002/14651858.CD010973.pub2
16 10.1002/14651858.CD010971.pub2
17 10.1002/14651858.CD010972.pub2
18 10.1002/14651858.CD008524.pub3
19 10.1002/14651858.CD009242.pub3
20 10.1002/14651858.CD008559.pub3
21 10.1002/14651858.CD010914.pub2
22 10.1002/14651858.CD011660.pub2
23 10.1002/14651858.CD009885.pub2
24 10.1002/14651858.CD005198.pub3
25 10.1002/14651858.CD008818.pub2
26 10.1002/14651858.CD008235.pub2
27 10.1002/14651858.CD006505.pub2
28 10.1002/14651858.CD007678.pub2
29 10.1002/14651858.CD008078.pub2
30 10.1002/14651858.CD003188.pub3
31 10.1002/14651858.CD009355.pub2
32 10.1002/14651858.CD009045.pub2
33 10.1002/14651858.CD004626.pub3
34 10.1002/14651858.CD004269.pub3
35 10.1002/14651858.CD008079.pub2
36 10.1002/14651858.CD008238.pub3
37 10.1002/14651858.CD009159.pub2
38 10.1002/14651858.CD006503.pub3
39 10.1002/14651858.CD009411.pub2
40 10.1002/14651858.CD008909.pub2
41 10.1002/14651858.CD009594.pub2
42 10.1002/14651858.CD006407.pub2
43 10.1002/14651858.CD010146.pub2
44 10.1002/14651858.CD010189.pub2
45 10.1002/14651858.CD009211.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD010280.pub2
4 10.1002/14651858.CD003407.pub5
5 10.1002/14651858.CD010340.pub2
6 10.1002/14651858.CD009075.pub2
7 10.1002/14651858.CD010533.pub2
8 10.1002/14651858.CD010298.pub2
9 10.1002/14651858.CD009311.pub2
10 10.1002/14651858.CD008562.pub3
11 10.1002/14651858.CD010615.pub2
12 10.1002/14651858.CD011577.pub2
13 10.1002/14651858.CD010432.pub2
14 10.1002/14651858.CD010981.pub2
15 10.1002/14651858.CD010248.pub2
16 10.1002/14651858.CD010984.pub2
17 10.1002/14651858.CD011157.pub2
18 10.1002/14651858.CD010983.pub2
19 10.1002/14651858.CD007107.pub3
20 10.1002/14651858.CD009624.pub2
21 10.1002/14651858.CD009310.pub2
22 10.1002/14651858.CD009733.pub3
23 10.1002/14651858.CD010816.pub2
24 10.1002/14651858.CD011756.pub2
25 10.1002/14651858.CD010982.pub2
26 10.1002/14651858.CD012055.pub2
27 10.1002/14651858.CD011305.pub2
28 10.1002/14651858.CD007941.pub3
29 10.1002/14651858.CD007110.pub3
30 10.1002/14651858.CD008814.pub2
31 10.1002/14651858.CD008414.pub2
32 10.1002/14651858.CD008013.pub2
33 10.1002/14651858.CD008538.pub2
34 10.1002/14651858.CD007443.pub2
35 10.1002/14651858.CD006913.pub2
36 10.1002/14651858.CD008424.pub2
37 10.1002/14651858.CD004118.pub2
38 10.1002/14651858.CD009710.pub2
39 10.1002/14651858.CD009400.pub2
40 10.1002/14651858.CD005111.pub3
41 10.1002/14651858.CD006095.pub3
42 10.1002/14651858.CD010410.pub2
43 10.1002/14651858.CD003460.pub3
44 10.1002/14651858.CD006320.pub4
45 10.1002/14651858.CD008486.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD003459.pub4
4 10.1002/14651858.CD010233.pub2
5 10.1002/14651858.CD007571.pub2
6 10.1002/14651858.CD006884.pub3
7 10.1002/14651858.CD006618.pub3
8 10.1002/14651858.CD002913.pub3
9 10.1002/14651858.CD007744.pub2
10 10.1002/14651858.CD006774.pub4
11 10.1002/14651858.CD007560.pub3
12 10.1002/14651858.CD006790.pub3
13 10.1002/14651858.CD000296.pub4
14 10.1002/14651858.CD008655.pub3
15 10.1002/14651858.CD001176.pub3
16 10.1002/14651858.CD000067.pub3
17 10.1002/14651858.CD007698.pub3
18 10.1002/14651858.CD011661.pub2
19 10.1002/14651858.CD007348.pub2
20 10.1002/14651858.CD004827.pub4
21 10.1002/14651858.CD000478.pub4
22 10.1002/14651858.CD000299.pub3
23 10.1002/14651858.CD000543.pub4
24 10.1002/14651858.CD000544.pub4
25 10.1002/14651858.CD010642.pub2
26 10.1002/14651858.CD008870.pub2
27 10.1002/14651858.CD003715.pub3
28 10.1002/14651858.CD009118.pub3
29 10.1002/14651858.CD000545.pub5
30 10.1002/14651858.CD010873.pub4
31 10.1002/14651858.CD007572.pub3
32 10.1002/14651858.CD006096.pub4
33 10.1002/14651858.CD011256.pub2
34 10.1002/14651858.CD004610.pub5
35 10.1002/14651858.CD012351.pub2
36 10.1002/14651858.CD005606.pub2
37 10.1002/14651858.CD008234.pub2
38 10.1002/14651858.CD002211.pub2
39 10.1002/14651858.CD001935.pub3
40 10.1002/14651858.CD008607.pub2
41 10.1002/14651858.CD008514.pub2
42 10.1002/14651858.CD008515.pub2
43 10.1002/14651858.CD002851.pub4
44 10.1002/14651858.CD007960.pub2
45 10.1002/14651858.CD008263.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
50

1
2
3 10.1002/14651858.CD003997.pub2
4 10.1002/14651858.CD003423.pub3
5 10.1002/14651858.CD007946.pub2
6 10.1002/14651858.CD008675.pub2
7 10.1002/14651858.CD009238.pub2
8 10.1002/14651858.CD008693.pub2
9 10.1002/14651858.CD006987.pub2
10 10.1002/14651858.CD004461.pub3
11 10.1002/14651858.CD004739.pub4
12 10.1002/14651858.CD005053.pub4
13 10.1002/14651858.CD006371.pub3
14 10.1002/14651858.CD005607.pub4
15 10.1002/14651858.CD005395.pub3
16 10.1002/14651858.CD003852.pub3
17 10.1002/14651858.CD007904.pub3
18 10.1002/14651858.CD006285.pub2
19 10.1002/14651858.CD008512.pub2
20 10.1002/14651858.CD009441.pub2
21 10.1002/14651858.CD003998.pub3
22 10.1002/14651858.CD007806.pub4
23 10.1002/14651858.CD009810.pub2
24 10.1002/14651858.CD010151.pub2
25 10.1002/14651858.CD008669.pub2
26 10.1002/14651858.CD006991.pub2
27 10.1002/14651858.CD001802.pub3
28 10.1002/14651858.CD002027.pub2
29 10.1002/14651858.CD003162.pub3
30 10.1002/14651858.CD008419.pub2
31 10.1002/14651858.CD005397.pub4
32 10.1002/14651858.CD010198.pub2
33 10.1002/14651858.CD010591.pub2
34 10.1002/14651858.CD011165.pub2
35 10.1002/14651858.CD010375.pub2
36 10.1002/14651858.CD011992.pub2
37 10.1002/14651858.CD011991.pub2
38 10.1002/14651858.CD011995.pub2
39 10.1002/14651858.CD011996.pub2
40 10.1002/14651858.CD011994.pub2
41 10.1002/14651858.CD010696.pub2
42 10.1002/14651858.CD011993.pub2
43 10.1002/14651858.CD009163.pub3
44 10.1002/14651858.CD011112.pub2
45 10.1002/14651858.CD010342.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD009832.pub2
4 10.1002/14651858.CD011684.pub2
5 10.1002/14651858.CD006287.pub4
6 10.1002/14651858.CD007294.pub2
7 10.1002/14651858.CD007584.pub2
8 10.1002/14651858.CD003752.pub3
9 10.1002/14651858.CD007697.pub2
10 10.1002/14651858.CD002224.pub2
11 10.1002/14651858.CD001040.pub2
12 10.1002/14651858.CD003911.pub2
13 10.1002/14651858.CD002834.pub2
14 10.1002/14651858.CD007930.pub2
15 10.1002/14651858.CD001035.pub2
16 10.1002/14651858.CD003175.pub2
17 10.1002/14651858.CD007565.pub2
18 10.1002/14651858.CD008018.pub2
19 10.1002/14651858.CD007927.pub3
20 10.1002/14651858.CD006013.pub3
21 10.1002/14651858.CD008664.pub2
22 10.1002/14651858.CD007945.pub2
23 10.1002/14651858.CD003916.pub4
24 10.1002/14651858.CD005007.pub3
25 10.1002/14651858.CD007583.pub3
26 10.1002/14651858.CD004386.pub3
27 10.1002/14651858.CD005343.pub3
28 10.1002/14651858.CD003915.pub4
29 10.1002/14651858.CD006655.pub2
30 10.1002/14651858.CD007406.pub3
31 10.1002/14651858.CD006469.pub2
32 10.1002/14651858.CD007064.pub2
33 10.1002/14651858.CD005196.pub4
34 10.1002/14651858.CD008765.pub3
35 10.1002/14651858.CD006812.pub3
36 10.1002/14651858.CD007566.pub2
37 10.1002/14651858.CD008465.pub2
38 10.1002/14651858.CD007730.pub2
39 10.1002/14651858.CD008217.pub3
40 10.1002/14651858.CD003751.pub3
41 10.1002/14651858.CD007415.pub2
42 10.1002/14651858.CD009620.pub2
43 10.1002/14651858.CD003296.pub3
44 10.1002/14651858.CD007414.pub3
45 10.1002/14651858.CD003038.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
50

1
2
3 10.1002/14651858.CD006910.pub2
4 10.1002/14651858.CD009884.pub2
5 10.1002/14651858.CD006651.pub3
6 10.1002/14651858.CD008215.pub2
7 10.1002/14651858.CD010482.pub2
8 10.1002/14651858.CD003992.pub3
9 10.1002/14651858.CD010192.pub2
10 10.1002/14651858.CD008983.pub2
11 10.1002/14651858.CD001421.pub3
12 10.1002/14651858.CD003295.pub3
13 10.1002/14651858.CD009685.pub2
14 10.1002/14651858.CD009896.pub2
15 10.1002/14651858.CD004707.pub3
16 10.1002/14651858.CD001318.pub3
17 10.1002/14651858.CD009454.pub2
18 10.1002/14651858.CD007928.pub3
19 10.1002/14651858.CD012023.pub2
20 10.1002/14651858.CD004121.pub3
21 10.1002/14651858.CD005216.pub2
22 10.1002/14651858.CD004861.pub2
23 10.1002/14651858.CD007104.pub2
24 10.1002/14651858.CD010681.pub2
25 10.1002/14651858.CD006912.pub2
26 10.1002/14651858.CD002855.pub4
27 10.1002/14651858.CD003553.pub3
28 10.1002/14651858.CD006649.pub6
29 10.1002/14651858.CD009447.pub2
30 10.1002/14651858.CD006466.pub5
31 10.1002/14651858.CD000969.pub2
32 10.1002/14651858.CD002033.pub2
33 10.1002/14651858.CD000239.pub2
34 10.1002/14651858.CD006650.pub4
35 10.1002/14651858.CD000026.pub2
36 10.1002/14651858.CD006119.pub3
37 10.1002/14651858.CD008218.pub3
38 10.1002/14651858.CD007563.pub3
39 10.1002/14651858.CD005590.pub3
40 10.1002/14651858.CD010401.pub2
41 10.1002/14651858.CD007287.pub3
42 10.1002/14651858.CD003039.pub2
43 10.1002/14651858.CD006468.pub5
44 10.1002/14651858.CD011335.pub2
45 10.1002/14651858.CD011422
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD007103.pub3
4 10.1002/14651858.CD010260.pub2
5 10.1002/14651858.CD007929.pub3
6 10.1002/14651858.CD009229.pub2
7 10.1002/14651858.CD005341.pub3
8 10.1002/14651858.CD007924.pub3
9 10.1002/14651858.CD011006.pub2
10 10.1002/14651858.CD008478.pub2
11 10.1002/14651858.CD004706.pub5
12 10.1002/14651858.CD006014.pub7
13 10.1002/14651858.CD009464.pub2
14 10.1002/14651858.CD005340.pub4
15 10.1002/14651858.CD011837.pub2
16 10.1002/14651858.CD011732.pub2
17 10.1002/14651858.CD007731.pub3
18 10.1002/14651858.CD011376.pub2
19 10.1002/14651858.CD005008.pub4
20 10.1002/14651858.CD005005.pub4
21 10.1002/14651858.CD007102.pub4
22 10.1002/14651858.CD003455.pub2
23 10.1002/14651858.CD005339.pub2
24 10.1002/14651858.CD011322.pub2
25 10.1002/14651858.CD006120.pub4
26 10.1002/14651858.CD011475.pub2
27 10.1002/14651858.CD011325.pub2
28 10.1002/14651858.CD009957.pub2
29 10.1002/14651858.CD005342.pub4
30 10.1002/14651858.CD006911.pub3
31 10.1002/14651858.CD009836.pub2
32 10.1002/14651858.CD010931.pub2
33 10.1002/14651858.CD008216.pub5
34 10.1002/14651858.CD007387.pub4
35 10.1002/14651858.CD011773.pub2
36 10.1002/14651858.CD003914.pub4
37 10.1002/14651858.CD007289.pub3
38 10.1002/14651858.CD009038.pub2
39 10.1002/14651858.CD005217.pub2
40 10.1002/14651858.CD008896.pub2
41 10.1002/14651858.CD009251.pub2
42 10.1002/14651858.CD004316.pub4
43 10.1002/14651858.CD006260.pub3
44 10.1002/14651858.CD003990.pub4
45 10.1002/14651858.CD004425.pub6
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD006964.pub3
4 10.1002/14651858.CD003989.pub5
5 10.1002/14651858.CD003449.pub5
6 10.1002/14651858.CD007541.pub3
7 10.1002/14651858.CD010662.pub2
8 10.1002/14651858.CD005218.pub4
9 10.1002/14651858.CD004317.pub4
10 10.1002/14651858.CD003552.pub4
11 10.1002/14651858.CD003987.pub5
12 10.1002/14651858.CD004112.pub4
13 10.1002/14651858.CD003991.pub4
14 10.1002/14651858.CD006134.pub5
15 10.1002/14651858.CD010915.pub2
16 10.1002/14651858.CD006133.pub5
17 10.1002/14651858.CD006033.pub5
18 10.1002/14651858.CD001777.pub4
19 10.1002/14651858.CD007444.pub4
20 10.1002/14651858.CD011298.pub2
21 10.1002/14651858.CD004695.pub3
22 10.1002/14651858.CD007595.pub3
23 10.1002/14651858.CD003988.pub2
24 10.1002/14651858.CD011159.pub2
25 10.1002/14651858.CD011242.pub2
26 10.1002/14651858.CD009849.pub3
27 10.1002/14651858.CD003036.pub3
28 10.1002/14651858.CD009805.pub3
29 10.1002/14651858.CD001863.pub4
30 10.1002/14651858.CD001329.pub2
31 10.1002/14651858.CD007373.pub3
32 10.1002/14651858.CD011054.pub2
33 10.1002/14651858.CD011528.pub2
34 10.1002/14651858.CD012025.pub2
35 10.1002/14651858.CD012249
36 10.1002/14651858.CD003034.pub4
37 10.1002/14651858.CD005215.pub3
38 10.1002/14651858.CD010243.pub3
39 10.1002/14651858.CD008452.pub4
40 10.1002/14651858.CD008815.pub4
41 10.1002/14651858.CD011913.pub2
42 10.1002/14651858.CD011031.pub2
43 10.1002/14651858.CD008582.pub2
44 10.1002/14651858.CD007683.pub3
45 10.1002/14651858.CD007249.pub5
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD001298.pub4
4 10.1002/14651858.CD009592.pub2
5 10.1002/14651858.CD006567.pub3
6 10.1002/14651858.CD005289.pub3
7 10.1002/14651858.CD005355.pub5
8 10.1002/14651858.CD010047.pub2
9 10.1002/14651858.CD010461.pub2
10 10.1002/14651858.CD010001.pub2
11 10.1002/14651858.CD004638.pub3
12 10.1002/14651858.CD006108.pub4
13 10.1002/14651858.CD004508.pub4
14 10.1002/14651858.CD005999.pub2
15 10.1002/14651858.CD008046.pub4
16 10.1002/14651858.CD006105.pub3
17 10.1002/14651858.CD006942.pub3
18 10.1002/14651858.CD007411.pub3
19 10.1002/14651858.CD011320.pub2
20 10.1002/14651858.CD011066.pub2
21 10.1002/14651858.CD009461.pub3
22 10.1002/14651858.CD011345.pub2
23 10.1002/14651858.CD005073.pub4
24 10.1002/14651858.CD010854.pub2
25 10.1002/14651858.CD005998.pub2
26 10.1002/14651858.CD009517.pub3
27 10.1002/14651858.CD000475.pub3
28 10.1002/14651858.CD003718.pub4
29 10.1002/14651858.CD009577.pub3
30 10.1002/14651858.CD002126.pub3
31 10.1002/14651858.CD003677.pub5
32 10.1002/14651858.CD010290.pub2
33 10.1002/14651858.CD006106.pub3
34 10.1002/14651858.CD006583.pub4
35 10.1002/14651858.CD003357.pub4
36 10.1002/14651858.CD006919.pub4
37 10.1002/14651858.CD001751.pub3
38 10.1002/14651858.CD009154.pub3
39 10.1002/14651858.CD007245.pub3
40 10.1002/14651858.CD009749.pub2
41 10.1002/14651858.CD009814.pub2
42 10.1002/14651858.CD007876.pub2
43 10.1002/14651858.CD003855.pub3
44 10.1002/14651858.CD001838.pub5
45 10.1002/14651858.CD012079
46
47
48
49
50
51
52
53
54
55
56
57
58
59
50

1
2
3 10.1002/14651858.CD000360.pub5
4 10.1002/14651858.CD009023.pub2
5 10.1002/14651858.CD006107.pub4
6 10.1002/14651858.CD002124.pub2
7 10.1002/14651858.CD011034.pub2
8 10.1002/14651858.CD007854.pub3
9 10.1002/14651858.CD003719.pub4
10 10.1002/14651858.CD007689.pub3
11 10.1002/14651858.CD011537.pub2
12 10.1002/14651858.CD001750.pub4
13 10.1002/14651858.CD011424.pub2
14 10.1002/14651858.CD002118.pub5
15 10.1002/14651858.CD001302.pub3
16 10.1002/14651858.CD010407.pub2
17 10.1002/14651858.CD012376
18 10.1002/14651858.CD004832.pub4
19 10.1002/14651858.CD001500.pub3
20 10.1002/14651858.CD008536.pub3
21 10.1002/14651858.CD007535.pub3
22 10.1002/14651858.CD003938.pub2
23 10.1002/14651858.CD008741.pub2
24 10.1002/14651858.CD007501.pub2
25 10.1002/14651858.CD001220.pub3
26 10.1002/14651858.CD007496.pub2
27 10.1002/14651858.CD009337
28 10.1002/14651858.CD007844.pub2
29 10.1002/14651858.CD008739.pub2
30 10.1002/14651858.CD006045.pub3
31 10.1002/14651858.CD004776.pub3
32 10.1002/14651858.CD009513
33 10.1002/14651858.CD005274.pub3
34 10.1002/14651858.CD009756
35 10.1002/14651858.CD005272.pub3
36 10.1002/14651858.CD007189.pub3
37 10.1002/14651858.CD009755
38 10.1002/14651858.CD009748.pub2
39 10.1002/14651858.CD001224.pub4
40 10.1002/14651858.CD003510.pub3
41 10.1002/14651858.CD009192.pub2
42 10.1002/14651858.CD009468.pub2
43 10.1002/14651858.CD007191.pub2
44 10.1002/14651858.CD005175.pub3
45 10.1002/14651858.CD010119
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD009190.pub2
4 10.1002/14651858.CD009153.pub3
5 10.1002/14651858.CD004536.pub3
6 10.1002/14651858.CD009012.pub2
7 10.1002/14651858.CD005481.pub3
8 10.1002/14651858.CD009189.pub2
9 10.1002/14651858.CD008270.pub2
10 10.1002/14651858.CD010929.pub2
11 10.1002/14651858.CD009826.pub2
12 10.1002/14651858.CD010309.pub2
13 10.1002/14651858.CD009987.pub2
14 10.1002/14651858.CD010666
15 10.1002/14651858.CD004772.pub4
16 10.1002/14651858.CD008439.pub3
17 10.1002/14651858.CD009886.pub2
18 10.1002/14651858.CD007331.pub3
19 10.1002/14651858.CD008720.pub2
20 10.1002/14651858.CD007497.pub2
21 10.1002/14651858.CD003256.pub2
22 10.1002/14651858.CD003363.pub3
23 10.1002/14651858.CD011323
24 10.1002/14651858.CD008605.pub3
25 10.1002/14651858.CD002249.pub5
26 10.1002/14651858.CD004014.pub6
27 10.1002/14651858.CD004378.pub3
28 10.1002/14651858.CD004753.pub4
29 10.1002/14651858.CD009090.pub2
30 10.1002/14651858.CD004752.pub2
31 10.1002/14651858.CD010503.pub2
32 10.1002/14651858.CD011872.pub2
33 10.1002/14651858.CD002811.pub4
34 10.1002/14651858.CD011184.pub2
35 10.1002/14651858.CD010770.pub2
36 10.1002/14651858.CD004143.pub5
37 10.1002/14651858.CD005070.pub3
38 10.1002/14651858.CD009881.pub2
39 10.1002/14651858.CD003414.pub3
40 10.1002/14651858.CD006150.pub2
41 10.1002/14651858.CD006109.pub3
42 10.1002/14651858.CD004637.pub2
43 10.1002/14651858.CD004472.pub3
44 10.1002/14651858.CD007038.pub2
45 10.1002/14651858.CD008012.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD005566.pub3
4 10.1002/14651858.CD001561.pub3
5 10.1002/14651858.CD003040.pub2
6 10.1002/14651858.CD005158.pub3
7 10.1002/14651858.CD004466.pub3
8 10.1002/14651858.CD007101.pub2
9 10.1002/14651858.CD007224.pub2
10 10.1002/14651858.CD002752.pub3
11 10.1002/14651858.CD008523.pub2
12 10.1002/14651858.CD004194.pub3
13 10.1002/14651858.CD003334.pub2
14 10.1002/14651858.CD002137.pub3
15 10.1002/14651858.CD008844.pub2
16 10.1002/14651858.CD008685.pub2
17 10.1002/14651858.CD010118.pub2
18 10.1002/14651858.CD009581.pub2
19 10.1002/14651858.CD009671.pub2
20 10.1002/14651858.CD003611.pub3
21 10.1002/14651858.CD004816.pub5
22 10.1002/14651858.CD009874.pub2
23 10.1002/14651858.CD003464.pub2
24 10.1002/14651858.CD005151.pub2
25 10.1002/14651858.CD009507.pub2
26 10.1002/14651858.CD002751.pub3
27 10.1002/14651858.CD009934.pub2
28 10.1002/14651858.CD005351.pub3
29 10.1002/14651858.CD009825.pub2
30 10.1002/14651858.CD004471.pub3
31 10.1002/14651858.CD010392.pub2
32 10.1002/14651858.CD010393.pub2
33 10.1002/14651858.CD010395.pub2
34 10.1002/14651858.CD002128.pub5
35 10.1002/14651858.CD002130.pub4
36 10.1002/14651858.CD003336.pub3
37 10.1002/14651858.CD008842.pub2
38 10.1002/14651858.CD006577.pub3
39 10.1002/14651858.CD007260.pub3
40 10.1002/14651858.CD010366.pub2
41 10.1002/14651858.CD002901.pub3
42 10.1002/14651858.CD010072.pub2
43 10.1002/14651858.CD009917.pub2
44 10.1002/14651858.CD003463.pub2
45 10.1002/14651858.CD008684.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD003331.pub4
4 10.1002/14651858.CD009752.pub2
5 10.1002/14651858.CD009669.pub2
6 10.1002/14651858.CD007131.pub3
7 10.1002/14651858.CD009387.pub2
8 10.1002/14651858.CD003462.pub3
9 10.1002/14651858.CD010652.pub2
10 10.1002/14651858.CD010191.pub2
11 10.1002/14651858.CD010405.pub2
12 10.1002/14651858.CD006870.pub3
13 10.1002/14651858.CD009502.pub3
14 10.1002/14651858.CD007259.pub2
15 10.1002/14651858.CD009217.pub3
16 10.1002/14651858.CD003712.pub3
17 10.1002/14651858.CD009515.pub2
18 10.1002/14651858.CD002229.pub4
19 10.1002/14651858.CD007398.pub3
20 10.1002/14651858.CD005050.pub3
21 10.1002/14651858.CD004370.pub3
22 10.1002/14651858.CD009503.pub3
23 10.1002/14651858.CD003176.pub3
24 10.1002/14651858.CD010237.pub2
25 10.1002/14651858.CD005049.pub4
26 10.1002/14651858.CD010390.pub2
27 10.1002/14651858.CD004101.pub5
28 10.1002/14651858.CD004818.pub4
29 10.1002/14651858.CD007614.pub2
30 10.1002/14651858.CD006886.pub2
31 10.1002/14651858.CD011148.pub2
32 10.1002/14651858.CD011163.pub2
33 10.1002/14651858.CD011737
34 10.1002/14651858.CD011168.pub2
35 10.1002/14651858.CD011583.pub2
36 10.1002/14651858.CD008553.pub2
37 10.1002/14651858.CD009580.pub2
38 10.1002/14651858.CD011094.pub2
39 10.1002/14651858.CD009889.pub2
40 10.1002/14651858.CD006536.pub4
41 10.1002/14651858.CD008093.pub2
42 10.1002/14651858.CD009386.pub2
43 10.1002/14651858.CD006781.pub3
44 10.1002/14651858.CD011834
45 10.1002/14651858.CD011472.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD007037.pub3
4 10.1002/14651858.CD006762.pub2
5 10.1002/14651858.CD001800.pub3
6 10.1002/14651858.CD010411.pub2
7 10.1002/14651858.CD010988.pub2
8 10.1002/14651858.CD011047.pub2
9 10.1002/14651858.CD007228.pub3
10 10.1002/14651858.CD011637.pub2
11 10.1002/14651858.CD010876.pub2
12 10.1002/14651858.CD004815.pub4
13 10.1002/14651858.CD009586.pub3
14 10.1002/14651858.CD009077.pub3
15 10.1002/14651858.CD009880.pub2
16 10.1002/14651858.CD009571.pub2
17 10.1002/14651858.CD003839.pub3
18 10.1002/14651858.CD003333.pub3
19 10.1002/14651858.CD009753.pub2
20 10.1002/14651858.CD009462.pub2
21 10.1002/14651858.CD007160.pub4
22 10.1002/14651858.CD012088.pub2
23 10.1002/14651858.CD011747.pub2
24 10.1002/14651858.CD011197.pub2
25 10.1002/14651858.CD009868.pub3
26 10.1002/14651858.CD008966.pub2
27 10.1002/14651858.CD004371.pub4
28 10.1002/14651858.CD011814.pub2
29 10.1002/14651858.CD007888.pub3
30 10.1002/14651858.CD012264.pub2
31 10.1002/14651858.CD011114.pub2
32 10.1002/14651858.CD006887.pub4
33 10.1002/14651858.CD011793.pub2
34 10.1002/14651858.CD011851.pub2
35 10.1002/14651858.CD011986.pub2
36 10.1002/14651858.CD011719.pub3
37 10.1002/14651858.CD008600.pub3
38 10.1002/14651858.CD011748.pub2
39 10.1002/14651858.CD007130.pub4
40 10.1002/14651858.CD011312.pub3
41 10.1002/14651858.CD008895.pub3
42 10.1002/14651858.CD009744.pub2
43 10.1002/14651858.CD004467.pub3
44 10.1002/14651858.CD006612.pub5
45 10.1002/14651858.CD005051.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD002902.pub4
4 10.1002/14651858.CD012481.pub2
5 10.1002/14651858.CD003186.pub3
6 10.1002/14651858.CD008118.pub2
7 10.1002/14651858.CD005184.pub2
8 10.1002/14651858.CD004184.pub2
9 10.1002/14651858.CD007653.pub2
10 10.1002/14651858.CD004643.pub3
11 10.1002/14651858.CD006742.pub2
12 10.1002/14651858.CD009096.pub2
13 10.1002/14651858.CD008167.pub3
14 10.1002/14651858.CD007452.pub2
15 10.1002/14651858.CD008277.pub2
16 10.1002/14651858.CD003824.pub2
17 10.1002/14651858.CD010052.pub2
18 10.1002/14651858.CD008117.pub2
19 10.1002/14651858.CD007450.pub2
20 10.1002/14651858.CD004937.pub2
21 10.1002/14651858.CD008170.pub2
22 10.1002/14651858.CD003825.pub4
23 10.1002/14651858.CD010037.pub2
24 10.1002/14651858.CD007449.pub2
25 10.1002/14651858.CD010254.pub2
26 10.1002/14651858.CD007435.pub3
27 10.1002/14651858.CD007654.pub4
28 10.1002/14651858.CD011745.pub2
29 10.1002/14651858.CD008274.pub3
30 10.1002/14651858.CD010316.pub2
31 10.1002/14651858.CD007451.pub2
32 10.1002/14651858.CD002003.pub5
33 10.1002/14651858.CD008996.pub2
34 10.1002/14651858.CD007655.pub3
35 10.1002/14651858.CD011499.pub2
36 10.1002/14651858.CD007066.pub3
37 10.1002/14651858.CD008652.pub3
38 10.1002/14651858.CD008276.pub2
39 10.1002/14651858.CD011575.pub2
40 10.1002/14651858.CD004022.pub4
41 10.1002/14651858.CD008893.pub3
42 10.1002/14651858.CD008226.pub3
43 10.1002/14651858.CD003882.pub4
44 10.1002/14651858.CD002240.pub4
45 10.1002/14651858.CD009252
46
47
48
49
50
51
52
53
54
55
56
57
58
59
50

1
2
3 10.1002/14651858.CD005493.pub3
4 10.1002/14651858.CD005230.pub2
5 10.1002/14651858.CD004201.pub3
6 10.1002/14651858.CD003306.pub2
7 10.1002/14651858.CD009508
8 10.1002/14651858.CD008224.pub2
9 10.1002/14651858.CD004997.pub3
10 10.1002/14651858.CD007471.pub2
11 10.1002/14651858.CD003193.pub4
12 10.1002/14651858.CD006934.pub3
13 10.1002/14651858.CD005429.pub2
14 10.1002/14651858.CD007959.pub3
15 10.1002/14651858.CD004010.pub3
16 10.1002/14651858.CD002238.pub2
17 10.1002/14651858.CD001405.pub3
18 10.1002/14651858.CD001202.pub5
19 10.1002/14651858.CD002116.pub2
20 10.1002/14651858.CD009408.pub2
21 10.1002/14651858.CD002111.pub3
22 10.1002/14651858.CD005428.pub2
23 10.1002/14651858.CD001757.pub4
24 10.1002/14651858.CD002114.pub2
25 10.1002/14651858.CD003637.pub3
26 10.1002/14651858.CD003195.pub3
27 10.1002/14651858.CD004927.pub4
28 10.1002/14651858.CD006744.pub3
29 10.1002/14651858.CD002115.pub5
30 10.1002/14651858.CD008306.pub3
31 10.1002/14651858.CD005654.pub3
32 10.1002/14651858.CD004013.pub4
33 10.1002/14651858.CD010258.pub2
34 10.1002/14651858.CD001756.pub6
35 10.1002/14651858.CD005086.pub4
36 10.1002/14651858.CD011179.pub2
37 10.1002/14651858.CD010217.pub2
38 10.1002/14651858.CD004464.pub3
39 10.1002/14651858.CD003505.pub5
40 10.1002/14651858.CD010551.pub3
41 10.1002/14651858.CD001843.pub5
42 10.1002/14651858.CD011115.pub2
43 10.1002/14651858.CD004012.pub5
44 10.1002/14651858.CD001758.pub3
45 10.1002/14651858.CD004203.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD003636.pub4
4 10.1002/14651858.CD011627.pub2
5 10.1002/14651858.CD002117.pub2
6 10.1002/14651858.CD003881.pub4
7 10.1002/14651858.CD002239.pub3
8 10.1002/14651858.CD008709.pub3
9 10.1002/14651858.CD001755.pub2
10 10.1002/14651858.CD001754.pub4
11 10.1002/14651858.CD002912.pub7
12 10.1002/14651858.CD001088.pub3
13 10.1002/14651858.CD006375.pub4
14 10.1002/14651858.CD010098.pub4
15 10.1002/14651858.CD005353.pub4
16 10.1002/14651858.CD001837.pub3
17 10.1002/14651858.CD009046.pub2
18 10.1002/14651858.CD005084.pub3
19 10.1002/14651858.CD001291.pub2
20 10.1002/14651858.CD006219.pub3
21 10.1002/14651858.CD000214.pub2
22 10.1002/14651858.CD000191.pub2
23 10.1002/14651858.CD007072.pub2
24 10.1002/14651858.CD009325.pub2
25 10.1002/14651858.CD002928.pub3
26 10.1002/14651858.CD008033.pub3
27 10.1002/14651858.CD009187.pub2
28 10.1002/14651858.CD000165.pub4
29 10.1002/14651858.CD004705.pub4
30 10.1002/14651858.CD003086.pub3
31 10.1002/14651858.CD007253.pub3
32 10.1002/14651858.CD001188.pub4
33 10.1002/14651858.CD003999.pub4
34 10.1002/14651858.CD006102.pub2
35 10.1002/14651858.CD000146.pub4
36 10.1002/14651858.CD001293.pub3
37 10.1002/14651858.CD002850.pub3
38 10.1002/14651858.CD000009.pub4
39 10.1002/14651858.CD002294.pub4
40 10.1002/14651858.CD009990.pub2
41 10.1002/14651858.CD002295.pub5
42 10.1002/14651858.CD008743.pub3
43 10.1002/14651858.CD001746.pub3
44 10.1002/14651858.CD001118.pub3
45 10.1002/14651858.CD009164.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD003440.pub4
4 10.1002/14651858.CD005549.pub3
5 10.1002/14651858.CD004493.pub3
6 10.1002/14651858.CD007505.pub2
7 10.1002/14651858.CD004307.pub5
8 10.1002/14651858.CD006936.pub3
9 10.1002/14651858.CD009670.pub3
10 10.1002/14651858.CD004306.pub5
11 10.1002/14651858.CD000031.pub4
12 10.1002/14651858.CD006611.pub4
13 10.1002/14651858.CD005992.pub3
14 10.1002/14651858.CD010078.pub2
15 10.1002/14651858.CD008286.pub3
16 10.1002/14651858.CD011120.pub2
17 10.1002/14651858.CD011045.pub2
18 10.1002/14651858.CD010274.pub2
19 10.1002/14651858.CD010742.pub2
20 10.1002/14651858.CD010216.pub3
21 10.1002/14651858.CD011856.pub2
22 10.1002/14651858.CD005231.pub3
23 10.1002/14651858.CD006103.pub7
24 10.1002/14651858.CD008645.pub3
25 10.1002/14651858.CD001006.pub3
26 10.1002/14651858.CD007078.pub5
27 10.1002/14651858.CD011244.pub2
28 10.1002/14651858.CD001292.pub3
29 10.1002/14651858.CD001007.pub3
30 10.1002/14651858.CD001055.pub5
31 10.1002/14651858.CD008976.pub2
32 10.1002/14651858.CD007349.pub2
33 10.1002/14651858.CD006885.pub2
34 10.1002/14651858.CD006576.pub2
35 10.1002/14651858.CD008195.pub2
36 10.1002/14651858.CD001532.pub4
37 10.1002/14651858.CD009294.pub2
38 10.1002/14651858.CD004926.pub3
39 10.1002/14651858.CD009427.pub2
40 10.1002/14651858.CD007234.pub2
41 10.1002/14651858.CD004292.pub3
42 10.1002/14651858.CD008007.pub2
43 10.1002/14651858.CD006029.pub4
44 10.1002/14651858.CD004135.pub3
45 10.1002/14651858.CD009063.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD008871.pub2
4 10.1002/14651858.CD004720.pub3
5 10.1002/14651858.CD008569.pub2
6 10.1002/14651858.CD003382.pub3
7 10.1002/14651858.CD003546.pub3
8 10.1002/14651858.CD009071.pub2
9 10.1002/14651858.CD007044.pub3
10 10.1002/14651858.CD001423.pub3
11 10.1002/14651858.CD008973.pub2
12 10.1002/14651858.CD008529.pub3
13 10.1002/14651858.CD011442.pub2
14 10.1002/14651858.CD010716.pub2
15 10.1002/14651858.CD009266.pub2
16 10.1002/14651858.CD012111.pub2
17 10.1002/14651858.CD012112.pub2
18 10.1002/14651858.CD012045.pub2
19 10.1002/14651858.CD009625.pub2
20 10.1002/14651858.CD010723.pub2
21 10.1002/14651858.CD011673.pub2
22 10.1002/14651858.CD007152.pub2
23 10.1002/14651858.CD001168.pub2
24 10.1002/14651858.CD006545.pub2
25 10.1002/14651858.CD005205.pub3
26 10.1002/14651858.CD008092.pub2
27 10.1002/14651858.CD008596.pub2
28 10.1002/14651858.CD001541.pub3
29 10.1002/14651858.CD008240.pub2
30 10.1002/14651858.CD008838.pub2
31 10.1002/14651858.CD003584.pub2
32 10.1002/14651858.CD006983.pub3
33 10.1002/14651858.CD008946.pub2
34 10.1002/14651858.CD002086.pub2
35 10.1002/14651858.CD004416.pub2
36 10.1002/14651858.CD007633.pub2
37 10.1002/14651858.CD008955.pub2
38 10.1002/14651858.CD008642.pub2
39 10.1002/14651858.CD007281.pub2
40 10.1002/14651858.CD004054.pub3
41 10.1002/14651858.CD009481.pub2
42 10.1002/14651858.CD009446.pub2
43 10.1002/14651858.CD004415.pub2
44 10.1002/14651858.CD005028.pub3
45 10.1002/14651858.CD005506.pub5
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD008533.pub3
4 10.1002/14651858.CD009779.pub2
5 10.1002/14651858.CD004778.pub3
6 10.1002/14651858.CD009662.pub2
7 10.1002/14651858.CD008370.pub3
8 10.1002/14651858.CD008107.pub2
9 10.1002/14651858.CD002095.pub5
10 10.1002/14651858.CD009179.pub2
11 10.1002/14651858.CD010326.pub2
12 10.1002/14651858.CD007999.pub2
13 10.1002/14651858.CD005096.pub4
14 10.1002/14651858.CD008415.pub2
15 10.1002/14651858.CD010244.pub2
16 10.1002/14651858.CD008446.pub3
17 10.1002/14651858.CD008945.pub2
18 10.1002/14651858.CD005584.pub3
19 10.1002/14651858.CD008487.pub2
20 10.1002/14651858.CD006640.pub3
21 10.1002/14651858.CD005048.pub4
22 10.1002/14651858.CD008337.pub2
23 10.1002/14651858.CD005046.pub3
24 10.1002/14651858.CD003353.pub2
25 10.1002/14651858.CD008550.pub2
26 10.1002/14651858.CD010623.pub2
27 10.1002/14651858.CD010605.pub2
28 10.1002/14651858.CD005583.pub2
29 10.1002/14651858.CD008788.pub3
30 10.1002/14651858.CD007884.pub3
31 10.1002/14651858.CD001556.pub3
32 10.1002/14651858.CD001964.pub4
33 10.1002/14651858.CD008096.pub4
34 10.1002/14651858.CD003243.pub3
35 10.1002/14651858.CD008688.pub2
36 10.1002/14651858.CD011382.pub2
37 10.1002/14651858.CD011522.pub2
38 10.1002/14651858.CD011521.pub2
39 10.1002/14651858.CD004520.pub7
40 10.1002/14651858.CD006053.pub6
41 10.1002/14651858.CD011498.pub2
42 10.1002/14651858.CD009621.pub2
43 10.1002/14651858.CD011523.pub2
44 10.1002/14651858.CD011390.pub2
45 10.1002/14651858.CD009477.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD011389.pub2
4 10.1002/14651858.CD011392.pub2
5 10.1002/14651858.CD011391.pub2
6 10.1002/14651858.CD008914.pub3
7 10.1002/14651858.CD010571.pub2
8 10.1002/14651858.CD011383.pub2
9 10.1002/14651858.CD011461.pub2
10 10.1002/14651858.CD009034.pub2
11 10.1002/14651858.CD011862.pub2
12 10.1002/14651858.CD011194.pub2
13 10.1002/14651858.CD011969.pub2
14 10.1002/14651858.CD010511.pub2
15 10.1002/14651858.CD010583.pub3
16 10.1002/14651858.CD011384.pub2
17 10.1002/14651858.CD012257.pub2
18 10.1002/14651858.CD004064.pub4
19 10.1002/14651858.CD000536.pub2
20 10.1002/14651858.CD008472.pub2
21 10.1002/14651858.CD008826.pub2
22 10.1002/14651858.CD001272.pub2
23 10.1002/14651858.CD007162.pub2
24 10.1002/14651858.CD002070.pub2
25 10.1002/14651858.CD007921.pub2
26 10.1002/14651858.CD006687.pub3
27 10.1002/14651858.CD000188.pub2
28 10.1002/14651858.CD003635.pub3
29 10.1002/14651858.CD009536.pub2
30 10.1002/14651858.CD003230.pub4
31 10.1002/14651858.CD002071.pub3
32 10.1002/14651858.CD006512.pub2
33 10.1002/14651858.CD007057.pub3
34 10.1002/14651858.CD001368.pub4
35 10.1002/14651858.CD000988.pub4
36 10.1002/14651858.CD004001.pub3
37 10.1002/14651858.CD000095.pub2
38 10.1002/14651858.CD000986.pub3
39 10.1002/14651858.CD001486.pub2
40 10.1002/14651858.CD006888.pub3
41 10.1002/14651858.CD003833.pub4
42 10.1002/14651858.CD002784.pub2
43 10.1002/14651858.CD009894.pub2
44 10.1002/14651858.CD003074.pub3
45 10.1002/14651858.CD004982.pub5
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD003285.pub2
4 10.1002/14651858.CD005507.pub3
5 10.1002/14651858.CD005508.pub3
6 10.1002/14651858.CD008201.pub2
7 10.1002/14651858.CD005263.pub3
8 10.1002/14651858.CD010308.pub2
9 10.1002/14651858.CD010389.pub2
10 10.1002/14651858.CD008426.pub2
11 10.1002/14651858.CD009436.pub2
12 10.1002/14651858.CD006137.pub2
13 10.1002/14651858.CD010307.pub2
14 10.1002/14651858.CD009992.pub2
15 10.1002/14651858.CD003263.pub5
16 10.1002/14651858.CD008138.pub3
17 10.1002/14651858.CD008736.pub2
18 10.1002/14651858.CD009864.pub2
19 10.1002/14651858.CD010497.pub2
20 10.1002/14651858.CD010017.pub2
21 10.1002/14651858.CD010095.pub2
22 10.1002/14651858.CD003262.pub5
23 10.1002/14651858.CD007346.pub3
24 10.1002/14651858.CD010081.pub2
25 10.1002/14651858.CD010334.pub2
26 10.1002/14651858.CD008774.pub2
27 10.1002/14651858.CD005491.pub3
28 10.1002/14651858.CD004685.pub3
29 10.1002/14651858.CD011946.pub2
30 10.1002/14651858.CD009687.pub2
31 10.1002/14651858.CD011161.pub2
32 10.1002/14651858.CD002954.pub3
33 10.1002/14651858.CD004767.pub4
34 10.1002/14651858.CD006345.pub3
35 10.1002/14651858.CD009758.pub2
36 10.1002/14651858.CD007628.pub4
37 10.1002/14651858.CD004981.pub4
38 10.1002/14651858.CD007917.pub2
39 10.1002/14651858.CD010031.pub2
40 10.1002/14651858.CD012119.pub2
41 10.1002/14651858.CD003075.pub3
42 10.1002/14651858.CD010525.pub2
43 10.1002/14651858.CD001099.pub3
44 10.1002/14651858.CD008819.pub3
45 10.1002/14651858.CD005983.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD003504.pub2
4 10.1002/14651858.CD004178.pub2
5 10.1002/14651858.CD010196.pub2
6 10.1002/14651858.CD005982.pub2
7 10.1002/14651858.CD003749.pub3
8 10.1002/14651858.CD006680.pub2
9 10.1002/14651858.CD001999.pub2
10 10.1002/14651858.CD003747.pub4
11 10.1002/14651858.CD009162.pub2
12 10.1002/14651858.CD008207.pub3
13 10.1002/14651858.CD001367.pub3
14 10.1002/14651858.CD006767.pub3
15 10.1002/14651858.CD010149.pub2
16 10.1002/14651858.CD000990.pub3
17 10.1002/14651858.CD009638.pub2
18 10.1002/14651858.CD005624.pub3
19 10.1002/14651858.CD003748.pub4
20 10.1002/14651858.CD008462.pub2
21 10.1002/14651858.CD010019.pub2
22 10.1002/14651858.CD009543.pub3
23 10.1002/14651858.CD002944.pub2
24 10.1002/14651858.CD008347.pub3
25 10.1002/14651858.CD006342.pub2
26 10.1002/14651858.CD008203.pub3
27 10.1002/14651858.CD001484.pub3
28 10.1002/14651858.CD001835.pub4
29 10.1002/14651858.CD001097.pub3
30 10.1002/14651858.CD007561.pub2
31 10.1002/14651858.CD005260.pub3
32 10.1002/14651858.CD000535.pub3
33 10.1002/14651858.CD009658.pub2
34 10.1002/14651858.CD009648.pub3
35 10.1002/14651858.CD007798.pub4
36 10.1002/14651858.CD002786.pub3
37 10.1002/14651858.CD010956.pub2
38 10.1002/14651858.CD005625.pub3
39 10.1002/14651858.CD010996.pub2
40 10.1002/14651858.CD011015.pub2
41 10.1002/14651858.CD005262.pub3
42 10.1002/14651858.CD004437.pub4
43 10.1002/14651858.CD010373.pub2
44 10.1002/14651858.CD007699.pub3
45 10.1002/14651858.CD010957.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
50

1
2
3 10.1002/14651858.CD007371.pub3
4 10.1002/14651858.CD011033.pub3
5 10.1002/14651858.CD004179.pub2
6 10.1002/14651858.CD002069.pub5
7 10.1002/14651858.CD009541.pub2
8 10.1002/14651858.CD008942.pub2
9 10.1002/14651858.CD003229.pub3
10 10.1002/14651858.CD011319.pub2
11 10.1002/14651858.CD005258.pub3
12 10.1002/14651858.CD004002.pub3
13 10.1002/14651858.CD009418.pub3
14 10.1002/14651858.CD010878.pub2
15 10.1002/14651858.CD002783.pub4
16 10.1002/14651858.CD010637.pub2
17 10.1002/14651858.CD008500.pub4
18 10.1002/14651858.CD010447.pub3
19 10.1002/14651858.CD011188.pub2
20 10.1002/14651858.CD005134.pub3
21 10.1002/14651858.CD010185.pub3
22 10.1002/14651858.CD006771.pub3
23 10.1002/14651858.CD001100.pub4
24 10.1002/14651858.CD012302.pub2
25 10.1002/14651858.CD002000.pub3
26 10.1002/14651858.CD007557.pub3
27 10.1002/14651858.CD005261.pub4
28 10.1002/14651858.CD002001.pub3
29 10.1002/14651858.CD011741.pub2
30 10.1002/14651858.CD006681.pub4
31 10.1002/14651858.CD010837.pub3
32 10.1002/14651858.CD004174.pub3
33 10.1002/14651858.CD009170.pub2
34 10.1002/14651858.CD006308.pub3
35 10.1002/14651858.CD010183.pub2
36 10.1002/14651858.CD008570.pub2
37 10.1002/14651858.CD009209.pub2
38 10.1002/14651858.CD010208.pub2
39 10.1002/14651858.CD008742.pub2
40 10.1002/14651858.CD009776.pub2
41 10.1002/14651858.CD006237.pub3
42 10.1002/14651858.CD010090.pub2
43 10.1002/14651858.CD002892.pub5
44 10.1002/14651858.CD010305.pub2
45 10.1002/14651858.CD007569.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD009573.pub2
4 10.1002/14651858.CD009385.pub2
5 10.1002/14651858.CD006955.pub3
6 10.1002/14651858.CD008881.pub2
7 10.1002/14651858.CD010306.pub2
8 10.1002/14651858.CD011621.pub2
9 10.1002/14651858.CD010912.pub3
10 10.1002/14651858.CD010157.pub2
11 10.1002/14651858.CD009778.pub2
12 10.1002/14651858.CD010641.pub2
13 10.1002/14651858.CD011899.pub2
14 10.1002/14651858.CD011618.pub2
15 10.1002/14651858.CD011867.pub2
16 10.1002/14651858.CD006396.pub4
17 10.1002/14651858.CD011255.pub2
18 10.1002/14651858.CD012462.pub2
19 10.1002/14651858.CD011918.pub2
20 10.1002/14651858.CD006868.pub3
21 10.1002/14651858.CD011202.pub2
22 10.1002/14651858.CD007238.pub2
23 10.1002/14651858.CD009701.pub2
24 10.1002/14651858.CD004075.pub4
25 10.1002/14651858.CD000112.pub3
26 10.1002/14651858.CD008825.pub2
27 10.1002/14651858.CD010660.pub2
28 10.1002/14651858.CD001807.pub2
29 10.1002/14651858.CD010385.pub2
30 10.1002/14651858.CD009708.pub2
31 10.1002/14651858.CD007482.pub3
32 10.1002/14651858.CD007772.pub3
33 10.1002/14651858.CD007873.pub3
34 10.1002/14651858.CD009394.pub2
35 10.1002/14651858.CD004453.pub3
36 10.1002/14651858.CD007715.pub2
37 10.1002/14651858.CD006167.pub4
38 10.1002/14651858.CD007123.pub3
39 10.1002/14651858.CD009243.pub3
40 10.1002/14651858.CD009241.pub3
41 10.1002/14651858.CD006431.pub3
42 10.1002/14651858.CD007201.pub3
43 10.1002/14651858.CD005461.pub4
44 10.1002/14651858.CD004074.pub3
45 10.1002/14651858.CD008534.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
50

1
2
3 10.1002/14651858.CD000493.pub2
4 10.1002/14651858.CD008982.pub2
5 10.1002/14651858.CD006760.pub2
6 10.1002/14651858.CD010088.pub2
7 10.1002/14651858.CD003767.pub3
8 10.1002/14651858.CD004665.pub3
9 10.1002/14651858.CD008019.pub2
10 10.1002/14651858.CD008580.pub2
11 10.1002/14651858.CD003094.pub3
12 10.1002/14651858.CD002256.pub2
13 10.1002/14651858.CD004226.pub3
14 10.1002/14651858.CD001337.pub2
15 10.1002/14651858.CD000220.pub2
16 10.1002/14651858.CD008410.pub2
17 10.1002/14651858.CD006168.pub2
18 10.1002/14651858.CD004908.pub2
19 10.1002/14651858.CD006907.pub2
20 10.1002/14651858.CD009215
21 10.1002/14651858.CD009514
22 10.1002/14651858.CD007559.pub2
23 10.1002/14651858.CD005943.pub4
24 10.1002/14651858.CD009232
25 10.1002/14651858.CD009107.pub2
26 10.1002/14651858.CD000013.pub2
27 10.1002/14651858.CD004456.pub3
28 10.1002/14651858.CD000331.pub3
29 10.1002/14651858.CD009290.pub2
30 10.1002/14651858.CD009037.pub2
31 10.1002/14651858.CD005544.pub2
32 10.1002/14651858.CD008679.pub2
33 10.1002/14651858.CD009148.pub2
34 10.1002/14651858.CD001233.pub2
35 10.1002/14651858.CD006176.pub2
36 10.1002/14651858.CD003928.pub3
37 10.1002/14651858.CD003518.pub3
38 10.1002/14651858.CD009200.pub2
39 10.1002/14651858.CD008681.pub2
40 10.1002/14651858.CD001064.pub2
41 10.1002/14651858.CD005457.pub4
42 10.1002/14651858.CD008510.pub2
43 10.1002/14651858.CD001065.pub2
44 10.1002/14651858.CD004945.pub3
45 10.1002/14651858.CD001062.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD009062.pub2
4 10.1002/14651858.CD006304.pub3
5 10.1002/14651858.CD007113.pub3
6 10.1002/14651858.CD000108.pub2
7 10.1002/14651858.CD009021.pub2
8 10.1002/14651858.CD003248.pub3
9 10.1002/14651858.CD007426.pub2
10 10.1002/14651858.CD003517.pub2
11 10.1002/14651858.CD000012.pub4
12 10.1002/14651858.CD009223.pub2
13 10.1002/14651858.CD006636.pub3
14 10.1002/14651858.CD000004.pub2
15 10.1002/14651858.CD008678.pub2
16 10.1002/14651858.CD000176.pub2
17 10.1002/14651858.CD005460.pub3
18 10.1002/14651858.CD007096.pub3
19 10.1002/14651858.CD000352.pub2
20 10.1002/14651858.CD003397.pub2
21 10.1002/14651858.CD000494.pub4
22 10.1002/14651858.CD005937.pub3
23 10.1002/14651858.CD000133.pub3
24 10.1002/14651858.CD009351.pub2
25 10.1002/14651858.CD007579.pub2
26 10.1002/14651858.CD003401.pub3
27 10.1002/14651858.CD007239.pub3
28 10.1002/14651858.CD007748.pub2
29 10.1002/14651858.CD004350.pub3
30 10.1002/14651858.CD000051.pub2
31 10.1002/14651858.CD000066.pub2
32 10.1002/14651858.CD003577.pub3
33 10.1002/14651858.CD000947.pub3
34 10.1002/14651858.CD007885.pub2
35 10.1002/14651858.CD000136.pub2
36 10.1002/14651858.CD000114.pub2
37 10.1002/14651858.CD007235.pub3
38 10.1002/14651858.CD003927.pub3
39 10.1002/14651858.CD000262.pub4
40 10.1002/14651858.CD007707.pub2
41 10.1002/14651858.CD005458.pub3
42 10.1002/14651858.CD009395.pub2
43 10.1002/14651858.CD009617.pub2
44 10.1002/14651858.CD008611.pub2
45 10.1002/14651858.CD006896.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD008407.pub2
4 10.1002/14651858.CD007623.pub3
5 10.1002/14651858.CD001134.pub3
6 10.1002/14651858.CD004351.pub3
7 10.1002/14651858.CD007752.pub3
8 10.1002/14651858.CD005123.pub3
9 10.1002/14651858.CD000940.pub3
10 10.1002/14651858.CD008635.pub2
11 10.1002/14651858.CD000330.pub4
12 10.1002/14651858.CD003099.pub2
13 10.1002/14651858.CD006780.pub3
14 10.1002/14651858.CD003106.pub2
15 10.1002/14651858.CD009338.pub2
16 10.1002/14651858.CD005627.pub3
17 10.1002/14651858.CD010041.pub2
18 10.1002/14651858.CD006795.pub3
19 10.1002/14651858.CD006794.pub4
20 10.1002/14651858.CD004947.pub3
21 10.1002/14651858.CD003930.pub3
22 10.1002/14651858.CD006764.pub3
23 10.1002/14651858.CD010073.pub2
24 10.1002/14651858.CD001449.pub3
25 10.1002/14651858.CD000078.pub3
26 10.1002/14651858.CD004907.pub3
27 10.1002/14651858.CD010648.pub2
28 10.1002/14651858.CD008977.pub2
29 10.1002/14651858.CD009278.pub2
30 10.1002/14651858.CD006947.pub3
31 10.1002/14651858.CD008878.pub2
32 10.1002/14651858.CD005938.pub3
33 10.1002/14651858.CD009104.pub2
34 10.1002/14651858.CD003934.pub4
35 10.1002/14651858.CD001808.pub2
36 10.1002/14651858.CD003096.pub2
37 10.1002/14651858.CD010087.pub2
38 10.1002/14651858.CD007372.pub3
39 10.1002/14651858.CD003511.pub3
40 10.1002/14651858.CD004071.pub3
41 10.1002/14651858.CD009328.pub2
42 10.1002/14651858.CD003396.pub2
43 10.1002/14651858.CD000019.pub3
44 10.1002/14651858.CD002963.pub2
45 10.1002/14651858.CD000246.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD002866.pub3
4 10.1002/14651858.CD001058.pub3
5 10.1002/14651858.CD004224.pub3
6 10.1002/14651858.CD004068.pub4
7 10.1002/14651858.CD002073.pub3
8 10.1002/14651858.CD000014.pub4
9 10.1002/14651858.CD006770.pub3
10 10.1002/14651858.CD010441.pub2
11 10.1002/14651858.CD003582.pub2
12 10.1002/14651858.CD004352.pub3
13 10.1002/14651858.CD009951.pub2
14 10.1002/14651858.CD010800.pub2
15 10.1002/14651858.CD002252.pub3
16 10.1002/14651858.CD000942.pub3
17 10.1002/14651858.CD007062.pub3
18 10.1002/14651858.CD004943.pub4
19 10.1002/14651858.CD003249.pub3
20 10.1002/14651858.CD008053.pub3
21 10.1002/14651858.CD000937.pub2
22 10.1002/14651858.CD010312.pub2
23 10.1002/14651858.CD010322.pub2
24 10.1002/14651858.CD002860.pub2
25 10.1002/14651858.CD008758.pub2
26 10.1002/14651858.CD002255.pub2
27 10.1002/14651858.CD004452.pub3
28 10.1002/14651858.CD007467.pub4
29 10.1002/14651858.CD003101.pub3
30 10.1002/14651858.CD006169.pub2
31 10.1002/14651858.CD004734.pub4
32 10.1002/14651858.CD004732.pub3
33 10.1002/14651858.CD001059.pub4
34 10.1002/14651858.CD009166.pub2
35 10.1002/14651858.CD001338.pub3
36 10.1002/14651858.CD004070.pub3
37 10.1002/14651858.CD001060.pub2
38 10.1002/14651858.CD007462.pub3
39 10.1002/14651858.CD005125.pub4
40 10.1002/14651858.CD010209.pub2
41 10.1002/14651858.CD000163.pub2
42 10.1002/14651858.CD000203.pub3
43 10.1002/14651858.CD000209.pub2
44 10.1002/14651858.CD004718.pub3
45 10.1002/14651858.CD006626.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD006622.pub2
4 10.1002/14651858.CD002831.pub2
5 10.1002/14651858.CD004026.pub2
6 10.1002/14651858.CD000381.pub3
7 10.1002/14651858.CD007967.pub2
8 10.1002/14651858.CD004162.pub2
9 10.1002/14651858.CD000525.pub3
10 10.1002/14651858.CD006374.pub2
11 10.1002/14651858.CD008712.pub2
12 10.1002/14651858.CD007198.pub2
13 10.1002/14651858.CD001236.pub2
14 10.1002/14651858.CD008296.pub2
15 10.1002/14651858.CD009414.pub3
16 10.1002/14651858.CD008016.pub2
17 10.1002/14651858.CD009516.pub2
18 10.1002/14651858.CD007892.pub5
19 10.1002/14651858.CD010976.pub2
20 10.1002/14651858.CD008726.pub2
21 10.1002/14651858.CD009298.pub2
22 10.1002/14651858.CD003520.pub3
23 10.1002/14651858.CD007366.pub2
24 10.1002/14651858.CD004903.pub4
25 10.1002/14651858.CD008020.pub2
26 10.1002/14651858.CD006178.pub3
27 10.1002/14651858.CD007622.pub3
28 10.1002/14651858.CD000230.pub5
29 10.1002/14651858.CD000184.pub4
30 10.1002/14651858.CD007079.pub3
31 10.1002/14651858.CD000083.pub3
32 10.1002/14651858.CD003581.pub3
33 10.1002/14651858.CD007412.pub4
34 10.1002/14651858.CD010450.pub2
35 10.1002/14651858.CD007754.pub3
36 10.1002/14651858.CD006174.pub3
37 10.1002/14651858.CD010708.pub2
38 10.1002/14651858.CD001450.pub4
39 10.1002/14651858.CD000032.pub3
40 10.1002/14651858.CD006965.pub4
41 10.1002/14651858.CD009982.pub2
42 10.1002/14651858.CD001992.pub3
43 10.1002/14651858.CD000179.pub3
44 10.1002/14651858.CD010762.pub2
45 10.1002/14651858.CD001067.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD005547.pub3
4 10.1002/14651858.CD007872.pub3
5 10.1002/14651858.CD011158.pub2
6 10.1002/14651858.CD002250.pub3
7 10.1002/14651858.CD001451.pub4
8 10.1002/14651858.CD007145.pub3
9 10.1002/14651858.CD003935.pub4
10 10.1002/14651858.CD002959.pub4
11 10.1002/14651858.CD007058.pub3
12 10.1002/14651858.CD007901.pub3
13 10.1002/14651858.CD000084.pub3
14 10.1002/14651858.CD000166.pub2
15 10.1002/14651858.CD000934.pub3
16 10.1002/14651858.CD010085.pub2
17 10.1002/14651858.CD010655.pub2
18 10.1002/14651858.CD000490.pub3
19 10.1002/14651858.CD007208.pub3
20 10.1002/14651858.CD009279.pub3
21 10.1002/14651858.CD011448.pub2
22 10.1002/14651858.CD004069.pub3
23 10.1002/14651858.CD000020.pub3
24 10.1002/14651858.CD010490.pub2
25 10.1002/14651858.CD008136.pub3
26 10.1002/14651858.CD007863.pub4
27 10.1002/14651858.CD010861.pub2
28 10.1002/14651858.CD007575.pub4
29 10.1002/14651858.CD011379.pub2
30 10.1002/14651858.CD011263.pub2
31 10.1002/14651858.CD011625.pub2
32 10.1002/14651858.CD001066.pub3
33 10.1002/14651858.CD002856.pub3
34 10.1002/14651858.CD001139.pub4
35 10.1002/14651858.CD004736.pub5
36 10.1002/14651858.CD004909.pub3
37 10.1002/14651858.CD006171.pub4
38 10.1002/14651858.CD008666.pub3
39 10.1002/14651858.CD010826.pub2
40 10.1002/14651858.CD011445.pub2
41 10.1002/14651858.CD009997.pub2
42 10.1002/14651858.CD005300.pub4
43 10.1002/14651858.CD004072.pub3
44 10.1002/14651858.CD009954.pub2
45 10.1002/14651858.CD000491.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD007708.pub3
4 10.1002/14651858.CD009433.pub2
5 10.1002/14651858.CD008076.pub2
6 10.1002/14651858.CD008186.pub2
7 10.1002/14651858.CD007755.pub2
8 10.1002/14651858.CD006609.pub2
9 10.1002/14651858.CD007551.pub2
10 10.1002/14651858.CD007039.pub2
11 10.1002/14651858.CD002005.pub2
12 10.1002/14651858.CD001719.pub4
13 10.1002/14651858.CD009929.pub2
14 10.1002/14651858.CD005950.pub4
15 10.1002/14651858.CD009777.pub2
16 10.1002/14651858.CD006391.pub2
17 10.1002/14651858.CD003079.pub3
18 10.1002/14651858.CD007815.pub2
19 10.1002/14651858.CD005147.pub2
20 10.1002/14651858.CD006352.pub2
21 10.1002/14651858.CD001951.pub2
22 10.1002/14651858.CD001711.pub2
23 10.1002/14651858.CD008297.pub2
24 10.1002/14651858.CD009531.pub2
25 10.1002/14651858.CD009582.pub2
26 10.1002/14651858.CD001949.pub3
27 10.1002/14651858.CD006196.pub2
28 10.1002/14651858.CD003082.pub3
29 10.1002/14651858.CD006625.pub3
30 10.1002/14651858.CD010226.pub2
31 10.1002/14651858.CD002832.pub3
32 10.1002/14651858.CD009802.pub2
33 10.1002/14651858.CD000384.pub3
34 10.1002/14651858.CD000284.pub3
35 10.1002/14651858.CD008567.pub3
36 10.1002/14651858.CD006569.pub5
37 10.1002/14651858.CD009413.pub2
38 10.1002/14651858.CD007479.pub2
39 10.1002/14651858.CD007811.pub2
40 10.1002/14651858.CD009960.pub2
41 10.1002/14651858.CD001258.pub3
42 10.1002/14651858.CD001470.pub2
43 10.1002/14651858.CD009396.pub2
44 10.1002/14651858.CD009268.pub2
45 10.1002/14651858.CD009227.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD009230.pub2
4 10.1002/14651858.CD009369.pub2
5 10.1002/14651858.CD004837.pub3
6 10.1002/14651858.CD009928.pub2
7 10.1002/14651858.CD005475.pub2
8 10.1002/14651858.CD010501.pub2
9 10.1002/14651858.CD010823.pub2
10 10.1002/14651858.CD009831.pub2
11 10.1002/14651858.CD009785.pub2
12 10.1002/14651858.CD010540.pub2
13 10.1002/14651858.CD000307.pub2
14 10.1002/14651858.CD004716.pub4
15 10.1002/14651858.CD009006.pub2
16 10.1002/14651858.CD010554.pub2
17 10.1002/14651858.CD006081.pub2
18 10.1002/14651858.CD010598.pub2
19 10.1002/14651858.CD003834.pub3
20 10.1002/14651858.CD011458.pub2
21 10.1002/14651858.CD003443.pub3
22 10.1002/14651858.CD001087.pub5
23 10.1002/14651858.CD006995.pub2
24 10.1002/14651858.CD012122.pub2
25 10.1002/14651858.CD008802.pub3
26 10.1002/14651858.CD010832.pub2
27 10.1002/14651858.CD008919.pub2
28 10.1002/14651858.CD012029.pub2
29 10.1002/14651858.CD004161.pub2
30 10.1002/14651858.CD009830.pub2
31 10.1002/14651858.CD010631.pub2
32 10.1002/14651858.CD004028.pub4
33 10.1002/14651858.CD009780.pub3
34 10.1002/14651858.CD002830.pub3
35 10.1002/14651858.CD005146.pub3
36 10.1002/14651858.CD011464.pub2
37 10.1002/14651858.CD011128.pub2
38 10.1002/14651858.CD004408.pub5
39 10.1002/14651858.CD006324.pub3
40 10.1002/14651858.CD006918.pub3
41 10.1002/14651858.CD011810.pub2
42 10.1002/14651858.CD010006.pub2
43 10.1002/14651858.CD007906.pub3
44 10.1002/14651858.CD007778.pub2
45 10.1002/14651858.CD011655.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD004025.pub4
4 10.1002/14651858.CD012217.pub2
5 10.1002/14651858.CD011831.pub2
6 10.1002/14651858.CD009005.pub2
7 10.1002/14651858.CD012052.pub2
8 10.1002/14651858.CD009377.pub3
9 10.1002/14651858.CD011200.pub2
10 10.1002/14651858.CD008925.pub2
11 10.1002/14651858.CD010994.pub2
12 10.1002/14651858.CD004733.pub4
13 10.1002/14651858.CD009916.pub2
14 10.1002/14651858.CD006553.pub3
15 10.1002/14651858.CD011507.pub2
16 10.1002/14651858.CD000116.pub5
17 10.1002/14651858.CD010845.pub2
18 10.1002/14651858.CD010568.pub2
19 10.1002/14651858.CD004944.pub3
20 10.1002/14651858.CD007950.pub3
21 10.1002/14651858.CD008873.pub3
22 10.1002/14651858.CD010647.pub2
23 10.1002/14651858.CD005944.pub3
24 10.1002/14651858.CD011624.pub2
25 10.1002/14651858.CD011491.pub2
26 10.1002/14651858.CD008540.pub4
27 10.1002/14651858.CD010607.pub2
28 10.1002/14651858.CD009356.pub3
29 10.1002/14651858.CD005542.pub3
30 10.1002/14651858.CD004073.pub4
31 10.1002/14651858.CD004667.pub5
32 10.1002/14651858.CD000938.pub2
33 10.1002/14651858.CD011876.pub2
34 10.1002/14651858.CD006946.pub3
35 10.1002/14651858.CD010218.pub2
36 10.1002/14651858.CD008968.pub3
37 10.1002/14651858.CD008883.pub2
38 10.1002/14651858.CD011622.pub2
39 10.1002/14651858.CD006641.pub3
40 10.1002/14651858.CD007202.pub4
41 10.1002/14651858.CD011352.pub2
42 10.1002/14651858.CD006462.pub4
43 10.1002/14651858.CD012048.pub2
44 10.1002/14651858.CD011562.pub2
45 10.1002/14651858.CD006170.pub5
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD010378.pub3
4 10.1002/14651858.CD001688.pub3
5 10.1002/14651858.CD006425.pub4
6 10.1002/14651858.CD009273.pub2
7 10.1002/14651858.CD005122.pub5
8 10.1002/14651858.CD011967.pub2
9 10.1002/14651858.CD006901.pub3
10 10.1002/14651858.CD005302.pub3
11 10.1002/14651858.CD006674.pub3
12 10.1002/14651858.CD003519.pub4
13 10.1002/14651858.CD011880.pub2
14 10.1002/14651858.CD006066.pub3
15 10.1002/14651858.CD007223.pub4
16 10.1002/14651858.CD008070.pub3
17 10.1002/14651858.CD000081.pub3
18 10.1002/14651858.CD012129.pub2
19 10.1002/14651858.CD008680.pub2
20 10.1002/14651858.CD006172.pub4
21 10.1002/14651858.CD012003.pub2
22 10.1002/14651858.CD009275.pub3
23 10.1002/14651858.CD012031.pub2
24 10.1002/14651858.CD001141.pub5
25 10.1002/14651858.CD006067.pub3
26 10.1002/14651858.CD004735.pub4
27 10.1002/14651858.CD000161.pub2
28 10.1002/14651858.CD009124.pub3
29 10.1002/14651858.CD011761.pub2
30 10.1002/14651858.CD004454.pub3
31 10.1002/14651858.CD011516.pub2
32 10.1002/14651858.CD004905.pub5
33 10.1002/14651858.CD011970.pub2
34 10.1002/14651858.CD002006.pub4
35 10.1002/14651858.CD008991.pub3
36 10.1002/14651858.CD011989.pub2
37 10.1002/14651858.CD009792.pub3
38 10.1002/14651858.CD009613.pub3
39 10.1002/14651858.CD012202.pub2
40 10.1002/14651858.CD003766.pub6
41 10.1002/14651858.CD009326.pub3
42 10.1002/14651858.CD007529.pub4
43 10.1002/14651858.CD004455.pub4
44 10.1002/14651858.CD007222.pub4
45 10.1002/14651858.CD007122.pub4
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD007776.pub3
4 10.1002/14651858.CD011192.pub2
5 10.1002/14651858.CD002251.pub3
6 10.1002/14651858.CD007701.pub3
7 10.1002/14651858.CD009963.pub2
8 10.1002/14651858.CD009382.pub2
9 10.1002/14651858.CD010067.pub2
10 10.1002/14651858.CD007825.pub6
11 10.1002/14651858.CD008366.pub3
12 10.1002/14651858.CD008657.pub2
13 10.1002/14651858.CD001871.pub3
14 10.1002/14651858.CD011247.pub2
15 10.1002/14651858.CD009823.pub3
16 10.1002/14651858.CD010697.pub2
17 10.1002/14651858.CD011779.pub2
18 10.1002/14651858.CD010321.pub2
19 10.1002/14651858.CD010166.pub2
20 10.1002/14651858.CD011683.pub2
21 10.1002/14651858.CD009905.pub2
22 10.1002/14651858.CD009467.pub2
23 10.1002/14651858.CD010351.pub2
24 10.1002/14651858.CD003261.pub3
25 10.1002/14651858.CD010638.pub2
26 10.1002/14651858.CD010522.pub2
27 10.1002/14651858.CD009820.pub2
28 10.1002/14651858.CD009542.pub2
29 10.1002/14651858.CD009014.pub2
30 10.1002/14651858.CD008711.pub3
31 10.1002/14651858.CD000064.pub2
32 10.1002/14651858.CD003435.pub2
33 10.1002/14651858.CD009264.pub2
34 10.1002/14651858.CD007230.pub2
35 10.1002/14651858.CD008389.pub2
36 10.1002/14651858.CD008530.pub2
37 10.1002/14651858.CD008388.pub2
38 10.1002/14651858.CD008179.pub2
39 10.1002/14651858.CD000091.pub2
40 10.1002/14651858.CD000419.pub3
41 10.1002/14651858.CD009360.pub2
42 10.1002/14651858.CD008354.pub2
43 10.1002/14651858.CD006755.pub2
44 10.1002/14651858.CD008449.pub2
45 10.1002/14651858.CD001928.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD001342.pub3
4 10.1002/14651858.CD008348.pub3
5 10.1002/14651858.CD008656.pub2
6 10.1002/14651858.CD000323.pub2
7 10.1002/14651858.CD001919.pub3
8 10.1002/14651858.CD008184.pub2
9 10.1002/14651858.CD000515.pub4
10 10.1002/14651858.CD009286.pub2
11 10.1002/14651858.CD002842.pub2
12 10.1002/14651858.CD008862.pub2
13 10.1002/14651858.CD008391.pub2
14 10.1002/14651858.CD000514.pub3
15 10.1002/14651858.CD008444.pub2
16 10.1002/14651858.CD008728.pub2
17 10.1002/14651858.CD004294.pub3
18 10.1002/14651858.CD010116.pub2
19 10.1002/14651858.CD005207.pub4
20 10.1002/14651858.CD009689.pub2
21 10.1002/14651858.CD008980.pub2
22 10.1002/14651858.CD003586.pub3
23 10.1002/14651858.CD001245.pub2
24 10.1002/14651858.CD010255.pub2
25 10.1002/14651858.CD000197.pub3
26 10.1002/14651858.CD008357.pub2
27 10.1002/14651858.CD000126.pub4
28 10.1002/14651858.CD005346.pub4
29 10.1002/14651858.CD005208.pub3
30 10.1002/14651858.CD000029.pub3
31 10.1002/14651858.CD009893.pub2
32 10.1002/14651858.CD007890.pub3
33 10.1002/14651858.CD007232.pub4
34 10.1002/14651858.CD000103.pub2
35 10.1002/14651858.CD000190.pub3
36 10.1002/14651858.CD009103.pub2
37 10.1002/14651858.CD001920.pub3
38 10.1002/14651858.CD004954.pub3
39 10.1002/14651858.CD000213.pub3
40 10.1002/14651858.CD008349.pub3
41 10.1002/14651858.CD000039.pub3
42 10.1002/14651858.CD010200.pub2
43 10.1002/14651858.CD009760.pub3
44 10.1002/14651858.CD007028.pub3
45 10.1002/14651858.CD000024.pub4
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD009570.pub2
4 10.1002/14651858.CD007030.pub3
5 10.1002/14651858.CD011398.pub2
6 10.1002/14651858.CD011138.pub2
7 10.1002/14651858.CD009938.pub2
8 10.1002/14651858.CD010693.pub3
9 10.1002/14651858.CD004433.pub3
10 10.1002/14651858.CD004955.pub3
11 10.1002/14651858.CD008445.pub3
12 10.1002/14651858.CD010882.pub2
13 10.1002/14651858.CD006876.pub4
14 10.1002/14651858.CD009645.pub3
15 10.1002/14651858.CD009622.pub4
16 10.1002/14651858.CD010442.pub2
17 10.1002/14651858.CD002293.pub3
18 10.1002/14651858.CD011401.pub2
19 10.1002/14651858.CD004131.pub3
20 10.1002/14651858.CD010362.pub2
21 10.1002/14651858.CD000425.pub4
22 10.1002/14651858.CD003316.pub6
23 10.1002/14651858.CD002088.pub3
24 10.1002/14651858.CD006073.pub3
25 10.1002/14651858.CD011058.pub2
26 10.1002/14651858.CD000119.pub4
27 10.1002/14651858.CD006787.pub3
28 10.1002/14651858.CD000398.pub2
29 10.1002/14651858.CD007933.pub2
30 10.1002/14651858.CD007026.pub5
31 10.1002/14651858.CD007270.pub2
32 10.1002/14651858.CD007961.pub2
33 10.1002/14651858.CD011317.pub2
34 10.1002/14651858.CD011701.pub2
35 10.1002/14651858.CD010866.pub2
36 10.1002/14651858.CD009036.pub2
37 10.1002/14651858.CD010285.pub2
38 10.1002/14651858.CD010684.pub2
39 10.1002/14651858.CD008860.pub3
40 10.1002/14651858.CD001081.pub3
41 10.1002/14651858.CD002843.pub2
42 10.1002/14651858.CD006185.pub4
43 10.1002/14651858.CD007513.pub3
44 10.1002/14651858.CD011968.pub2
45 10.1002/14651858.CD012144.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD000443.pub4
4 10.1002/14651858.CD003585.pub3
5 10.1002/14651858.CD012432.pub2
6 10.1002/14651858.CD002840.pub4
7 10.1002/14651858.CD011367.pub2
8 10.1002/14651858.CD001080.pub2
9 10.1002/14651858.CD006979.pub2
10 10.1002/14651858.CD007374.pub2
11 10.1002/14651858.CD001534.pub3
12 10.1002/14651858.CD006023.pub2
13 10.1002/14651858.CD007751.pub2
14 10.1002/14651858.CD006124.pub2
15 10.1002/14651858.CD003962.pub2
16 10.1002/14651858.CD005279.pub4
17 10.1002/14651858.CD007857.pub2
18 10.1002/14651858.CD007016.pub2
19 10.1002/14651858.CD006800.pub2
20 10.1002/14651858.CD003964.pub3
21 10.1002/14651858.CD003264.pub3
22 10.1002/14651858.CD006943.pub2
23 10.1002/14651858.CD008000.pub2
24 10.1002/14651858.CD003236.pub2
25 10.1002/14651858.CD006857.pub2
26 10.1002/14651858.CD003265.pub3
27 10.1002/14651858.CD005426.pub3
28 10.1002/14651858.CD001321.pub5
29 10.1002/14651858.CD008176.pub2
30 10.1002/14651858.CD004136.pub3
31 10.1002/14651858.CD005016.pub2
32 10.1002/14651858.CD006740.pub2
33 10.1002/14651858.CD007248.pub2
34 10.1002/14651858.CD006182.pub2
35 10.1002/14651858.CD003309.pub2
36 10.1002/14651858.CD008308.pub2
37 10.1002/14651858.CD003062.pub2
38 10.1002/14651858.CD008309.pub2
39 10.1002/14651858.CD007645.pub2
40 10.1002/14651858.CD004214.pub4
41 10.1002/14651858.CD002922.pub3
42 10.1002/14651858.CD004213.pub3
43 10.1002/14651858.CD004595.pub2
44 10.1002/14651858.CD001817.pub2
45 10.1002/14651858.CD007615.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD003956.pub2
4 10.1002/14651858.CD001453.pub2
5 10.1002/14651858.CD007453.pub3
6 10.1002/14651858.CD001452.pub4
7 10.1002/14651858.CD001819.pub2
8 10.1002/14651858.CD000512.pub2
9 10.1002/14651858.CD003662.pub4
10 10.1002/14651858.CD007969.pub2
11 10.1002/14651858.CD004500.pub2
12 10.1002/14651858.CD007966.pub2
13 10.1002/14651858.CD003740.pub2
14 10.1002/14651858.CD003065.pub2
15 10.1002/14651858.CD001454.pub3
16 10.1002/14651858.CD000510.pub2
17 10.1002/14651858.CD005095.pub2
18 10.1002/14651858.CD005257.pub3
19 10.1002/14651858.CD003953.pub3
20 10.1002/14651858.CD006818.pub2
21 10.1002/14651858.CD004496.pub3
22 10.1002/14651858.CD006817.pub3
23 10.1002/14651858.CD007448.pub2
24 10.1002/14651858.CD008310.pub2
25 10.1002/14651858.CD004865.pub3
26 10.1002/14651858.CD005249.pub2
27 10.1002/14651858.CD001456.pub2
28 10.1002/14651858.CD009017.pub2
29 10.1002/14651858.CD003952.pub3
30 10.1002/14651858.CD004950.pub3
31 10.1002/14651858.CD004866.pub4
32 10.1002/14651858.CD003487.pub3
33 10.1002/14651858.CD003483.pub2
34 10.1002/14651858.CD003311.pub3
35 10.1002/14651858.CD003951.pub3
36 10.1002/14651858.CD000504.pub4
37 10.1002/14651858.CD006474.pub3
38 10.1002/14651858.CD004591.pub3
39 10.1002/14651858.CD003486.pub2
40 10.1002/14651858.CD008771.pub2
41 10.1002/14651858.CD000122.pub2
42 10.1002/14651858.CD001691.pub3
43 10.1002/14651858.CD007263.pub2
44 10.1002/14651858.CD001073.pub2
45 10.1002/14651858.CD000361.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD005387.pub3
4 10.1002/14651858.CD003959.pub3
5 10.1002/14651858.CD005496.pub4
6 10.1002/14651858.CD002971.pub3
7 10.1002/14651858.CD004863.pub4
8 10.1002/14651858.CD007805.pub2
9 10.1002/14651858.CD004868.pub4
10 10.1002/14651858.CD001145.pub3
11 10.1002/14651858.CD001146.pub4
12 10.1002/14651858.CD010018.pub2
13 10.1002/14651858.CD000503.pub3
14 10.1002/14651858.CD001970.pub5
15 10.1002/14651858.CD002054.pub3
16 10.1002/14651858.CD005947.pub4
17 10.1002/14651858.CD000366.pub3
18 10.1002/14651858.CD010333.pub2
19 10.1002/14651858.CD004205.pub3
20 10.1002/14651858.CD007835.pub2
21 10.1002/14651858.CD010061.pub2
22 10.1002/14651858.CD003481.pub6
23 10.1002/14651858.CD001239.pub5
24 10.1002/14651858.CD000104.pub4
25 10.1002/14651858.CD003774.pub4
26 10.1002/14651858.CD008817.pub2
27 10.1002/14651858.CD008568.pub2
28 10.1002/14651858.CD006861.pub3
29 10.1002/14651858.CD008834.pub3
30 10.1002/14651858.CD004925.pub3
31 10.1002/14651858.CD005133.pub3
32 10.1002/14651858.CD007594.pub3
33 10.1002/14651858.CD004289.pub5
34 10.1002/14651858.CD006335.pub3
35 10.1002/14651858.CD005425.pub2
36 10.1002/14651858.CD008597.pub2
37 10.1002/14651858.CD002290.pub4
38 10.1002/14651858.CD006022.pub4
39 10.1002/14651858.CD008927.pub2
40 10.1002/14651858.CD009297.pub2
41 10.1002/14651858.CD008509.pub2
42 10.1002/14651858.CD005019.pub4
43 10.1002/14651858.CD008566.pub2
44 10.1002/14651858.CD007004.pub3
45 10.1002/14651858.CD005284.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD003895.pub3
4 10.1002/14651858.CD007034.pub3
5 10.1002/14651858.CD007554.pub2
6 10.1002/14651858.CD007333.pub2
7 10.1002/14651858.CD009120.pub2
8 10.1002/14651858.CD007784.pub2
9 10.1002/14651858.CD003078.pub2
10 10.1002/14651858.CD007669.pub2
11 10.1002/14651858.CD006881.pub2
12 10.1002/14651858.CD003772.pub4
13 10.1002/14651858.CD009735.pub2
14 10.1002/14651858.CD007861.pub2
15 10.1002/14651858.CD008369.pub2
16 10.1002/14651858.CD009535.pub2
17 10.1002/14651858.CD004293.pub3
18 10.1002/14651858.CD010699.pub2
19 10.1002/14651858.CD006254.pub2
20 10.1002/14651858.CD008353.pub2
21 10.1002/14651858.CD010138.pub2
22 10.1002/14651858.CD009403.pub2
23 10.1002/14651858.CD010590.pub2
24 10.1002/14651858.CD010070.pub2
25 10.1002/14651858.CD010480.pub2
26 10.1002/14651858.CD009534.pub2
27 10.1002/14651858.CD007910.pub2
28 10.1002/14651858.CD006819.pub2
29 10.1002/14651858.CD001533.pub5
30 10.1002/14651858.CD010446.pub2
31 10.1002/14651858.CD006027.pub2
32 10.1002/14651858.CD006258.pub2
33 10.1002/14651858.CD010294.pub2
34 10.1002/14651858.CD005128.pub3
35 10.1002/14651858.CD010350.pub2
36 10.1002/14651858.CD007013.pub2
37 10.1002/14651858.CD007003.pub2
38 10.1002/14651858.CD003965.pub2
39 10.1002/14651858.CD009698.pub2
40 10.1002/14651858.CD010057.pub2
41 10.1002/14651858.CD003232.pub3
42 10.1002/14651858.CD010481.pub2
43 10.1002/14651858.CD008327.pub2
44 10.1002/14651858.CD008772.pub2
45 10.1002/14651858.CD010344.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD010709.pub2
4 10.1002/14651858.CD003266.pub3
5 10.1002/14651858.CD009631.pub2
6 10.1002/14651858.CD010737.pub2
7 10.1002/14651858.CD006420.pub2
8 10.1002/14651858.CD010741.pub2
9 10.1002/14651858.CD010850.pub2
10 10.1002/14651858.CD005282.pub3
11 10.1002/14651858.CD004541.pub3
12 10.1002/14651858.CD007746.pub2
13 10.1002/14651858.CD010613.pub2
14 10.1002/14651858.CD009440.pub2
15 10.1002/14651858.CD010690.pub2
16 10.1002/14651858.CD004683.pub4
17 10.1002/14651858.CD011690.pub2
18 10.1002/14651858.CD003594.pub5
19 10.1002/14651858.CD004759.pub2
20 10.1002/14651858.CD010777.pub2
21 10.1002/14651858.CD011998.pub2
22 10.1002/14651858.CD005632.pub3
23 10.1002/14651858.CD004679.pub3
24 10.1002/14651858.CD009966.pub2
25 10.1002/14651858.CD004756.pub4
26 10.1002/14651858.CD010137.pub2
27 10.1002/14651858.CD006750.pub2
28 10.1002/14651858.CD009904.pub2
29 10.1002/14651858.CD005085.pub2
30 10.1002/14651858.CD003600.pub3
31 10.1002/14651858.CD004172.pub2
32 10.1002/14651858.CD002041.pub3
33 10.1002/14651858.CD001208.pub4
34 10.1002/14651858.CD003985.pub3
35 10.1002/14651858.CD008931.pub3
36 10.1002/14651858.CD001886.pub4
37 10.1002/14651858.CD001046.pub2
38 10.1002/14651858.CD006676.pub3
39 10.1002/14651858.CD001319.pub5
40 10.1002/14651858.CD010245.pub2
41 10.1002/14651858.CD005011.pub4
42 10.1002/14651858.CD004609.pub3
43 10.1002/14651858.CD000033.pub2
44 10.1002/14651858.CD005014.pub3
45 10.1002/14651858.CD007700.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD008303.pub2
4 10.1002/14651858.CD000567.pub6
5 10.1002/14651858.CD006020.pub3
6 10.1002/14651858.CD008481.pub2
7 10.1002/14651858.CD010562.pub2
8 10.1002/14651858.CD001049.pub5
9 10.1002/14651858.CD010109.pub2
10 10.1002/14651858.CD009331.pub2
11 10.1002/14651858.CD002245.pub2
12 10.1002/14651858.CD008507.pub2
13 10.1002/14651858.CD008084.pub4
14 10.1002/14651858.CD003109.pub3
15 10.1002/14651858.CD009532.pub2
16 10.1002/14651858.CD007379.pub2
17 10.1002/14651858.CD011386.pub2
18 10.1002/14651858.CD009457.pub2
19 10.1002/14651858.CD004896.pub4
20 10.1002/14651858.CD009177.pub2
21 10.1002/14651858.CD009439.pub2
22 10.1002/14651858.CD010801.pub2
23 10.1002/14651858.CD004446.pub4
24 10.1002/14651858.CD009330.pub2
25 10.1002/14651858.CD009919.pub2
26 10.1002/14651858.CD002043.pub3
27 10.1002/14651858.CD010640.pub2
28 10.1002/14651858.CD007383.pub3
29 10.1002/14651858.CD009745.pub2
30 10.1002/14651858.CD011588.pub2
31 10.1002/14651858.CD009871.pub2
32 10.1002/14651858.CD004170.pub3
33 10.1002/14651858.CD010415.pub2
34 10.1002/14651858.CD009228.pub3
35 10.1002/14651858.CD002042.pub4
36 10.1002/14651858.CD008409.pub4
37 10.1002/14651858.CD011402.pub2
38 10.1002/14651858.CD011020.pub2
39 10.1002/14651858.CD010246.pub2
40 10.1002/14651858.CD001884.pub3
41 10.1002/14651858.CD010336.pub2
42 10.1002/14651858.CD003669.pub2
43 10.1002/14651858.CD008432.pub2
44 10.1002/14651858.CD003743.pub2
45 10.1002/14651858.CD005248.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD002271.pub2
4 10.1002/14651858.CD000144.pub3
5 10.1002/14651858.CD009106.pub2
6 10.1002/14651858.CD011078.pub2
7 10.1002/14651858.CD010464.pub2
8 10.1002/14651858.CD000437.pub3
9 10.1002/14651858.CD004219.pub4
10 10.1002/14651858.CD003478.pub5
11 10.1002/14651858.CD009816.pub2
12 10.1002/14651858.CD003850.pub5
13 10.1002/14651858.CD003064.pub3
14 10.1002/14651858.CD011724.pub2
15 10.1002/14651858.CD001150.pub3
16 10.1002/14651858.CD011484.pub2
17 10.1002/14651858.CD010435.pub2
18 10.1002/14651858.CD010249.pub2
19 10.1002/14651858.CD009734.pub2
20 10.1002/14651858.CD011493.pub2
21 10.1002/14651858.CD006405.pub3
22 10.1002/14651858.CD005495.pub4
23 10.1002/14651858.CD011636.pub2
24 10.1002/14651858.CD009172.pub2
25 10.1002/14651858.CD001816.pub3
26 10.1002/14651858.CD011082.pub2
27 10.1002/14651858.CD001457.pub6
28 10.1002/14651858.CD008313.pub3
29 10.1002/14651858.CD011027.pub2
30 10.1002/14651858.CD001240.pub3
31 10.1002/14651858.CD011718.pub2
32 10.1002/14651858.CD011877.pub2
33 10.1002/14651858.CD011878.pub2
34 10.1002/14651858.CD000343.pub3
35 10.1002/14651858.CD010531.pub2
36 10.1002/14651858.CD006982.pub4
37 10.1002/14651858.CD001243.pub3
38 10.1002/14651858.CD001069.pub5
39 10.1002/14651858.CD002771.pub4
40 10.1002/14651858.CD005092.pub3
41 10.1002/14651858.CD005255.pub5
42 10.1002/14651858.CD000501.pub4
43 10.1002/14651858.CD000456.pub5
44 10.1002/14651858.CD009720.pub2
45 10.1002/14651858.CD007480.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
50

1
2
3 10.1002/14651858.CD005252.pub4
4 10.1002/14651858.CD001071.pub3
5 10.1002/14651858.CD011219.pub3
6 10.1002/14651858.CD003668.pub4
7 10.1002/14651858.CD003214.pub3
8 10.1002/14651858.CD004696.pub5
9 10.1002/14651858.CD005384.pub2
10 10.1002/14651858.CD010112.pub2
11 10.1002/14651858.CD000375.pub5
12 10.1002/14651858.CD005091.pub4
13 10.1002/14651858.CD000509.pub5
14 10.1002/14651858.CD000399.pub3
15 10.1002/14651858.CD001969.pub4
16 10.1002/14651858.CD003059.pub3
17 10.1002/14651858.CD004951.pub3
18 10.1002/14651858.CD002052.pub3
19 10.1002/14651858.CD010941.pub2
20 10.1002/14651858.CD005389.pub2
21 10.1002/14651858.CD003212.pub3
22 10.1002/14651858.CD010331.pub2
23 10.1002/14651858.CD003310.pub2
24 10.1002/14651858.CD006980.pub3
25 10.1002/14651858.CD008435.pub3
26 10.1002/14651858.CD011065.pub2
27 10.1002/14651858.CD000376.pub4
28 10.1002/14651858.CD004339.pub4
29 10.1002/14651858.CD000216.pub2
30 10.1002/14651858.CD010332.pub2
31 10.1002/14651858.CD011791.pub2
32 10.1002/14651858.CD007137.pub5
33 10.1002/14651858.CD006183.pub2
34 10.1002/14651858.CD011190.pub2
35 10.1002/14651858.CD012468.pub2
36 10.1002/14651858.CD012362.pub2
37 10.1002/14651858.CD011891.pub2
38 10.1002/14651858.CD005494.pub4
39 10.1002/14651858.CD004953.pub3
40 10.1002/14651858.CD001241.pub7
41 10.1002/14651858.CD002311.pub4
42 10.1002/14651858.CD008050.pub2
43 10.1002/14651858.CD003315.pub3
44 10.1002/14651858.CD006205.pub3
45 10.1002/14651858.CD007592.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD004970.pub5
4 10.1002/14651858.CD006386.pub3
5 10.1002/14651858.CD008934.pub2
6 10.1002/14651858.CD003814.pub2
7 10.1002/14651858.CD000978.pub5
8 10.1002/14651858.CD008829.pub2
9 10.1002/14651858.CD006697.pub2
10 10.1002/14651858.CD006963.pub2
11 10.1002/14651858.CD006540.pub2
12 10.1002/14651858.CD007261.pub2
13 10.1002/14651858.CD003877.pub4
14 10.1002/14651858.CD008948.pub2
15 10.1002/14651858.CD005411.pub2
16 10.1002/14651858.CD003811.pub2
17 10.1002/14651858.CD004621.pub3
18 10.1002/14651858.CD006968.pub2
19 10.1002/14651858.CD008305.pub2
20 10.1002/14651858.CD006383.pub2
21 10.1002/14651858.CD008488.pub2
22 10.1002/14651858.CD008288.pub2
23 10.1002/14651858.CD006423.pub2
24 10.1002/14651858.CD006165.pub3
25 10.1002/14651858.CD005060.pub3
26 10.1002/14651858.CD008101.pub2
27 10.1002/14651858.CD007675.pub2
28 10.1002/14651858.CD007845.pub3
29 10.1002/14651858.CD007315.pub2
30 10.1002/14651858.CD005449.pub2
31 10.1002/14651858.CD009361.pub2
32 10.1002/14651858.CD007170.pub2
33 10.1002/14651858.CD008650.pub2
34 10.1002/14651858.CD008381.pub2
35 10.1002/14651858.CD008613.pub2
36 10.1002/14651858.CD010223.pub2
37 10.1002/14651858.CD008776.pub2
38 10.1002/14651858.CD010063.pub2
39 10.1002/14651858.CD007651.pub2
40 10.1002/14651858.CD009560.pub2
41 10.1002/14651858.CD009128.pub3
42 10.1002/14651858.CD009518.pub2
43 10.1002/14651858.CD010492.pub2
44 10.1002/14651858.CD007469.pub2
45 10.1002/14651858.CD009578.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD004098.pub2
4 10.1002/14651858.CD008066.pub3
5 10.1002/14651858.CD003641.pub4
6 10.1002/14651858.CD009122.pub2
7 10.1002/14651858.CD007470.pub3
8 10.1002/14651858.CD010370.pub2
9 10.1002/14651858.CD010888.pub2
10 10.1002/14651858.CD005525.pub3
11 10.1002/14651858.CD010094.pub2
12 10.1002/14651858.CD011740
13 10.1002/14651858.CD012008
14 10.1002/14651858.CD010576.pub2
15 10.1002/14651858.CD012105
16 10.1002/14651858.CD006424.pub3
17 10.1002/14651858.CD011281.pub2
18 10.1002/14651858.CD011361.pub2
19 10.1002/14651858.CD012151.pub2
20 10.1002/14651858.CD012204.pub2
21 10.1002/14651858.CD012161
22 10.1002/14651858.CD009840.pub2
23 10.1002/14651858.CD006992.pub2
24 10.1002/14651858.CD012691
25 10.1002/14651858.CD011469.pub2
26 10.1002/14651858.CD012436
27 10.1002/14651858.CD012651
28 10.1002/14651858.CD007795.pub2
29 10.1002/14651858.CD003279.pub3
30 10.1002/14651858.CD006981.pub2
31 10.1002/14651858.CD007312.pub2
32 10.1002/14651858.CD004156.pub4
33 10.1002/14651858.CD009318.pub2
34 10.1002/14651858.CD008496.pub2
35 10.1002/14651858.CD009600
36 10.1002/14651858.CD006283.pub3
37 10.1002/14651858.CD001447.pub3
38 10.1002/14651858.CD006281.pub4
39 10.1002/14651858.CD004426.pub3
40 10.1002/14651858.CD004157.pub2
41 10.1002/14651858.CD006282.pub4
42 10.1002/14651858.CD007543.pub2
43 10.1002/14651858.CD009899
44 10.1002/14651858.CD003643.pub4
45 10.1002/14651858.CD010003
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD002064.pub3
4 10.1002/14651858.CD009402.pub2
5 10.1002/14651858.CD002948.pub2
6 10.1002/14651858.CD003525.pub2
7 10.1002/14651858.CD000333.pub2
8 10.1002/14651858.CD003113.pub3
9 10.1002/14651858.CD008920.pub2
10 10.1002/14651858.CD008886.pub2
11 10.1002/14651858.CD008951.pub2
12 10.1002/14651858.CD008872.pub2
13 10.1002/14651858.CD008921.pub2
14 10.1002/14651858.CD008922.pub2
15 10.1002/14651858.CD009807
16 10.1002/14651858.CD009147.pub2
17 10.1002/14651858.CD006193.pub2
18 10.1002/14651858.CD007323.pub3
19 10.1002/14651858.CD007911.pub2
20 10.1002/14651858.CD002277.pub4
21 10.1002/14651858.CD005081.pub3
22 10.1002/14651858.CD005225.pub3
23 10.1002/14651858.CD005229.pub3
24 10.1002/14651858.CD007963.pub2
25 10.1002/14651858.CD005582.pub4
26 10.1002/14651858.CD008554.pub3
27 10.1002/14651858.CD009601.pub2
28 10.1002/14651858.CD004760.pub4
29 10.1002/14651858.CD003907.pub4
30 10.1002/14651858.CD007468.pub3
31 10.1002/14651858.CD008314.pub3
32 10.1002/14651858.CD007796.pub3
33 10.1002/14651858.CD010044.pub2
34 10.1002/14651858.CD004029.pub4
35 10.1002/14651858.CD001797.pub3
36 10.1002/14651858.CD006832.pub3
37 10.1002/14651858.CD006866.pub3
38 10.1002/14651858.CD007115.pub3
39 10.1002/14651858.CD008123.pub3
40 10.1002/14651858.CD008265.pub2
41 10.1002/14651858.CD002063.pub6
42 10.1002/14651858.CD008602.pub3
43 10.1002/14651858.CD006986.pub3
44 10.1002/14651858.CD005228.pub4
45 10.1002/14651858.CD007218.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
50

1
2
3 10.1002/14651858.CD003458.pub5
4 10.1002/14651858.CD008953.pub2
5 10.1002/14651858.CD010404.pub2
6 10.1002/14651858.CD008146.pub2
7 10.1002/14651858.CD001941.pub3
8 10.1002/14651858.CD003217.pub5
9 10.1002/14651858.CD009950.pub3
10 10.1002/14651858.CD005044.pub3
11 10.1002/14651858.CD005376.pub3
12 10.1002/14651858.CD001869.pub8
13 10.1002/14651858.CD003906.pub4
14 10.1002/14651858.CD007818.pub3
15 10.1002/14651858.CD001555.pub5
16 10.1002/14651858.CD004303.pub4
17 10.1002/14651858.CD011952
18 10.1002/14651858.CD001942.pub5
19 10.1002/14651858.CD007791.pub4
20 10.1002/14651858.CD002827.pub4
21 10.1002/14651858.CD003725.pub4
22 10.1002/14651858.CD004158.pub3
23 10.1002/14651858.CD006839.pub4
24 10.1002/14651858.CD008630.pub4
25 10.1002/14651858.CD001446.pub5
26 10.1002/14651858.CD006978.pub2
27 10.1002/14651858.CD006049.pub2
28 10.1002/14651858.CD001798.pub3
29 10.1002/14651858.CD010899.pub2
30 10.1002/14651858.CD006521.pub4
31 10.1002/14651858.CD003280.pub5
32 10.1002/14651858.CD003726.pub4
33 10.1002/14651858.CD012765
34 10.1002/14651858.CD008653.pub2
35 10.1002/14651858.CD008618.pub2
36 10.1002/14651858.CD010292
37 10.1002/14651858.CD002265.pub3
38 10.1002/14651858.CD004524.pub4
39 10.1002/14651858.CD000332.pub3
40 10.1002/14651858.CD010039.pub2
41 10.1002/14651858.CD007070.pub2
42 10.1002/14651858.CD010538
43 10.1002/14651858.CD000951.pub2
44 10.1002/14651858.CD003686.pub2
45 10.1002/14651858.CD008322.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD004803.pub3
4 10.1002/14651858.CD004525.pub2
5 10.1002/14651858.CD003523.pub2
6 10.1002/14651858.CD004260.pub3
7 10.1002/14651858.CD010519.pub2
8 10.1002/14651858.CD010884
9 10.1002/14651858.CD008963.pub2
10 10.1002/14651858.CD007912.pub2
11 10.1002/14651858.CD003526.pub3
12 10.1002/14651858.CD000957.pub2
13 10.1002/14651858.CD009993.pub2
14 10.1002/14651858.CD005117.pub3
15 10.1002/14651858.CD002947.pub2
16 10.1002/14651858.CD006190.pub2
17 10.1002/14651858.CD011275
18 10.1002/14651858.CD005467.pub2
19 10.1002/14651858.CD003115.pub4
20 10.1002/14651858.CD010156.pub2
21 10.1002/14651858.CD010455.pub2
22 10.1002/14651858.CD010120.pub2
23 10.1002/14651858.CD011324
24 10.1002/14651858.CD006077.pub3
25 10.1002/14651858.CD010069.pub2
26 10.1002/14651858.CD003528.pub2
27 10.1002/14651858.CD004019.pub4
28 10.1002/14651858.CD004376.pub3
29 10.1002/14651858.CD003130.pub3
30 10.1002/14651858.CD004800.pub3
31 10.1002/14651858.CD010457.pub2
32 10.1002/14651858.CD004020.pub3
33 10.1002/14651858.CD011336
34 10.1002/14651858.CD000518.pub2
35 10.1002/14651858.CD001980.pub3
36 10.1002/14651858.CD011735
37 10.1002/14651858.CD005468.pub2
38 10.1002/14651858.CD006349.pub2
39 10.1002/14651858.CD007356.pub2
40 10.1002/14651858.CD005614.pub2
41 10.1002/14651858.CD010643.pub2
42 10.1002/14651858.CD010952.pub2
43 10.1002/14651858.CD005328.pub3
44 10.1002/14651858.CD010143.pub2
45 10.1002/14651858.CD005523.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD008334.pub2
4 10.1002/14651858.CD010203.pub2
5 10.1002/14651858.CD010815.pub2
6 10.1002/14651858.CD012225
7 10.1002/14651858.CD001347.pub2
8 10.1002/14651858.CD012224
9 10.1002/14651858.CD010388.pub2
10 10.1002/14651858.CD007455.pub3
11 10.1002/14651858.CD012095.pub2
12 10.1002/14651858.CD009865.pub2
13 10.1002/14651858.CD012700
14 10.1002/14651858.CD007649.pub4
15 10.1002/14651858.CD007295.pub2
16 10.1002/14651858.CD008386.pub3
17 10.1002/14651858.CD007280.pub3
18 10.1002/14651858.CD007621.pub2
19 10.1002/14651858.CD005181.pub3
20 10.1002/14651858.CD006921.pub3
21 10.1002/14651858.CD004192.pub3
22 10.1002/14651858.CD009974.pub2
23 10.1002/14651858.CD002127.pub3
24 10.1002/14651858.CD010475.pub2
25 10.1002/14651858.CD009130.pub3
26 10.1002/14651858.CD008933.pub2
27 10.1002/14651858.CD008127.pub4
28 10.1002/14651858.CD010242.pub2
29 10.1002/14651858.CD008876.pub3
30 10.1002/14651858.CD010508.pub2
31 10.1002/14651858.CD008757.pub2
32 10.1002/14651858.CD009131.pub3
33 10.1002/14651858.CD011076.pub2
34 10.1002/14651858.CD010422.pub2
35 10.1002/14651858.CD009956.pub2
36 10.1002/14651858.CD009882.pub3
37 10.1002/14651858.CD011381.pub2
38 10.1002/14651858.CD008754.pub3
39 10.1002/14651858.CD011203.pub2
40 10.1002/14651858.CD009371.pub2
41 10.1002/14651858.CD009333.pub3
42 10.1002/14651858.CD012200.pub2
43 10.1002/14651858.CD007464.pub2
44 10.1002/14651858.CD004282.pub3
45 10.1002/14651858.CD002141.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD009955.pub2
4 10.1002/14651858.CD004284.pub3
5 10.1002/14651858.CD009256.pub2
6 10.1002/14651858.CD001991.pub3
7 10.1002/14651858.CD001990.pub3
8 10.1002/14651858.CD009948.pub2
9 10.1002/14651858.CD002143.pub4
10 10.1002/14651858.CD010355.pub2
11 10.1002/14651858.CD011430
12 10.1002/14651858.CD006849.pub3
13 10.1002/14651858.CD010463.pub2
14 10.1002/14651858.CD002142.pub4
15 10.1002/14651858.CD012020.pub2
16 10.1002/14651858.CD010383.pub2
17 10.1002/14651858.CD011917.pub2
18 10.1002/14651858.MR000031.pub2
19 10.1002/14651858.MR000012.pub3
20 10.1002/14651858.MR000027.pub2
21 10.1002/14651858.MR000025.pub2
22 10.1002/14651858.MR000024.pub3
23 10.1002/14651858.MR000034.pub2
24 10.1002/14651858.MR000022.pub3
25 10.1002/14651858.MR000030.pub2
26 10.1002/14651858.MR000035.pub2
27 10.1002/14651858.MR000032.pub2
28 10.1002/14651858.MR000036.pub2
29 10.1002/14651858.MR000042.pub2
30 10.1002/14651858.MR000043.pub2
31 10.1002/14651858.MR000038.pub2
32 10.1002/14651858.MR000033.pub3
33 10.1002/14651858.CD005504.pub2
34 10.1002/14651858.CD009097.pub2
35 10.1002/14651858.CD006009.pub2
36 10.1002/14651858.CD007834.pub2
37 10.1002/14651858.CD002814.pub2
38 10.1002/14651858.CD009646.pub2
39 10.1002/14651858.CD002812.pub2
40 10.1002/14651858.CD008624.pub3
41 10.1002/14651858.CD002817.pub4
42 10.1002/14651858.CD002815.pub2
43 10.1002/14651858.CD005578.pub2
44 10.1002/14651858.CD009681.pub2
45 10.1002/14651858.CD007830.pub4
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD010925.pub2
4 10.1002/14651858.CD006941.pub2
5 10.1002/14651858.CD004315.pub3
6 10.1002/14651858.CD004552.pub2
7 10.1002/14651858.CD010916.pub2
8 10.1002/14651858.CD009682.pub2
9 10.1002/14651858.CD004314.pub3
10 10.1002/14651858.CD009684.pub2
11 10.1002/14651858.CD009683.pub2
12 10.1002/14651858.CD010760.pub2
13 10.1002/14651858.CD007859.pub3
14 10.1002/14651858.CD003808.pub3
15 10.1002/14651858.CD003878.pub5
16 10.1002/14651858.CD009378.pub2
17 10.1002/14651858.CD006087.pub3
18 10.1002/14651858.CD002279.pub2
19 10.1002/14651858.CD004152.pub4
20 10.1002/14651858.CD003603.pub3
21 10.1002/14651858.CD009603.pub3
22 10.1002/14651858.CD003813.pub4
23 10.1002/14651858.CD003451.pub2
24 10.1002/14651858.CD008375.pub2
25 10.1002/14651858.CD004625.pub4
26 10.1002/14651858.CD004150.pub4
27 10.1002/14651858.CD003452.pub3
28 10.1002/14651858.CD005516.pub2
29 10.1002/14651858.CD004624.pub2
30 10.1002/14651858.CD003809.pub3
31 10.1002/14651858.CD010514.pub2
32 10.1002/14651858.CD004346.pub4
33 10.1002/14651858.CD009857.pub2
34 10.1002/14651858.CD005620.pub2
35 10.1002/14651858.CD005293.pub2
36 10.1002/14651858.CD000979.pub2
37 10.1002/14651858.CD010136.pub2
38 10.1002/14651858.CD008397.pub2
39 10.1002/14651858.CD004345.pub2
40 10.1002/14651858.CD003220.pub2
41 10.1002/14651858.CD003815.pub4
42 10.1002/14651858.CD002281.pub3
43 10.1002/14651858.CD005515.pub3
44 10.1002/14651858.CD005098.pub3
45 10.1002/14651858.CD005101.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD008694.pub2
4 10.1002/14651858.CD009742.pub2
5 10.1002/14651858.CD010470.pub2
6 10.1002/14651858.CD010743.pub2
7 10.1002/14651858.CD011018.pub2
8 10.1002/14651858.CD008457.pub2
9 10.1002/14651858.CD004622.pub3
10 10.1002/14651858.CD010176.pub2
11 10.1002/14651858.CD010572.pub2
12 10.1002/14651858.CD003876.pub4
13 10.1002/14651858.CD002280.pub2
14 10.1002/14651858.CD009109.pub3
15 10.1002/14651858.CD011116.pub2
16 10.1002/14651858.CD010431.pub2
17 10.1002/14651858.CD010887.pub2
18 10.1002/14651858.CD010856.pub2
19 10.1002/14651858.CD004714.pub3
20 10.1002/14651858.CD010341.pub2
21 10.1002/14651858.CD005512.pub3
22 10.1002/14651858.CD011552.pub2
23 10.1002/14651858.CD004969.pub4
24 10.1002/14651858.CD003067.pub4
25 10.1002/14651858.CD002283.pub4
26 10.1002/14651858.CD007517.pub3
27 10.1002/14651858.CD008455.pub2
28 10.1002/14651858.CD011784.pub2
29 10.1002/14651858.CD008392.pub3
30 10.1002/14651858.CD003879.pub4
31 10.1002/14651858.CD009858.pub2
32 10.1002/14651858.CD002284.pub2
33 10.1002/14651858.CD001829.pub4
34 10.1002/14651858.CD010535.pub2
35 10.1002/14651858.CD010403.pub2
36 10.1002/14651858.CD005520.pub3
37 10.1002/14651858.CD004485.pub4
38 10.1002/14651858.CD010526.pub2
39 10.1002/14651858.CD010229.pub2
40 10.1002/14651858.CD005511.pub3
41 10.1002/14651858.CD008367.pub3
42 10.1002/14651858.CD005517.pub2
43 10.1002/14651858.CD005296.pub3
44 10.1002/14651858.CD002779.pub3
45 10.1002/14651858.CD008236.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD010263.pub2
4 10.1002/14651858.CD005297.pub3
5 10.1002/14651858.CD006966.pub3
6 10.1002/14651858.CD006204.pub3
7 10.1002/14651858.CD008676.pub2
8 10.1002/14651858.CD012744
9 10.1002/14651858.CD001830.pub5
10 10.1002/14651858.CD007556.pub2
11 10.1002/14651858.CD007553.pub2
12 10.1002/14651858.CD007519.pub2
13 10.1002/14651858.CD009183.pub2
14 10.1002/14651858.CD007132.pub2
15 10.1002/14651858.CD009664
16 10.1002/14651858.CD009007.pub2
17 10.1002/14651858.CD009663
18 10.1002/14651858.CD006276.pub3
19 10.1002/14651858.CD008615.pub2
20 10.1002/14651858.CD009665
21 10.1002/14651858.CD007544.pub2
22 10.1002/14651858.CD002067.pub2
23 10.1002/14651858.CD008943.pub2
24 10.1002/14651858.CD010111
25 10.1002/14651858.CD004770.pub2
26 10.1002/14651858.CD008025.pub2
27 10.1002/14651858.CD008768.pub2
28 10.1002/14651858.CD006145.pub3
29 10.1002/14651858.CD008411.pub2
30 10.1002/14651858.CD007407.pub3
31 10.1002/14651858.CD008041.pub3
32 10.1002/14651858.CD001792.pub3
33 10.1002/14651858.CD008783.pub3
34 10.1002/14651858.CD008039.pub3
35 10.1002/14651858.CD004310.pub3
36 10.1002/14651858.CD008040.pub3
37 10.1002/14651858.CD005539.pub2
38 10.1002/14651858.CD010609
39 10.1002/14651858.CD010210.pub2
40 10.1002/14651858.CD010608
41 10.1002/14651858.CD010289.pub2
42 10.1002/14651858.CD007760.pub2
43 10.1002/14651858.CD010611
44 10.1002/14651858.CD004844.pub3
45 10.1002/14651858.CD006146.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD010610
4 10.1002/14651858.CD009796.pub2
5 10.1002/14651858.CD010270.pub2
6 10.1002/14651858.CD008307.pub2
7 10.1002/14651858.CD009455.pub2
8 10.1002/14651858.CD004233.pub4
9 10.1002/14651858.CD007550.pub3
10 10.1002/14651858.CD005179.pub3
11 10.1002/14651858.CD009688.pub2
12 10.1002/14651858.CD006044.pub4
13 10.1002/14651858.CD008042.pub3
14 10.1002/14651858.CD006273.pub3
15 10.1002/14651858.CD002918.pub3
16 10.1002/14651858.CD004309.pub4
17 10.1002/14651858.CD010152.pub2
18 10.1002/14651858.CD005451.pub3
19 10.1002/14651858.CD003968.pub4
20 10.1002/14651858.CD008208.pub3
21 10.1002/14651858.CD010769.pub2
22 10.1002/14651858.CD008616.pub2
23 10.1002/14651858.CD010943.pub2
24 10.1002/14651858.CD010958.pub2
25 10.1002/14651858.CD007533.pub3
26 10.1002/14651858.CD011056.pub2
27 10.1002/14651858.CD009583.pub2
28 10.1002/14651858.CD011003.pub2
29 10.1002/14651858.CD006601.pub4
30 10.1002/14651858.CD005622.pub4
31 10.1002/14651858.CD007403.pub3
32 10.1002/14651858.CD009281.pub3
33 10.1002/14651858.CD010206.pub2
34 10.1002/14651858.CD011209.pub2
35 10.1002/14651858.CD010937.pub2
36 10.1002/14651858.CD011241.pub2
37 10.1002/14651858.CD010107.pub3
38 10.1002/14651858.CD011404.pub2
39 10.1002/14651858.CD010750.pub2
40 10.1002/14651858.CD009574.pub2
41 10.1002/14651858.CD011118.pub2
42 10.1002/14651858.CD002919.pub3
43 10.1002/14651858.CD002286.pub3
44 10.1002/14651858.CD009596.pub4
45 10.1002/14651858.CD010756.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD009660.pub3
4 10.1002/14651858.CD003448.pub4
5 10.1002/14651858.CD007771.pub3
6 10.1002/14651858.CD008408.pub3
7 10.1002/14651858.CD011681
8 10.1002/14651858.CD009923.pub2
9 10.1002/14651858.CD007881.pub3
10 10.1002/14651858.CD006788.pub3
11 10.1002/14651858.CD003348.pub3
12 10.1002/14651858.CD009389.pub3
13 10.1002/14651858.CD007402.pub3
14 10.1002/14651858.CD006142.pub3
15 10.1002/14651858.CD011789
16 10.1002/14651858.CD010720.pub2
17 10.1002/14651858.CD011509.pub2
18 10.1002/14651858.CD007887.pub3
19 10.1002/14651858.CD011824
20 10.1002/14651858.CD011474.pub2
21 10.1002/14651858.CD004768.pub3
22 10.1002/14651858.CD008242.pub3
23 10.1002/14651858.CD011091.pub2
24 10.1002/14651858.CD009509.pub3
25 10.1002/14651858.CD011460.pub2
26 10.1002/14651858.CD006716.pub3
27 10.1002/14651858.CD003782.pub3
28 10.1002/14651858.CD010967.pub2
29 10.1002/14651858.CD007753.pub3
30 10.1002/14651858.CD011259.pub2
31 10.1002/14651858.CD008244.pub3
32 10.1002/14651858.CD010902.pub2
33 10.1002/14651858.CD006271.pub3
34 10.1002/14651858.CD005219.pub3
35 10.1002/14651858.CD002764.pub2
36 10.1002/14651858.CD008006.pub4
37 10.1002/14651858.CD005540.pub3
38 10.1002/14651858.CD009199.pub3
39 10.1002/14651858.CD006275.pub3
40 10.1002/14651858.CD011131.pub2
41 10.1002/14651858.CD011008.pub2
42 10.1002/14651858.CD010853.pub2
43 10.1002/14651858.CD005220.pub2
44 10.1002/14651858.CD007587.pub2
45 10.1002/14651858.CD011421.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD008541.pub3
4 10.1002/14651858.CD003868.pub4
5 10.1002/14651858.CD008918.pub2
6 10.1002/14651858.CD007400.pub3
7 10.1002/14651858.CD011604.pub2
8 10.1002/14651858.CD011804.pub2
9 10.1002/14651858.CD009873.pub3
10 10.1002/14651858.CD010529.pub2
11 10.1002/14651858.CD007126.pub3
12 10.1002/14651858.CD011694.pub2
13 10.1002/14651858.CD001218.pub3
14 10.1002/14651858.CD011889.pub2
15 10.1002/14651858.CD010692.pub3
16 10.1002/14651858.CD011476.pub2
17 10.1002/14651858.CD004598.pub4
18 10.1002/14651858.CD012190.pub2
19 10.1002/14651858.CD012232.pub2
20 10.1002/14651858.CD011108.pub2
21 10.1002/14651858.CD011790.pub2
22 10.1002/14651858.CD011605.pub2
23 10.1002/14651858.CD009419.pub3
24 10.1002/14651858.CD006380.pub3
25 10.1002/14651858.CD007354.pub3
26 10.1002/14651858.CD011248.pub2
27 10.1002/14651858.CD012188.pub2
28 10.1002/14651858.CD003971.pub4
29 10.1002/14651858.CD008144.pub2
30 10.1002/14651858.CD011888.pub2
31 10.1002/14651858.CD007393.pub4
32 10.1002/14651858.CD011419.pub2
33 10.1002/14651858.CD008320.pub3
34 10.1002/14651858.CD012332.pub2
35 10.1002/14651858.CD012508.pub2
36 10.1002/14651858.CD012499.pub2
37 10.1002/14651858.CD011669.pub2
38 10.1002/14651858.CD007355.pub3
39 10.1002/14651858.CD012002.pub2
40 10.1002/14651858.CD003351.pub3
41 10.1002/14651858.CD007938.pub4
42 10.1002/14651858.CD012638.pub2
43 10.1002/14651858.CD012637.pub2
44 10.1002/14651858.CD009984.pub3
45 10.1002/14651858.CD012030.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD012537.pub2
4 10.1002/14651858.CD012536.pub2
5 10.1002/14651858.CD012051.pub2
6 10.1002/14651858.CD012535.pub2
7 10.1002/14651858.CD011976.pub2
8 10.1002/14651858.CD003870.pub6
9 10.1002/14651858.CD009595.pub2
10 10.1002/14651858.CD008160.pub2
11 10.1002/14651858.CD008938.pub2
12 10.1002/14651858.CD010026.pub2
13 10.1002/14651858.CD005055.pub3
14 10.1002/14651858.CD010555.pub2
15 10.1002/14651858.CD010357.pub2
16 10.1002/14651858.CD009176.pub2
17 10.1002/14651858.CD002788.pub3
18 10.1002/14651858.CD009161.pub2
19 10.1002/14651858.CD008638.pub2
20 10.1002/14651858.CD009901.pub2
21 10.1002/14651858.CD005277.pub3
22 10.1002/14651858.CD007274.pub2
23 10.1002/14651858.CD008343.pub2
24 10.1002/14651858.CD007598.pub2
25 10.1002/14651858.CD003590.pub4
26 10.1002/14651858.CD006616.pub2
27 10.1002/14651858.CD007105.pub2
28 10.1002/14651858.CD004958.pub2
29 10.1002/14651858.CD008112.pub2
30 10.1002/14651858.CD004919.pub2
31 10.1002/14651858.CD004084.pub3
32 10.1002/14651858.CD007119.pub2
33 10.1002/14651858.CD008257.pub2
34 10.1002/14651858.CD008402.pub2
35 10.1002/14651858.CD005958.pub3
36 10.1002/14651858.CD006717.pub2
37 10.1002/14651858.CD005106.pub4
38 10.1002/14651858.CD004871.pub4
39 10.1002/14651858.CD008880.pub2
40 10.1002/14651858.CD009565.pub2
41 10.1002/14651858.CD008326.pub2
42 10.1002/14651858.CD003010.pub5
43 10.1002/14651858.CD004251.pub5
44 10.1002/14651858.CD004959.pub4
45 10.1002/14651858.CD010712
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD001822.pub3
4 10.1002/14651858.CD009644.pub2
5 10.1002/14651858.CD004360.pub4
6 10.1002/14651858.CD004082.pub5
7 10.1002/14651858.CD003845.pub3
8 10.1002/14651858.CD003844.pub4
9 10.1002/14651858.CD004388.pub6
10 10.1002/14651858.CD003408.pub3
11 10.1002/14651858.CD009098.pub2
12 10.1002/14651858.CD008863.pub2
13 10.1002/14651858.CD006908.pub2
14 10.1002/14651858.CD006715.pub2
15 10.1002/14651858.CD009971.pub2
16 10.1002/14651858.CD006313.pub3
17 10.1002/14651858.CD003707.pub3
18 10.1002/14651858.CD004087.pub2
19 10.1002/14651858.CD003591.pub3
20 10.1002/14651858.CD007083.pub3
21 10.1002/14651858.CD009082.pub2
22 10.1002/14651858.CD005487.pub3
23 10.1002/14651858.CD008864.pub2
24 10.1002/14651858.CD010160.pub2
25 10.1002/14651858.CD005056.pub3
26 10.1002/14651858.CD001090.pub2
27 10.1002/14651858.CD004127.pub3
28 10.1002/14651858.CD010320.pub2
29 10.1002/14651858.CD009798.pub2
30 10.1002/14651858.CD010105.pub2
31 10.1002/14651858.CD009784.pub2
32 10.1002/14651858.CD003344.pub3
33 10.1002/14651858.CD007080.pub2
34 10.1002/14651858.CD009633.pub2
35 10.1002/14651858.CD006058.pub3
36 10.1002/14651858.CD009015.pub2
37 10.1002/14651858.CD008639.pub2
38 10.1002/14651858.CD002013.pub3
39 10.1002/14651858.CD009763.pub2
40 10.1002/14651858.CD007364.pub2
41 10.1002/14651858.CD009908.pub2
42 10.1002/14651858.CD006056.pub2
43 10.1002/14651858.CD009235.pub3
44 10.1002/14651858.CD009941.pub2
45 10.1002/14651858.CD007922.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD003843.pub3
4 10.1002/14651858.CD009169.pub2
5 10.1002/14651858.CD003007.pub3
6 10.1002/14651858.CD004504.pub4
7 10.1002/14651858.CD000963.pub3
8 10.1002/14651858.CD010328.pub2
9 10.1002/14651858.CD010387.pub2
10 10.1002/14651858.CD010664.pub2
11 10.1002/14651858.CD004250.pub5
12 10.1002/14651858.CD010036.pub2
13 10.1002/14651858.CD001929.pub3
14 10.1002/14651858.CD010264.pub2
15 10.1002/14651858.CD008572.pub2
16 10.1002/14651858.CD010513.pub2
17 10.1002/14651858.CD012087
18 10.1002/14651858.CD004249.pub4
19 10.1002/14651858.CD012085
20 10.1002/14651858.CD012004
21 10.1002/14651858.CD008325.pub2
22 10.1002/14651858.CD009772.pub2
23 10.1002/14651858.CD012421
24 10.1002/14651858.CD011674.pub2
25 10.1002/14651858.CD002193.pub2
26 10.1002/14651858.CD010671.pub2
27 10.1002/14651858.CD010050.pub2
28 10.1002/14651858.CD009942.pub2
29 10.1002/14651858.CD007084.pub2
30 10.1002/14651858.CD004476.pub2
31 10.1002/14651858.CD009892.pub2
32 10.1002/14651858.CD010468.pub2
33 10.1002/14651858.CD008877.pub2
34 10.1002/14651858.CD006904.pub3
35 10.1002/14651858.CD006902.pub3
36 10.1002/14651858.CD009771.pub2
37 10.1002/14651858.CD010225.pub2
38 10.1002/14651858.CD010269.pub2
39 10.1002/14651858.CD011447
40 10.1002/14651858.CD010381.pub2
41 10.1002/14651858.CD006638.pub3
42 10.1002/14651858.CD007271.pub3
43 10.1002/14651858.CD006962.pub2
44 10.1002/14651858.CD008807.pub2
45 10.1002/14651858.CD010645.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD009852.pub2
4 10.1002/14651858.CD010824.pub2
5 10.1002/14651858.CD004083.pub3
6 10.1002/14651858.CD009861.pub2
7 10.1002/14651858.CD008632.pub2
8 10.1002/14651858.CD009891.pub2
9 10.1002/14651858.CD008884.pub2
10 10.1002/14651858.CD004081.pub3
11 10.1002/14651858.CD006447.pub3
12 10.1002/14651858.CD007082.pub2
13 10.1002/14651858.CD009201.pub2
14 10.1002/14651858.CD011107.pub2
15 10.1002/14651858.CD007399.pub2
16 10.1002/14651858.CD009642.pub2
17 10.1002/14651858.CD003703.pub3
18 10.1002/14651858.CD006291.pub3
19 10.1002/14651858.CD010278.pub2
20 10.1002/14651858.CD006459.pub3
21 10.1002/14651858.CD009134.pub2
22 10.1002/14651858.CD010106.pub2
23 10.1002/14651858.CD010356.pub2
24 10.1002/14651858.CD008808.pub2
25 10.1002/14651858.CD001021.pub2
26 10.1002/14651858.CD003429.pub4
27 10.1002/14651858.CD002008.pub4
28 10.1002/14651858.CD008294.pub4
29 10.1002/14651858.CD002767.pub2
30 10.1002/14651858.CD002203.pub4
31 10.1002/14651858.CD008319.pub2
32 10.1002/14651858.CD001507.pub3
33 10.1002/14651858.CD007639.pub2
34 10.1002/14651858.CD009415.pub2
35 10.1002/14651858.CD008037.pub3
36 10.1002/14651858.CD007168.pub3
37 10.1002/14651858.CD006112.pub3
38 10.1002/14651858.CD003884.pub4
39 10.1002/14651858.CD001753.pub3
40 10.1002/14651858.CD009448.pub2
41 10.1002/14651858.CD004839.pub3
42 10.1002/14651858.CD002010.pub4
43 10.1002/14651858.CD004450.pub3
44 10.1002/14651858.CD005087.pub4
45 10.1002/14651858.CD010561.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD007298.pub4
4 10.1002/14651858.CD007477.pub3
5 10.1002/14651858.CD008190.pub2
6 10.1002/14651858.CD007020.pub3
7 10.1002/14651858.CD007641.pub3
8 10.1002/14651858.CD003148.pub3
9 10.1002/14651858.CD001918.pub3
10 10.1002/14651858.CD009961.pub2
11 10.1002/14651858.CD004731.pub4
12 10.1002/14651858.CD010297.pub2
13 10.1002/14651858.CD010893.pub2
14 10.1002/14651858.CD010324.pub2
15 10.1002/14651858.CD009841.pub2
16 10.1002/14651858.CD008005.pub4
17 10.1002/14651858.CD004448.pub5
18 10.1002/14651858.CD001916.pub3
19 10.1002/14651858.CD008901.pub3
20 10.1002/14651858.CD009191.pub3
21 10.1002/14651858.CD008253.pub4
22 10.1002/14651858.CD001914.pub2
23 10.1002/14651858.CD003147.pub4
24 10.1002/14651858.CD009730.pub2
25 10.1002/14651858.CD008191.pub2
26 10.1002/14651858.CD008068.pub2
27 10.1002/14651858.CD007546.pub2
28 10.1002/14651858.CD007220.pub2
29 10.1002/14651858.CD002955.pub4
30 10.1002/14651858.CD005379.pub3
31 10.1002/14651858.CD006504.pub2
32 10.1002/14651858.CD009425.pub2
33 10.1002/14651858.CD005562.pub2
34 10.1002/14651858.CD006378.pub2
35 10.1002/14651858.CD006929.pub2
36 10.1002/14651858.CD009132.pub2
37 10.1002/14651858.CD008634.pub2
38 10.1002/14651858.CD004744.pub3
39 10.1002/14651858.CD008900.pub2
40 10.1002/14651858.CD004033.pub3
41 10.1002/14651858.CD007726.pub2
42 10.1002/14651858.CD003260.pub2
43 10.1002/14651858.CD004396.pub3
44 10.1002/14651858.CD009125.pub2
45 10.1002/14651858.CD009537.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD003150.pub2
4 10.1002/14651858.CD003946.pub4
5 10.1002/14651858.CD005380.pub5
6 10.1002/14651858.CD007514.pub3
7 10.1002/14651858.CD009126.pub2
8 10.1002/14651858.CD009444.pub3
9 10.1002/14651858.CD008345.pub2
10 10.1002/14651858.CD009524.pub2
11 10.1002/14651858.CD006489.pub4
12 10.1002/14651858.CD005381.pub4
13 10.1002/14651858.CD010033.pub2
14 10.1002/14651858.CD010569.pub2
15 10.1002/14651858.CD009221.pub2
16 10.1002/14651858.CD001191.pub4
17 10.1002/14651858.CD003160.pub3
18 10.1002/14651858.CD009002.pub3
19 10.1002/14651858.CD011971.pub2
20 10.1002/14651858.CD011513.pub2
21 10.1002/14651858.CD009178.pub3
22 10.1002/14651858.CD005563.pub3
23 10.1002/14651858.CD009374.pub3
24 10.1002/14651858.CD011882.pub2
25 10.1002/14651858.CD002854.pub5
26 10.1002/14651858.CD003804.pub2
27 10.1002/14651858.CD003477.pub3
28 10.1002/14651858.CD004615.pub3
29 10.1002/14651858.CD007296.pub2
30 10.1002/14651858.CD006688.pub2
31 10.1002/14651858.CD006689.pub2
32 10.1002/14651858.CD008603.pub2
33 10.1002/14651858.CD003754.pub3
34 10.1002/14651858.CD006591.pub2
35 10.1002/14651858.CD004530.pub4
36 10.1002/14651858.CD002151.pub2
37 10.1002/14651858.CD003756.pub4
38 10.1002/14651858.CD005967.pub4
39 10.1002/14651858.CD007179.pub2
40 10.1002/14651858.CD009527.pub2
41 10.1002/14651858.CD008300.pub2
42 10.1002/14651858.CD001167.pub2
43 10.1002/14651858.CD006201.pub3
44 10.1002/14651858.CD007787.pub2
45 10.1002/14651858.CD004795.pub4
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD000528.pub2
4 10.1002/14651858.CD008521.pub3
5 10.1002/14651858.CD007401.pub3
6 10.1002/14651858.CD009029.pub2
7 10.1002/14651858.CD009572.pub2
8 10.1002/14651858.CD008492.pub3
9 10.1002/14651858.CD007545.pub2
10 10.1002/14651858.CD005433.pub2
11 10.1002/14651858.CD008923.pub2
12 10.1002/14651858.CD004389.pub3
13 10.1002/14651858.CD008090.pub2
14 10.1002/14651858.CD001261.pub3
15 10.1002/14651858.CD008846.pub2
16 10.1002/14651858.CD007953.pub2
17 10.1002/14651858.CD010927
18 10.1002/14651858.CD006404.pub2
19 10.1002/14651858.CD008998.pub2
20 10.1002/14651858.CD009964.pub2
21 10.1002/14651858.CD003488.pub3
22 10.1002/14651858.CD008625.pub2
23 10.1002/14651858.CD010678.pub2
24 10.1002/14651858.CD000169.pub3
25 10.1002/14651858.CD011370
26 10.1002/14651858.CD010767.pub2
27 10.1002/14651858.CD006594.pub3
28 10.1002/14651858.CD000053.pub3
29 10.1002/14651858.CD011547
30 10.1002/14651858.CD008152.pub4
31 10.1002/14651858.CD010458.pub2
32 10.1002/14651858.CD003343.pub4
33 10.1002/14651858.CD004265.pub3
34 10.1002/14651858.CD007952.pub3
35 10.1002/14651858.CD007745.pub3
36 10.1002/14651858.CD000371.pub6
37 10.1002/14651858.CD004794.pub3
38 10.1002/14651858.CD006419.pub4
39 10.1002/14651858.CD002244.pub4
40 10.1002/14651858.CD006589.pub4
41 10.1002/14651858.CD009913.pub2
42 10.1002/14651858.CD012163.pub2
43 10.1002/14651858.CD006086.pub4
44 10.1002/14651858.CD012091.pub2
45 10.1002/14651858.CD006417.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD008824.pub2
4 10.1002/14651858.CD004246.pub4
5 10.1002/14651858.CD006519.pub3
6 10.1002/14651858.CD001876.pub3
7 10.1002/14651858.CD010806.pub2
8 10.1002/14651858.CD009818.pub2
9 10.1002/14651858.CD005436.pub5
10 10.1002/14651858.CD006418.pub3
11 10.1002/14651858.CD003650.pub4
12 10.1002/14651858.CD011656.pub2
13 10.1002/14651858.CD008984.pub2
14 10.1002/14651858.CD003281.pub4
15 10.1002/14651858.CD005059.pub4
16 10.1002/14651858.CD009634.pub2
17 10.1002/14651858.CD008095.pub2
18 10.1002/14651858.CD011151.pub2
19 10.1002/14651858.CD004920.pub3
20 10.1002/14651858.CD002243.pub3
21 10.1002/14651858.CD009210.pub2
22 10.1002/14651858.CD005370.pub3
23 10.1002/14651858.CD009346.pub2
24 10.1002/14651858.CD004128.pub4
25 10.1002/14651858.CD003709.pub4
26 10.1002/14651858.CD009121.pub2
27 10.1002/14651858.CD011436.pub2
28 10.1002/14651858.CD000521.pub3
29 10.1002/14651858.CD010135.pub2
30 10.1002/14651858.CD007874.pub2
31 10.1002/14651858.CD003004.pub4
32 10.1002/14651858.CD010570.pub2
33 10.1002/14651858.CD004085.pub4
34 10.1002/14651858.CD009484.pub2
35 10.1002/14651858.CD007878.pub3
36 10.1002/14651858.CD005144.pub3
37 10.1002/14651858.CD009016.pub2
38 10.1002/14651858.CD009491.pub2
39 10.1002/14651858.CD007205.pub2
40 10.1002/14651858.CD005576.pub3
41 10.1002/14651858.CD012230
42 10.1002/14651858.CD008646.pub2
43 10.1002/14651858.CD006837.pub3
44 10.1002/14651858.CD002787.pub3
45 10.1002/14651858.CD008045.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD011052.pub2
4 10.1002/14651858.CD010726.pub2
5 10.1002/14651858.CD011364.pub2
6 10.1002/14651858.CD001893.pub2
7 10.1002/14651858.CD003842.pub5
8 10.1002/14651858.CD003587.pub3
9 10.1002/14651858.CD007871.pub3
10 10.1002/14651858.CD006623.pub3
11 10.1002/14651858.CD006883.pub3
12 10.1002/14651858.CD011812.pub2
13 10.1002/14651858.CD006667.pub3
14 10.1002/14651858.CD009906.pub2
15 10.1002/14651858.CD008075.pub3
16 10.1002/14651858.CD011833.pub2
17 10.1002/14651858.CD010698.pub2
18 10.1002/14651858.CD005364.pub3
19 10.1002/14651858.CD011413.pub2
20 10.1002/14651858.CD007272.pub2
21 10.1002/14651858.CD010172.pub2
22 10.1002/14651858.CD010807.pub2
23 10.1002/14651858.CD007733.pub3
24 10.1002/14651858.CD009761.pub2
25 10.1002/14651858.CD012763
26 10.1002/14651858.CD004711.pub3
27 10.1002/14651858.CD004089.pub3
28 10.1002/14651858.CD008674.pub2
29 10.1002/14651858.CD003474.pub3
30 10.1002/14651858.CD006243.pub2
31 10.1002/14651858.CD007847.pub2
32 10.1002/14651858.CD008926.pub2
33 10.1002/14651858.CD008941.pub2
34 10.1002/14651858.CD009553.pub2
35 10.1002/14651858.CD007913.pub2
36 10.1002/14651858.CD003721.pub3
37 10.1002/14651858.CD005212.pub3
38 10.1002/14651858.CD009557.pub2
39 10.1002/14651858.CD000563.pub7
40 10.1002/14651858.CD004253.pub4
41 10.1002/14651858.CD001877.pub5
42 10.1002/14651858.CD008792.pub2
43 10.1002/14651858.CD004272.pub3
44 10.1002/14651858.CD006242.pub2
45 10.1002/14651858.CD003475.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD009765.pub2
4 10.1002/14651858.CD009206.pub2
5 10.1002/14651858.CD008729.pub2
6 10.1002/14651858.CD010895.pub2
7 10.1002/14651858.CD001768.pub3
8 10.1002/14651858.CD003139.pub3
9 10.1002/14651858.CD003366.pub3
10 10.1002/14651858.CD007077.pub3
11 10.1002/14651858.CD003860.pub4
12 10.1002/14651858.CD011093.pub2
13 10.1002/14651858.CD008932.pub3
14 10.1002/14651858.CD011396.pub2
15 10.1002/14651858.CD005001.pub3
16 10.1002/14651858.CD011652.pub2
17 10.1002/14651858.CD010802.pub2
18 10.1002/14651858.CD004561.pub3
19 10.1002/14651858.CD003374.pub4
20 10.1002/14651858.CD011152.pub2
21 10.1002/14651858.CD006956.pub2
22 10.1002/14651858.CD005660.pub3
23 10.1002/14651858.CD007780.pub2
24 10.1002/14651858.CD007886.pub2
25 10.1002/14651858.CD007635.pub2
26 10.1002/14651858.CD007781.pub2
27 10.1002/14651858.CD008506.pub2
28 10.1002/14651858.CD004320.pub3
29 10.1002/14651858.CD007378.pub2
30 10.1002/14651858.CD008359.pub2
31 10.1002/14651858.CD005477.pub4
32 10.1002/14651858.CD002199.pub4
33 10.1002/14651858.CD001544.pub4
34 10.1002/14651858.CD008361.pub2
35 10.1002/14651858.CD003769.pub4
36 10.1002/14651858.CD003144.pub2
37 10.1002/14651858.CD003431.pub3
38 10.1002/14651858.CD001543.pub4
39 10.1002/14651858.CD008836.pub2
40 10.1002/14651858.CD004078.pub2
41 10.1002/14651858.CD008237.pub2
42 10.1002/14651858.CD005391.pub3
43 10.1002/14651858.CD008034.pub2
44 10.1002/14651858.CD009350.pub2
45 10.1002/14651858.CD007814.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
50

1
2
3 10.1002/14651858.CD004322.pub3
4 10.1002/14651858.CD009092.pub2
5 10.1002/14651858.CD009244.pub2
6 10.1002/14651858.CD008368.pub2
7 10.1002/14651858.CD008211.pub3
8 10.1002/14651858.CD009475.pub2
9 10.1002/14651858.CD006041.pub3
10 10.1002/14651858.CD004323.pub4
11 10.1002/14651858.CD009495.pub2
12 10.1002/14651858.CD008879.pub2
13 10.1002/14651858.CD009487.pub2
14 10.1002/14651858.CD009259.pub2
15 10.1002/14651858.CD010168.pub2
16 10.1002/14651858.CD005200.pub3
17 10.1002/14651858.CD008531.pub2
18 10.1002/14651858.CD009863.pub2
19 10.1002/14651858.CD006506.pub3
20 10.1002/14651858.CD008593.pub3
21 10.1002/14651858.CD006439.pub4
22 10.1002/14651858.CD007821.pub3
23 10.1002/14651858.CD001181.pub4
24 10.1002/14651858.CD002200.pub3
25 10.1002/14651858.CD003430.pub2
26 10.1002/14651858.CD011670.pub2
27 10.1002/14651858.CD010814.pub2
28 10.1002/14651858.CD006875.pub3
29 10.1002/14651858.CD006476.pub3
30 10.1002/14651858.CD009569.pub3
31 10.1002/14651858.CD009839.pub2
32 10.1002/14651858.CD007047.pub2
33 10.1002/14651858.CD006325.pub3
34 10.1002/14651858.CD008975.pub2
35 10.1002/14651858.CD008205.pub2
36 10.1002/14651858.CD009160.pub2
37 10.1002/14651858.CD006647.pub4
38 10.1002/14651858.CD008944.pub2
39 10.1002/14651858.CD010774.pub2
40 10.1002/14651858.CD003298.pub3
41 10.1002/14651858.CD006301.pub4
42 10.1002/14651858.CD008382.pub2
43 10.1002/14651858.CD008890.pub4
44 10.1002/14651858.CD008796.pub3
45 10.1002/14651858.CD007786.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD010439.pub2
4 10.1002/14651858.CD006247.pub3
5 10.1002/14651858.CD010885.pub3
6 10.1002/14651858.CD009678.pub2
7 10.1002/14651858.CD008011.pub3
8 10.1002/14651858.CD009219.pub4
9 10.1002/14651858.CD006945.pub4
10 10.1002/14651858.CD010349.pub2
11 10.1002/14651858.CD010685.pub3
12 10.1002/14651858.CD008483.pub2
13 10.1002/14651858.CD001025.pub3
14 10.1002/14651858.CD008591.pub2
15 10.1002/14651858.CD004857.pub2
16 10.1002/14651858.CD006528.pub2
17 10.1002/14651858.CD007139.pub2
18 10.1002/14651858.CD005472.pub3
19 10.1002/14651858.CD007504.pub2
20 10.1002/14651858.CD008937.pub2
21 10.1002/14651858.CD004851.pub3
22 10.1002/14651858.CD006533.pub2
23 10.1002/14651858.CD006525.pub2
24 10.1002/14651858.CD001760.pub2
25 10.1002/14651858.CD006726.pub2
26 10.1002/14651858.CD006534.pub2
27 10.1002/14651858.CD002317.pub2
28 10.1002/14651858.CD009138.pub2
29 10.1002/14651858.CD006389.pub2
30 10.1002/14651858.CD003196.pub2
31 10.1002/14651858.CD008696.pub2
32 10.1002/14651858.CD004185.pub3
33 10.1002/14651858.CD004366.pub6
34 10.1002/14651858.CD008705.pub2
35 10.1002/14651858.CD008142.pub2
36 10.1002/14651858.CD008704.pub2
37 10.1002/14651858.CD007662.pub2
38 10.1002/14651858.CD005330.pub4
39 10.1002/14651858.CD003388.pub4
40 10.1002/14651858.CD008851.pub2
41 10.1002/14651858.CD006239.pub2
42 10.1002/14651858.CD004687.pub4
43 10.1002/14651858.CD002018.pub2
44 10.1002/14651858.CD009083.pub2
45 10.1002/14651858.CD010828.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD006531.pub2
4 10.1002/14651858.CD009317.pub2
5 10.1002/14651858.CD005000.pub2
6 10.1002/14651858.CD011142.pub2
7 10.1002/14651858.CD004690.pub4
8 10.1002/14651858.CD008324.pub3
9 10.1002/14651858.CD009895.pub2
10 10.1002/14651858.CD008619.pub2
11 10.1002/14651858.CD010628.pub2
12 10.1002/14651858.CD006833.pub2
13 10.1002/14651858.CD007194.pub2
14 10.1002/14651858.CD003909.pub2
15 10.1002/14651858.CD007803.pub2
16 10.1002/14651858.CD011777
17 10.1002/14651858.CD004044.pub4
18 10.1002/14651858.CD011611.pub2
19 10.1002/14651858.CD011269.pub2
20 10.1002/14651858.CD004692.pub4
21 10.1002/14651858.CD011612.pub2
22 10.1002/14651858.CD011268.pub2
23 10.1002/14651858.CD012013
24 10.1002/14651858.CD011565.pub2
25 10.1002/14651858.CD010204.pub2
26 10.1002/14651858.CD003384.pub3
27 10.1002/14651858.CD006727.pub3
28 10.1002/14651858.CD011119.pub2
29 10.1002/14651858.CD012189
30 10.1002/14651858.CD011567.pub2
31 10.1002/14651858.CD010673.pub2
32 10.1002/14651858.CD011170.pub2
33 10.1002/14651858.CD011004.pub2
34 10.1002/14651858.CD012371
35 10.1002/14651858.CD011286.pub2
36 10.1002/14651858.CD011520.pub2
37 10.1002/14651858.CD003200.pub7
38 10.1002/14651858.CD003380.pub4
39 10.1002/14651858.CD003648.pub4
40 10.1002/14651858.CD005143.pub3
41 10.1002/14651858.CD006161.pub3
42 10.1002/14651858.CD006776.pub2
43 10.1002/14651858.CD007092.pub2
44 10.1002/14651858.CD007617.pub2
45 10.1002/14651858.CD005025.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD007456.pub2
4 10.1002/14651858.CD008273.pub2
5 10.1002/14651858.CD006777.pub2
6 10.1002/14651858.CD007982.pub2
7 10.1002/14651858.CD007978.pub2
8 10.1002/14651858.CD004811.pub3
9 10.1002/14651858.CD007457.pub2
10 10.1002/14651858.CD007459.pub2
11 10.1002/14651858.CD001865.pub3
12 10.1002/14651858.CD008722.pub2
13 10.1002/14651858.CD008416.pub2
14 10.1002/14651858.CD003267.pub2
15 10.1002/14651858.CD009453.pub2
16 10.1002/14651858.CD010038.pub2
17 10.1002/14651858.CD004807.pub2
18 10.1002/14651858.CD007458.pub3
19 10.1002/14651858.CD009445.pub2
20 10.1002/14651858.CD004134.pub3
21 10.1002/14651858.CD009405.pub2
22 10.1002/14651858.CD007979.pub3
23 10.1002/14651858.CD003717.pub3
24 10.1002/14651858.CD010232.pub2
25 10.1002/14651858.CD010523.pub2
26 10.1002/14651858.CD009736.pub2
27 10.1002/14651858.CD010825.pub2
28 10.1002/14651858.CD009727.pub2
29 10.1002/14651858.CD000011.pub4
30 10.1002/14651858.CD009921.pub2
31 10.1002/14651858.CD001399.pub4
32 10.1002/14651858.CD010790.pub2
33 10.1002/14651858.CD010288.pub3
34 10.1002/14651858.CD008649.pub2
35 10.1002/14651858.CD000407.pub4
36 10.1002/14651858.CD001917.pub4
37 10.1002/14651858.CD010155.pub3
38 10.1002/14651858.CD009530.pub3
39 10.1002/14651858.CD001401.pub3
40 10.1002/14651858.CD008185.pub4
41 10.1002/14651858.CD006111.pub3
42 10.1002/14651858.CD004449.pub4
43 10.1002/14651858.CD011130.pub2
44 10.1002/14651858.CD002201.pub5
45 10.1002/14651858.CD011385.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD009806.pub2
4 10.1002/14651858.CD009354.pub4
5 10.1002/14651858.CD010429.pub2
6 10.1002/14651858.CD003426.pub5
7 10.1002/14651858.CD001505.pub4
8 10.1002/14651858.CD003149.pub3
9 10.1002/14651858.CD001127.pub3
10 10.1002/14651858.CD004730.pub4
11 10.1002/14651858.CD010517.pub2
12 10.1002/14651858.CD005599.pub5
13 10.1002/14651858.CD007862.pub4
14 10.1002/14651858.CD007743.pub6
15 10.1002/14651858.CD011272.pub2
16 10.1002/14651858.CD005405.pub4
17 10.1002/14651858.CD007923.pub4
18 10.1002/14651858.CD003424.pub4
19 10.1002/14651858.CD007843.pub3
20 10.1002/14651858.CD001915.pub5
21 10.1002/14651858.CD008036.pub4
22 10.1002/14651858.CD006663.pub4
23 10.1002/14651858.CD004344.pub6
24 10.1002/14651858.CD011175.pub2
25 10.1002/14651858.CD011579.pub2
26 10.1002/14651858.CD010338.pub3
27 10.1002/14651858.CD005088.pub4
28 10.1002/14651858.CD008227.pub3
29 10.1002/14651858.CD011180.pub2
30 10.1002/14651858.CD002007.pub4
31 10.1002/14651858.CD008816.pub3
32 10.1002/14651858.CD012040.pub2
33 10.1002/14651858.CD010858.pub2
34 10.1002/14651858.CD009422.pub3
35 10.1002/14651858.CD003146.pub3
36 10.1002/14651858.CD002009.pub6
37 10.1002/14651858.CD001912.pub4
38 10.1002/14651858.CD002769.pub5
39 10.1002/14651858.CD011358.pub2
40 10.1002/14651858.CD000406.pub5
41 10.1002/14651858.CD002202.pub2
42 10.1002/14651858.CD004197.pub5
43 10.1002/14651858.CD006842.pub4
44 10.1002/14651858.CD012380.pub2
45 10.1002/14651858.CD012389.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD006401.pub4
4 10.1002/14651858.CD008482.pub5
5 10.1002/14651858.CD012284.pub2
6 10.1002/14651858.CD004198.pub3
7 10.1002/14651858.CD011441.pub2
8 10.1002/14651858.CD012330.pub2
9 10.1002/14651858.CD009803.pub2
10 10.1002/14651858.CD004878.pub4
11 10.1002/14651858.CD004976.pub3
12 10.1002/14651858.CD004877.pub3
13 10.1002/14651858.CD006607.pub4
14 10.1002/14651858.CD005530.pub3
15 10.1002/14651858.CD002744.pub4
16 10.1002/14651858.CD003645.pub3
17 10.1002/14651858.CD004418.pub4
18 10.1002/14651858.CD008268.pub2
19 10.1002/14651858.CD004872.pub3
20 10.1002/14651858.CD004879.pub4
21 10.1002/14651858.CD006435.pub2
22 10.1002/14651858.CD007720.pub2
23 10.1002/14651858.CD001955.pub3
24 10.1002/14651858.CD007368.pub2
25 10.1002/14651858.CD003123.pub3
26 10.1002/14651858.CD006207.pub4
27 10.1002/14651858.CD004882.pub3
28 10.1002/14651858.CD008395.pub2
29 10.1002/14651858.CD004407.pub3
30 10.1002/14651858.CD006338.pub3
31 10.1002/14651858.CD004559.pub4
32 10.1002/14651858.CD000422.pub3
33 10.1002/14651858.CD000980.pub4
34 10.1002/14651858.CD003124.pub4
35 10.1002/14651858.CD000247.pub3
36 10.1002/14651858.CD006602.pub4
37 10.1002/14651858.CD004874.pub4
38 10.1002/14651858.CD000436.pub3
39 10.1002/14651858.CD007074.pub2
40 10.1002/14651858.CD004823.pub4
41 10.1002/14651858.CD008695.pub2
42 10.1002/14651858.CD009039.pub2
43 10.1002/14651858.CD007718.pub2
44 10.1002/14651858.CD008008.pub2
45 10.1002/14651858.CD004106.pub4
46
47
48
49
50
51
52
53
54
55
56
57
58
59
50

1
2
3 10.1002/14651858.CD007033.pub3
4 10.1002/14651858.CD007695.pub3
5 10.1002/14651858.CD008469.pub2
6 10.1002/14651858.CD008328.pub2
7 10.1002/14651858.CD003797.pub2
8 10.1002/14651858.CD003533.pub2
9 10.1002/14651858.CD000994.pub3
10 10.1002/14651858.CD006100.pub2
11 10.1002/14651858.CD003573.pub2
12 10.1002/14651858.CD004357.pub4
13 10.1002/14651858.CD006923.pub3
14 10.1002/14651858.CD009339.pub2
15 10.1002/14651858.CD002986.pub2
16 10.1002/14651858.CD006829.pub2
17 10.1002/14651858.CD009157.pub2
18 10.1002/14651858.CD005304.pub3
19 10.1002/14651858.CD009293.pub2
20 10.1002/14651858.CD002991.pub3
21 10.1002/14651858.CD008250.pub2
22 10.1002/14651858.CD010256
23 10.1002/14651858.CD002314.pub3
24 10.1002/14651858.CD010257
25 10.1002/14651858.CD000998.pub3
26 10.1002/14651858.CD009611.pub3
27 10.1002/14651858.CD010179
28 10.1002/14651858.CD002742.pub2
29 10.1002/14651858.CD002308.pub2
30 10.1002/14651858.CD002316.pub2
31 10.1002/14651858.CD004434.pub5
32 10.1002/14651858.CD009296.pub2
33 10.1002/14651858.CD000364.pub4
34 10.1002/14651858.CD008888.pub2
35 10.1002/14651858.CD010352
36 10.1002/14651858.CD009305.pub2
37 10.1002/14651858.CD007313.pub3
38 10.1002/14651858.CD009041.pub2
39 10.1002/14651858.CD006922.pub3
40 10.1002/14651858.CD007891.pub3
41 10.1002/14651858.CD009607.pub2
42 10.1002/14651858.CD003563.pub2
43 10.1002/14651858.CD002878.pub2
44 10.1002/14651858.CD003792.pub2
45 10.1002/14651858.CD000060.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD006826.pub2
4 10.1002/14651858.CD003002.pub3
5 10.1002/14651858.CD009585.pub2
6 10.1002/14651858.CD000052.pub3
7 10.1002/14651858.CD001277.pub3
8 10.1002/14651858.CD001116.pub4
9 10.1002/14651858.CD006924.pub3
10 10.1002/14651858.CD010177.pub2
11 10.1002/14651858.CD009769.pub2
12 10.1002/14651858.CD010391.pub2
13 10.1002/14651858.CD009437.pub2
14 10.1002/14651858.CD010013.pub2
15 10.1002/14651858.CD009764.pub2
16 10.1002/14651858.CD009019.pub2
17 10.1002/14651858.CD003564.pub3
18 10.1002/14651858.CD008290.pub2
19 10.1002/14651858.CD007736.pub2
20 10.1002/14651858.CD003794.pub4
21 10.1002/14651858.CD003559.pub4
22 10.1002/14651858.CD009910.pub2
23 10.1002/14651858.CD003137.pub5
24 10.1002/14651858.CD008231.pub3
25 10.1002/14651858.CD008806.pub2
26 10.1002/14651858.CD006089.pub4
27 10.1002/14651858.CD008800.pub2
28 10.1002/14651858.CD006458.pub3
29 10.1002/14651858.CD010277.pub2
30 10.1002/14651858.CD001477.pub4
31 10.1002/14651858.CD005532.pub3
32 10.1002/14651858.CD006323.pub3
33 10.1002/14651858.CD006619.pub3
34 10.1002/14651858.CD004785.pub5
35 10.1002/14651858.CD003699.pub4
36 10.1002/14651858.CD000023.pub4
37 10.1002/14651858.CD005149.pub4
38 10.1002/14651858.CD006822.pub4
39 10.1002/14651858.CD009119.pub2
40 10.1002/14651858.CD004975.pub3
41 10.1002/14651858.CD009609.pub2
42 10.1002/14651858.CD006088.pub4
43 10.1002/14651858.CD008115.pub3
44 10.1002/14651858.CD000530.pub3
45 10.1002/14651858.CD001480.pub4
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD010056.pub2
4 10.1002/14651858.CD001266.pub4
5 10.1002/14651858.CD001269.pub5
6 10.1002/14651858.CD006452.pub4
7 10.1002/14651858.CD001833.pub3
8 10.1002/14651858.CD006639.pub4
9 10.1002/14651858.CD001478.pub6
10 10.1002/14651858.CD003257.pub5
11 10.1002/14651858.CD008965.pub4
12 10.1002/14651858.CD005189.pub4
13 10.1002/14651858.CD009066.pub2
14 10.1002/14651858.CD005188.pub3
15 10.1002/14651858.CD002109.pub4
16 10.1002/14651858.CD006482.pub4
17 10.1002/14651858.CD006206.pub4
18 10.1002/14651858.CD010130.pub2
19 10.1002/14651858.CD001831.pub5
20 10.1002/14651858.CD010473.pub2
21 10.1002/14651858.CD005975.pub3
22 10.1002/14651858.CD004875.pub5
23 10.1002/14651858.CD002745.pub4
24 10.1002/14651858.CD001957.pub6
25 10.1002/14651858.CD009088.pub3
26 10.1002/14651858.CD007094.pub4
27 10.1002/14651858.CD001954.pub4
28 10.1002/14651858.CD007716.pub4
29 10.1002/14651858.CD006895.pub3
30 10.1002/14651858.CD010636.pub2
31 10.1002/14651858.CD006821.pub3
32 10.1002/14651858.CD007897.pub3
33 10.1002/14651858.CD004884.pub4
34 10.1002/14651858.CD004783.pub5
35 10.1002/14651858.CD009194.pub3
36 10.1002/14651858.CD010596.pub2
37 10.1002/14651858.CD000219.pub4
38 10.1002/14651858.CD007577.pub3
39 10.1002/14651858.CD010586.pub2
40 10.1002/14651858.CD006915.pub3
41 10.1002/14651858.CD001726.pub5
42 10.1002/14651858.CD004405.pub5
43 10.1002/14651858.CD006362.pub4
44 10.1002/14651858.CD008116.pub3
45 10.1002/14651858.CD004402.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD011530.pub2
4 10.1002/14651858.CD010907.pub2
5 10.1002/14651858.CD009345.pub2
6 10.1002/14651858.CD007880.pub3
7 10.1002/14651858.CD009946.pub2
8 10.1002/14651858.CD008858.pub3
9 10.1002/14651858.CD004873.pub5
10 10.1002/14651858.CD005187.pub5
11 10.1002/14651858.CD007719.pub4
12 10.1002/14651858.CD011857.pub2
13 10.1002/14651858.CD007095.pub3
14 10.1002/14651858.CD004406.pub4
15 10.1002/14651858.CD004786.pub5
16 10.1002/14651858.CD009612.pub2
17 10.1002/14651858.CD005978.pub3
18 10.1002/14651858.CD011487.pub2
19 10.1002/14651858.CD011360.pub2
20 10.1002/14651858.CD004267.pub4
21 10.1002/14651858.CD011534.pub2
22 10.1002/14651858.CD010010.pub3
23 10.1002/14651858.CD005437.pub4
24 10.1002/14651858.CD010651.pub2
25 10.1002/14651858.CD002190.pub5
26 10.1002/14651858.CD011177.pub3
27 10.1002/14651858.CD000245.pub4
28 10.1002/14651858.CD004417.pub5
29 10.1002/14651858.CD010115.pub2
30 10.1002/14651858.CD001289.pub2
31 10.1002/14651858.CD002990.pub3
32 10.1002/14651858.CD010844.pub2
33 10.1002/14651858.CD010327.pub2
34 10.1002/14651858.CD002996.pub3
35 10.1002/14651858.CD007676.pub2
36 10.1002/14651858.CD000238.pub2
37 10.1002/14651858.CD010909.pub2
38 10.1002/14651858.CD007714.pub2
39 10.1002/14651858.CD010749.pub2
40 10.1002/14651858.CD010456.pub2
41 10.1002/14651858.CD006595.pub3
42 10.1002/14651858.CD009471.pub2
43 10.1002/14651858.CD009878.pub2
44 10.1002/14651858.CD010283.pub2
45 10.1002/14651858.CD001288.pub4
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD009285.pub3
4 10.1002/14651858.CD010509.pub2
5 10.1002/14651858.CD006322.pub3
6 10.1002/14651858.CD006897.pub3
7 10.1002/14651858.CD010382.pub2
8 10.1002/14651858.CD010139.pub2
9 10.1002/14651858.CD011306.pub2
10 10.1002/14651858.CD011438.pub2
11 10.1002/14651858.CD003793.pub3
12 10.1002/14651858.CD011090.pub2
13 10.1002/14651858.CD011437.pub2
14 10.1002/14651858.CD011032.pub2
15 10.1002/14651858.CD001287.pub5
16 10.1002/14651858.CD009552.pub3
17 10.1002/14651858.CD010066.pub2
18 10.1002/14651858.CD011397.pub2
19 10.1002/14651858.CD002997.pub4
20 10.1002/14651858.CD011293.pub2
21 10.1002/14651858.CD001392.pub3
22 10.1002/14651858.CD008351.pub3
23 10.1002/14651858.CD008989.pub3
24 10.1002/14651858.CD007949.pub2
25 10.1002/14651858.CD007525.pub3
26 10.1002/14651858.CD011721.pub2
27 10.1002/14651858.CD008202.pub2
28 10.1002/14651858.CD011017.pub2
29 10.1002/14651858.CD011715.pub2
30 10.1002/14651858.CD011050.pub2
31 10.1002/14651858.CD010346.pub2
32 10.1002/14651858.CD011801.pub2
33 10.1002/14651858.CD011716.pub2
34 10.1002/14651858.CD009953.pub2
35 10.1002/14651858.CD007524.pub4
36 10.1002/14651858.CD011205.pub2
37 10.1002/14651858.CD008532.pub3
38 10.1002/14651858.CD011714.pub2
39 10.1002/14651858.CD011826.pub2
40 10.1002/14651858.CD010744.pub2
41 10.1002/14651858.CD007851.pub3
42 10.1002/14651858.CD011440.pub2
43 10.1002/14651858.CD011511.pub2
44 10.1002/14651858.CD012067.pub2
45 10.1002/14651858.CD011818.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD010758.pub2
4 10.1002/14651858.CD011439.pub2
5 10.1002/14651858.CD001001.pub3
6 10.1002/14651858.CD011434.pub2
7 10.1002/14651858.CD005305.pub4
8 10.1002/14651858.CD006429.pub3
9 10.1002/14651858.CD005074.pub4
10 10.1002/14651858.CD011285.pub2
11 10.1002/14651858.CD001284.pub2
12 10.1002/14651858.CD001390.pub4
13 10.1002/14651858.CD011802.pub2
14 10.1002/14651858.CD012066.pub2
15 10.1002/14651858.CD012286.pub2
16 10.1002/14651858.CD012158.pub2
17 10.1002/14651858.CD012255.pub2
18 10.1002/14651858.CD012331.pub2
19 10.1002/14651858.CD011425.pub2
20 10.1002/14651858.CD011859.pub2
21 10.1002/14651858.CD009834.pub3
22 10.1002/14651858.CD011897.pub2
23 10.1002/14651858.CD010347.pub2
24 10.1002/14651858.CD005603.pub3
25 10.1002/14651858.CD006580.pub5
26 10.1002/14651858.CD011682.pub2
27 10.1002/14651858.CD012226.pub2
28 10.1002/14651858.CD011699.pub2
29 10.1002/14651858.CD010834.pub3
30 10.1002/14651858.CD005959.pub2
31 10.1002/14651858.CD008471.pub2
32 10.1002/14651858.CD008130.pub2
33 10.1002/14651858.CD001704.pub4
34 10.1002/14651858.CD001250.pub2
35 10.1002/14651858.CD004577.pub3
36 10.1002/14651858.CD004124.pub3
37 10.1002/14651858.CD001256.pub2
38 10.1002/14651858.CD005960.pub2
39 10.1002/14651858.CD000168.pub3
40 10.1002/14651858.CD008241.pub2
41 10.1002/14651858.CD007908.pub2
42 10.1002/14651858.CD009496.pub2
43 10.1002/14651858.CD000523.pub4
44 10.1002/14651858.CD008262.pub2
45 10.1002/14651858.CD004963.pub3
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD008470.pub2
4 10.1002/14651858.CD005595.pub3
5 10.1002/14651858.CD004575.pub3
6 10.1002/14651858.CD008628.pub2
7 10.1002/14651858.CD009030.pub2
8 10.1002/14651858.CD009890.pub2
9 10.1002/14651858.CD008413.pub2
10 10.1002/14651858.CD005465.pub3
11 10.1002/14651858.CD009073.pub2
12 10.1002/14651858.CD005079.pub3
13 10.1002/14651858.CD009363.pub2
14 10.1002/14651858.CD008987.pub2
15 10.1002/14651858.CD000339.pub3
16 10.1002/14651858.CD009587.pub2
17 10.1002/14651858.CD001255.pub5
18 10.1002/14651858.CD004439.pub3
19 10.1002/14651858.CD009808.pub2
20 10.1002/14651858.CD004962.pub3
21 10.1002/14651858.CD010071.pub3
22 10.1002/14651858.CD007146.pub3
23 10.1002/14651858.CD000227.pub4
24 10.1002/14651858.CD009065.pub2
25 10.1002/14651858.CD007601.pub4
26 10.1002/14651858.CD008579.pub3
27 10.1002/14651858.CD008887.pub2
28 10.1002/14651858.CD008129.pub2
29 10.1002/14651858.CD009949.pub2
30 10.1002/14651858.CD009076.pub2
31 10.1002/14651858.CD004961.pub4
32 10.1002/14651858.CD010144.pub2
33 10.1002/14651858.CD008106.pub3
34 10.1002/14651858.CD009651.pub2
35 10.1002/14651858.CD010960.pub2
36 10.1002/14651858.CD010261.pub2
37 10.1002/14651858.CD009699.pub2
38 10.1002/14651858.CD009848.pub2
39 10.1002/14651858.CD007789.pub2
40 10.1002/14651858.CD010606.pub2
41 10.1002/14651858.CD010836.pub2
42 10.1002/14651858.CD003324.pub3
43 10.1002/14651858.CD000434.pub4
44 10.1002/14651858.CD009679.pub2
45 10.1002/14651858.CD010789.pub2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 10.1002/14651858.CD007428.pub3
4 10.1002/14651858.CD010675.pub2
5 10.1002/14651858.CD011166.pub2
6 10.1002/14651858.CD010847.pub3
7 10.1002/14651858.CD007121.pub4
8 10.1002/14651858.CD001880.pub6
9 10.1002/14651858.CD007759.pub4
10 10.1002/14651858.CD009348.pub2
11 10.1002/14651858.CD010467.pub2
12 10.1002/14651858.CD008875.pub2
13 10.1002/14651858.CD011387.pub2
14 10.1002/14651858.CD010134.pub2
15 10.1002/14651858.CD010358.pub2
16 10.1002/14651858.CD010959.pub2
17 10.1002/14651858.CD001159.pub2
18 10.1002/14651858.CD011136.pub2
19 10.1002/14651858.CD009026.pub2
20 10.1002/14651858.CD007837.pub2
21 10.1002/14651858.CD009237.pub2
22 10.1002/14651858.CD010265.pub2
23 10.1002/14651858.CD006850.pub3
24 10.1002/14651858.CD010969.pub2
25 10.1002/14651858.CD012382
26 10.1002/14651858.CD008930.pub2
27 10.1002/14651858.CD001689.pub3
28 10.1002/14651858.CD001781.pub3
29 10.1002/14651858.CD001431.pub5
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—checklist of items that should be included in reports of observational studies

Item No	Recommendation	Page No
Title and abstract	<p>1 (a) Indicate the study's design with a commonly used term in the title or the abstract</p> <p>(b) Provide in the abstract an informative and balanced summary of what was done and what was found</p>	1,2 2
Introduction		
Background/rationale	2 Explain the scientific background and rationale for the investigation being reported	4
Objectives	3 State specific objectives, including any prespecified hypotheses	4
Methods		
Study design	4 Present key elements of study design early in the paper	4
Setting	5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4,5
Participants	<p>6 (a) <i>Cohort study</i>—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i>—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i>—Give the eligibility criteria, and the sources and methods of selection of participants</p> <p>(b) <i>Cohort study</i>—For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i>—For matched studies, give matching criteria and the number of controls per case</p>	5
Variables	7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5,6
Data sources/measurement	8* For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6
Bias	9 Describe any efforts to address potential sources of bias	7,8
Study size	10 Explain how the study size was arrived at	5
Quantitative variables	11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	N/A
Statistical methods	<p>12 (a) Describe all statistical methods, including those used to control for confounding</p> <p>(b) Describe any methods used to examine subgroups and interactions</p> <p>(c) Explain how missing data were addressed</p> <p>(d) <i>Cohort study</i>—If applicable, explain how loss to follow-up was addressed <i>Case-control study</i>—If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i>—If applicable, describe analytical methods taking account of sampling strategy</p> <p>(e) Describe any sensitivity analyses</p>	7 N/A 8 N/A N/A

Continued on next page

1
2 **Results**
3

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	5
		(b) Give reasons for non-participation at each stage	5
		(c) Consider use of a flow diagram	32
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	21
		(b) Indicate number of participants with missing data for each variable of interest	21
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	N/A
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	23
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	N/A
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	N/A
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7,8,9
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A

31 **Discussion**

Key results	18	Summarise key results with reference to study objectives	9,10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	9,10
Generalisability	21	Discuss the generalisability (external validity) of the study results	8

40 **Other information**

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	11
---------	----	---	----

45 *Give information separately for cases and controls in case-control studies and, if applicable, for exposed and
46 unexposed groups in cohort and cross-sectional studies.

48 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and
49 published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely
50 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at
51 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is
52 available at www.strobe-statement.org.
53
54